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Severe influenza virus infection, including human infection with highly 
pathogenic H5N1 viruses is characterised by massive pulmonary inflammation, 
immunopathology and excessive cytokine production, a process in which 
macrophages may play a vital role.  The aim of this project was to investigate 
the hypothesis that inhibition of inflammatory responses from infected 
macrophages, using either alternatively activated bone marrow derived 
macrophages (BMDMφ), or IFNγ receptor deficient (IFNγR-/-) mice may 
ameliorate the devastating immunopathology and inflammation routinely 
observed in highly pathogenic influenza virus infections. 
 
Infection of alternatively activated BMDMφ resulted in enhanced positivity for 
viral proteins, compared with classically activated, inflammatory BMDMφ.  
However, neither subset propagated the infection indicating that while 
infection is abortive in both classical and alternatively activated BMDMφ, the 
latter may prove more efficient at removing infectious virus from the site of 
infection due to enhanced infectivity.  However, influenza virus was capable of 
driving expression of proinflammatory mediators such as iNOS and TNFα from 
classical and alternatively activated BMDMφ even in the absence of IFNγ 
signalling.  IFNγR-/- BMDMφ demonstrated a reduced inflammatory response to 
infection compared to Sv129 counterparts, suggesting a potentially impaired 
inflammatory response in vivo. 
 
This was investigated by infection of IFNγR-/- mice, which resulted in 
ameliorated disease, lower viral titres and mild immunopathology, 
demonstrating that inhibition of IFNγ signalling limits the severity of disease.  
Additionally, mRNA expression for key inflammatory mediators was reduced, 
demonstrating that inhibition of the overwhelming inflammatory response to 
influenza virus infection is beneficial to the host, resulting in protection from 
immunopathology and improved prognosis, without impairing viral clearance. 
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1.1 Influenza A Virus 
 
A member of the Orthomyxoviridae family, influenza A virus is a negative sense 
RNA virus with an eight segmented genome.  This family comprises three 
different genera of influenza viruses; A, B and C, as well as thogotovirus and 
isavirus (Palese & Shaw, 2006).  While the generally mild symptoms of 
influenza A virus infection in humans include sneezing, headaches, coughing, 
fever and general aches and pains, infection in high risk groups such as the 
elderly, the immunocompromised or individuals with underlying medical 
conditions, can prove fatal particularly with the onset of secondary bacterial 
infections and pneumonia.  Several strains of virus can be circulating in a 
population at any one time.  
 
Each segment of the genome encodes at least one viral protein including the 
surface antigens haemagglutinin (H, HA) and neuraminadase (N, NA).  These 
are responsible for attachment, entry and exit of the virus to and from the cell, 
and also allow identification and differentiation between viral strains.  The 
segmented genome allows genetic reassortment between viral strains within a 
single genus, known as genetic shift (Palese & Shaw, 2006).   
 
Influenza A virus can infect birds and various mammalian hosts, including 
humans, in a strain dependent manner.  However, co-infection of a host can 
occur, leading to genetic shift and emergence of new viral strains.  This in turn 
can lead to pandemics as entire populations are naïve to the new virus.  
 
Of the sixteen HA and nine NA subtypes identified, viruses comprising subtype 
combinations H1N1, H2N2 and H3N2 have caused pandemic infections in 
humans, while others have been restricted to avian hosts.  This species 
restriction is facilitated by the preference of viral HA to bind to sialic acid (SA) 
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on the cell surface via different linkages in birds and humans (Connor et al., 
1994).  Despite this apparent incompatibility, avian influenza strains H5N1, 
H7N7 and H9N2 have been known to successfully infect humans causing 




1.2 Biology of Influenza A Virus 
 
1.2.1 Attachment and Entry 
 
Interactions between SA on the host cell surface and the viral HA protein result 
in viral attachment.  As mentioned above, avian and human viruses recognise 
and bind SA differently.  This is due to different amino acids present at the 
binding site for SA altering the shape of the binding pocket and therefore 
dictating interactions with different configurations of N-acetylneuraminic acid-
bound galactose (Connor et al., 1994).  Glaser and colleagues found that in two 
isolates of the 1918 H1N1 virus, a single differing amino acid at position 190 of 
HA enabled one isolate to bind both mammalian α2,6 linked and avian α2,3 
linked SA.  An isolate with sequence 190D, 225G successfully bound both 
forms of SA, while reversion of 190D to the avian consensus sequence 190E 
abrogated binding to α2,6 linked SA.   A further point mutation in the double 
binding virus resulting in the sequence 190D 225D, rendered it specific for the 
mammalian configuration of SA (Glaser et al., 2005).  This demonstrates the 
ability of the HA protein to undergo small rapid mutations, a process known as 
genetic drift, which can contribute to virus adaptation to mammalian hosts. 
 
Once attached to the host cell membrane, the virus utilises an as yet 
unidentified sialylated surface receptor(s) to become internalised in an 
endosome (Figure 1.1).  The matrix 2 (M2) protein forms a pore in the 
endosome membrane, allowing entry of H+ ions (Pinto et al., 1992).  This lowers  
Chapter 1  Introduction 
                                                                                                                                            
4 
 
Chapter 1  Introduction 




Figure 1.1  Replication cycle of influenza A virus 
Influenza virus attaches to the cell surface via sialylated receptor(s) and becomes internalised in an 
endosome.  Uncoating occurs as M2 forms a pore and allows influx of ions resulting in a 
conformational change in the HA protein which fuses the viral and endosomal membranes.  Viral 
ribonucleic proteins are released into the cytoplasm and translocate to the nucleus for replication.  
Viral mRNA, cRNA and genomic RNA are synthesised in the nucleus, viral proteins are synthesised in 
the cytoplasm and virion assembly takes place at regions of accumulation of viral glycoproteins at
the plasma membrane, resulting in budding and release of progeny virus. 
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the internal pH, allowing a conformational change in the HA protein.  It is 
cleaved into HA1 and HA2 proteins by cellular proteases, a process that is 
essential for viral infection (Klenk et al., 1975; Lazarowitz & Choppin, 1975).  
HA2 facilitates fusion of the viral membrane with that of the endosome, and 
several HA molecules come together to form a pore releasing the viral 
ribonucleic proteins (RNPs) into the cytoplasm (Palese & Shaw, 2006). 
 
1.2.2 Transcription and Replication 
 
As previously described, influenza A is a negative sense RNA virus comprised 
of eight gene segments, which have been found to code for up to 12 viral 
proteins. These are the viral surface antigens HA, NA and the M2 protein, the 
M1 protein, which lies just below the viral membrane, three viral polymerase 
complex proteins polymerase basic (PB) 1, PB2 and polymerase acid (PA), non-
structural (NS) proteins 1 and 2, the nuclear protein (NP).  In some strains, an 
eleventh protein encoded by an alternative open reading frame on the PB1 
gene, PB1-F2 is expressed (Chen et al., 2001).  A further twelfth peptide 
encoded by the PB1 gene segment, N40, has recently been identified but the 
function of this protein is yet to be determined (Wise et al., 2009).  These 
proteins and their functions are summarised in Table 1.1.  
 
The RNA segments are coated by NP to form RNPs.  The viral polymerase 
proteins are also involved in formation of RNPs, imposing a panhandle 
structure on the RNA (Gonzalez & Ortin, 1999a; Hsu et al., 1987).  Upon 
release from the virion into the cytoplasm, the RNPs are transported to the 
nucleus via localisation signals in NP (Cros et al., 2005; O'Neill et al., 1995).  
Once localised in the nucleus, the RNPs undergo transcription, producing viral 
mRNA.  To do this, PB2 binds the 5’ caps of cellular pre-mRNAs, which PB1 
then cleaves (Blaas et al., 1982).  After cleavage, a G residue is added to the 3’ 
end of the cap, allowing it to base pair with a C at the 3’ end of the viral mRNA 
held by the polymerase in its panhandle shape.  PB1 then elongates the 
capped molecule as the viral RNA is spooled through the polymerase complex  
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Gene Segment Proteins Encoded Function 
Haemagglutinin H spike Attachment to host cell 
 H1 Contains receptor binding site 
 H2 Facilitates fusion of endosome and viral 
membranes for uncoating 
Neuraminidase N Destruction of cellular sialic acid to 
complete release from host cell 
Non Structural NS1 IFN antagonist; role in immune 
  dysregulation 
 NS2 Nuclear export of genome 
Regulation of RNA species 
Polymerase Basic 1 PB1 Polymerase complex; binds and 





Virulence factor; induction of 
inflammation; induces apoptosis in 
some strains 
N terminally truncated PB1-related 
protein; function unkown 
Polymerase Basic 2 PB2 Polymerase complex; cap binding 
protein 
Polymerase Acid PA Polymerase complex protein 
Matrix 1 M1 Assembly and budding of new virions 
from host cell 
 M2 Forms ion pore to allow pH mediated 
uncoating 
Nuclear Protein NP Binds ribonucleic proteins, involved in 
nuclear export of genome 
   
Table 1.1  Influenza virus gene segments and proteins. 
Influenza A virus encodes up to 12 proteins from its 8 gene segments 
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(reviewed by Palese & Shaw, 2006).  The 5’ end remains bound, however, 
preventing further transcription and causing the polymerase to stutter at a 
polyU sequence, creating a polyA tail on the new viral mRNA (Luo et al., 1991).  
Once these viral mRNAs have been synthesised the virus then commandeers 
the cellular splicing machinery to produce templates for the spliced transcripts 
NS1, NS2 (Lamb et al., 1980), M1 and M2 (Lamb et al., 1981).  After 
transcription of the viral mRNAs, a full length cRNA must be synthesised to 
provide a template for viral genomic RNA (vRNA).  This template is neither 
capped or polyadenylated (Hay et al., 1977).  The mechanism by which the 
polymerase complex switches between transcription of mRNA and cRNA is 
largely unknown, although differing binding sites for vRNA and cRNA have 
been identified (Gonzalez & Ortin, 1999b).  The process is also dependent on 
newly synthesised NP, which is responsible for coating cRNA and protecting it 
from degradation.  It is hypothesised that the polymerase complex can 
transcribe both mRNA and cRNA (Vreede & Brownlee, 2007), but until NP and 
the polymerase complex have been translated, cRNA undergoes degradation 
and so is not readily detectable early in infection indicating that RNA stability 
may facilitate the switch to viral replication over mRNA transcription (Vreede et 
al., 2004).  The nuclear export protein NS2 has also been implicated in 
regulating the ratios of mRNA to cRNA, favouring accumulation of cRNA 
intermediates for replication over mRNA production (Robb et al., 2009).  
Recently, however, small viral RNAs (svRNA) have been discovered, the 
expression of which temporally correlates with accumulation of genomic vRNA.  
These svRNAs appear to be segment specific and interact with the polymerase 
complex.  Inhibition of svRNA results in reduced replication of the 
corresponding vRNA, implicating this newly discovered influenza RNA species 
in regulation of replication versus transcription (Perez et al., 2010). 
 
Once vRNAs are synthesised and assembled into RNPs in association with NP 
and the polymerase complex, they then interact with M1 (Martin & Helenius, 
1991) and NS2 (O'Neill et al., 1998), allowing nuclear export of the RNPs into 
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the cytoplasm for virion assembly.  It has also been suggested that NP may 
interact directly with the cellular CRM1 nuclear export pathway to facilitate 
this process (Elton et al., 2001). 
 
1.2.3 Assembly and Exit 
 
Once the mRNAs have been transcribed, viral proteins are synthesised on 
cellular ribosomes, passaged through the ER and golgi apparatus, from which 
they are transported to the cell membrane.  At the membrane, HA and NA are 
found to preferentially accumulate at areas rich in cholesterol and 
sphingolipids, with M2 accumulating at the edges of these regions.  This 
results in viral budding from these domains, known as lipid rafts (Scheiffele et 
al., 1999; Takeda et al., 2003).  Little is known of how the remaining viral 
components locate to these lipid rafts and assemble.  The ability of M1 to bind 
to HA may lead to it and associated RNPs being transported to the cell surface 
along with the HA protein (Ali et al., 2000).  It has also been suggested that M1 
and NP interact with the host cytoskeleton and are transported to the site of 
budding in this manner (Avalos et al., 1997).   
 
Packaging of the full complement of eight RNPs into each virion is also poorly 
understood.  It has been proposed that RNPs are packaged at random into 
virions to ensure a full complement (Enami et al., 1991), but more recently it 
has been suggested that individual packaging signals on the 5’ and 3’ end of 
the RNPs allow selective uptake of eight different RNPs into the virion (Fujii et 
al., 2003; Muramoto et al., 2006).  The virus buds through the plasma 
membrane, encapsulating the virion in the cell’s lipid bilayer with HA, NA and 
M2 protruding through.  This process has previously been shown to require 
only the M1 protein (Gomez-Puertas et al., 2000), although this is somewhat 
controversial.  Although M1 appears capable of forming virion-like particles, 
this may be dependent on targeting of M1 to the plasma membrane either by 
the VLP system being used (Gomez-Puertas et al., 2000), foreign targeting 
signals (Wang et al., 2010), or by M1 interactions with the cytpolasmic tail of 
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HA during translocation to the cell surface (Ali et al., 2000).  HA alone has also 
been demonstrated to form VLPs in a virus-free transfection system (Chen et 
al., 2007), implying that M1 is not essential for VLP formation.  However, 
efficiency of particle formation was greatest in the presence of HA, NA, M1 and 
M2 indicating roles for multiple viral proteins in virus release.  Further to this, 
Rossman et al showed that M2 is required for release of budding particles from 
the cell membrane by facilitating membrane scission (Rossman et al., 2010).  
NA functions to remove SA from the cell surface and the surface of the viral 
membrane preventing aggregation of virus (Palese et al., 1974) and releasing 
the virus to infect neighbouring cells and new hosts. 
 
 
1.3 Influenza Pandemics 
 
1.3.1 1918 – H1N1 
 
Otherwise known as ‘Spanish Flu’, the H1N1 virus that swept the globe in 
1918 was the most pathogenic strain of influenza A virus on record to infect 
humans.  The death toll rises with every reassessment, with the current figure 
conservatively around 50 million deaths worldwide (Kobasa et al., 2007). 
 
The 1918 pandemic arose in the USA, with soldiers falling ill in military camps 
when they reported for training.  However, the war prevented much of this 
early outbreak being publicised and it was not until the infection spread to 
Spain, more neutral in its wartime involvement, that this virus was publicly 
reported.  At this point, the infection was highly contagious but caused 
relatively few fatalities.  Later in the year, a highly virulent form of this H1N1 
virus emerged and spread rapidly around the world, causing extremely high 
mortality rates.  In the US, it thought that between 3 and 10 deaths occurred 
per 1,000 population, while Asian and African countries may have seen such 
high rates as high as 50 deaths per 1,000 (Wright et al., 2006). 
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Onset of symptoms of the 1918 H1N1 virus was sudden, characterised by high 
fever, severe headache, aches and pains with pathology mostly limited to the 
respiratory tract.  Although secondary bacterial pneumonia was the most 
common cause of death, some patients showed massive pulmonary oedema 
and haemorrhage (Wright et al., 2006).  This was studied in a macaque model 
using the 1918 virus, generated by reverse genetics.  The infected macaques 
became moribund within days of infection, ultimately leading to euthanasia at 
day 8 post infection.  These animals displayed elevated cytokine levels and 
dysregulated immune responses, thought to lead to the dramatic pulmonary 
pathology observed (Kobasa et al., 2007).  Indeed the ability of this virus to 
induce elevated cytokine production from macrophages, leading to influx of 
proinflammatory cells has been attributed to the 1918 HA gene (Kobasa et al., 
2004; Tumpey et al., 2005).  The polymerase genes (Tumpey et al., 2005) and 
NS (Geiss et al., 2002) have also been implicated in the extreme pathogenesis 
of this virus. This immune dysregulation and acute pathology has also been 
observed in H5N1 patients (To et al., 2001) and animal models (Gao et al., 
1999), suggesting that the ability to modulate the host immune response, 
leading to severe acute respiratory distress, may be a common feature of highly 
pathogenic influenza viruses. 
 
In addition to the unusually severe pathology seen in 1918 H1N1 infection, the 
pattern of infection was also different to that observed in previous influenza 
outbreaks.  Ordinarily, the most susceptible individuals to the virus are infants 
and the elderly.  However, during the 1918 pandemic, the majority of those 
succumbing to the virus were healthy young adults, with the 15-35 age 
bracket being struck down with unusual severity (Wright et al., 2006).  This 
suggests pre-existing cross protective immunity in the elderly, or a reduced 
capacity to mount the excessive inflammatory response that is thought to have 
contributed to the extreme morbidity and mortality in younger age groups. 
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H1N1 viruses continue to circulate in humans and cause seasonal illness.  
However 2009 saw the outbreak of a pandemic strain of H1N1 influenza virus.  
This novel virus is derived from a swine virus containing gene segments from 
human, avian and porcine viruses, leading to its description as a triple 
reassortant virus (Smith et al., 2009).  While both seasonal and pandemic 
H1N1 viruses express the same subtype of surface glycoproteins, these genes 
are derived from different origins and are antigenically distinct. 
 
1.3.2 1957 – H2N2 
 
1957 saw the outbreak of a strain of influenza with H2 and N2 subtypes, both 
acquired from avian viruses and also included an avian PB1 gene (Zamarin et 
al., 2006).  The outbreak was first isolated in Southern China before striking 
the US and UK, becoming known as Asian influenza.  Although mortality rates 
were less severe than in 1918, infection rates were extremely high, again with 
younger age groups being the most severely affected.  The virus itself was not 
excessively pathogenic, but still caused the death of over 1 million people 
worldwide (Wright et al., 2006).  It is thought that lack of previous exposure to 
these viral surface antigens resulted in the high infection and mortality rates 
observed.  The 1957 H2N2 virus expressed the PB1-F2 protein from its avian 
derived PB1 gene segment.  The effect of PB1-F2 on pathogenicity of this virus 
is unknown but it has been shown that C terminal fragments of this protein 
led to inflammatory infiltrate and induction of symptoms in mice, indicating a 
role in disease severity (McAuley et al., 2010a).   
 
1.3.3 1968 – H3N2 
 
The previously circulating H2N2 virus of 1957 was replaced by H3N2 in 1967, 
causing another pandemic originating in Hong Kong.  The H2N2 virus acquired 
new HA (H3) and PB1 genes by recombination with an avian virus, but 
retained a similar NA to its precursor.  Despite infection rates of up to 40%, 
mortality was fairly low, most likely due to the majority of the population 
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having been exposed to a very similar NA antigen 11 years earlier (Wright et al., 
2006).  Once again, the impact of the avian PB1-F2 is unknown but the C 
terminal region of this protein induced clinical symptoms and inflammation in 
the lungs of challenged mice, while failing to induce apoptosis in an in vitro 
model (McAuley et al., 2010a). 
 
H3N2 viruses continue to infect humans annually and remain in circulation 
despite the new pandemic H1N1 having effectively outcompeted seasonal H1N1 
viruses (Ilyushina et al., 2010). 
 
1.3.4 1977 – H1N1 
 
H1N1 re-emerged at the end of 1977 and caused illness among those under 
the age of 25.  This particular strain was found to be similar to H1N1 viruses 
that had circulated during the 1950s (Wright et al., 2006) and so the majority 
of the population had been previously exposed to these surface antigens.  Re-
emergence of this virus did not replace H3N2 viruses, and both continued to 
cause illness in humans. 
 
1.3.5 2009 – H1N1 
 
In April of 2009, the most recent influenza pandemic threat arose from a 
previously unsuspected origin.  An H1N1 virus, now thought to have been 
circulating undetected in swine for as long as a decade (Smith et al., 2009), 
made the transition to humans in Mexico, rapidly spreading throughout the 
country and beyond.  The 2009 pandemic strain is a triple reassortant virus, 
containing gene segments derived from avian, human and classical swine 
viruses of North American and Eurasian origin (Smith et al., 2009).  Although 
it has long been known that pigs can become infected with the virus, most 
attention has been focused in recent years on avian influenza and so the ‘swine 
flu’ outbreak caused some consternation among virologists.   
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Transmission studies utilising ferrets indicated increased morbidity and viral 
titres in experimentally infected animals compared to seasonal H1N1, but 
reduced efficiency of droplet transmission (Maines et al., 2009).  Despite this 
apparently poor transmissibility, the 2009 pandemic virus rapidly spread 
around the globe between its detection in March 2009 and the World Health 
Organisation declaration of pandemic status in June of that year. 
 
However, the virus has so far caused relatively mild disease and limited 
mortality.  Although there has been a high incidence of hospitalisations, many 
of these were due to complications related to underlying conditions, some of 
which were not previously recognised as risk factors for influenza, such as 
obesity and diabetes (Louie et al., 2009).  Isolates of the 2009 H1N1 virus 
replicated efficiently in human dendritic cells and macrophages, but induced a 
weak IFN response, similar to that observed during infection with seasonal 
H1N1 (Osterlund et al., 2010; Zeng et al., 2011).  Furthermore, the 2009 strain 
appeared to be impaired in its ability to replicate at 33oC, the temperature of 
the upper respiratory tract, compared with seasonal viruses (Zeng et al., 2011).  
Strong replicative capacity at 37oC indicates that this virus is adept at causing 
infection in the lower respiratory tract, confirmed by autopsy data of fatal 
infection cases which demonstrate strong positivity for virus in the alveoli 
(Calore et al., 2011).  This implies that the reduced severity of disease may be 
due to inefficient entry to the lower respiratory tract resulting in limited viral 
replication.  
  
Experimental infections in mice have demonstrated limited immunopathology 
and lethality, consistent with limited induction of antiviral cytokines (Belser et 
al., 2010; Maines et al., 2009).  However, the 2009 isolates could directly infect 
mice without prior adaptation (Maines et al., 2009), a trait commonly observed 
in highly pathogenic strains of influenza virus.  In contrast to such viruses, 
however, the 2009 H1N1 was sensitive to the antiviral action of IFNs, despite 
avoiding their induction (Osterlund et al., 2010). 
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Due to the capacity for rapid mutation inherent to RNA viruses, the possibility 
of this H1N1 obtaining increased virulence is an important concern.  As such, 
several groups have investigated the effect of known virulence factors on the 
2009 H1N1 backbone.  The currently circulating virus encodes three STOP 
codons in its PB1-F2 reading frame and therefore expresses a truncated, 11 
amino acid long protein.  Using reverse genetics to produce a 2009 H1N1 virus 
expressing a full length PB1-F2 did not result in enhanced virulence (Hai et al., 
2010).  Similarly, alteration of the STOP codon at position 88 to tryptophan did 
not increase the pathogenicity of the virus (Ozawa et al., 2011).  Recently, 
however, isolates have been identified with a naturally occurring mutation of 
the STOP codon at position 12 to lycine, resulting in a 57 residue long PB1-F2 
protein.  This increased pathogenicity both in vitro and in vivo but was not 
lethal in mice (Ozawa et al., 2011).  Furthermore, mutation of the STOP codon 
at NS1 position 220 to tryptophan, in concert with an XSEV motif in the final 
four C terminal amino acids of the NS1 protein results in enhanced virulence 
of the 2009 H1N1 virus (Ozawa et al., 2011).  
  
Avian and human viruses differ in particular amino acids within the 
polymerase complex proteins.  The consensus human sequence includes lycine 
and asparagine at positions 627 and 701 respectively in PB2, which is thought 
to be important for efficient replication in mammals.  The 2009 pandemic virus 
expresses the avian consensus sequence of glutamic acid at 627 and aspartic 
acid at 701.  Mutation of the 2009 PB2 to the consensus human sequence did 
not enhance replication or disease severity, but did increase viral shedding in 
ferrets, as did a further mutation to introduce glycine at position 677 (Herfst et 
al., 2010).   
 
It has been suggested that antigenic shift is more likely than antigenic drift to 
give rise to a virus with increased pathogenicity.  However, given that this virus 
has effectively outcompeted seasonal viruses, it has been suggested that the 
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limited capacity for antigenic shift may restrain the emergence of a more 
pathogenic strain (Ilyushina et al., 2010). 
 
 
1.3.6 The Threat of an H5N1 Pandemic 
 
In recent years, much attention has been given to the H5N1 strain of avian 
influenza after the outbreak of this virus in Hong Kong in 1997.  This highly 
pathogenic strain has caused widespread disease in domestic and migratory 
birds, and has jumped the species barrier to infect humans without apparent 
recombination of the viral genome (Gao et al., 1999).  Direct contact with 
infected poultry can lead to infection of humans, but despite the highly 
efficient transmission between birds, human to human transmission appears 
to be poor (Chan et al., 2005).  However, the disease that ensues in infected 
individuals has been severe with 553 confirmed cases and 323 fatalities to date 
with a mortality rate of over 80% in some south east Asian countries (WHO, 
2011). 
 
The emergence of an avian H5N1 virus with the ability to infect humans with 
no prior recombination in 1997 was totally unprecedented.  All previous 
influenza viruses of avian origin capable of infecting humans had undergone 
genetic recombination with human viruses.  In 1997, 18 cases of highly 
pathogenic H5N1 were identified in Hong Kong, of which 6 were fatal (To et al., 
2001).  All 18 patients were found to have had close, direct contact with 
poultry, leading to the decision to cull all live poultry in markets in Hong Kong.  
Human to human transmission appeared to be inefficient, if it occured at all 
and no further cases were reported at this time.  However, in 2001, poultry 
stocks again became infected with H5N1, resulting in another mass cull.  
H5N1 was maintained in the wild bird population and in early 2003, a young 
boy and his father were admitted to hospital in Hong Kong, infected with the 
H5N1 virus (Peiris et al., 2004).  By July 2003, the virus was rife in poultry 
stocks throughout Asia, leading to the death or culling of over 100 million 
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farmed birds.  The virus has also been identified in various European countries 
in migratory birds as well as some farmed poultry.  
  
Infection with H5N1 has been observed to lead to dysregulation of the immune 
system, with greatly elevated proinflammatory cytokine levels and acute 
respiratory distress syndrome (ARDS), leading to multiple organ failure and 
haemophagocytosis (To et al., 2001). Much of this pathology is due to disrupted 
immune regulation caused by the virus and has been the focus of many 
studies over the last decade.  Various viral genes have been implicated in 
alteration of the host immune response, including the NS and HA genes, as 
well as PB2 (Gao et al., 1999; Hatta et al., 2001; Li et al., 2005; Seo et al., 
2002).  H5N1 viruses appear to be resistant to cellular IFNγ and TNFα (Seo et 
al., 2002), while inducing expression of these and other proinflammatory 
cytokines from macrophages, CD4+ and CD8+ T cells infiltrating the infected 
respiratory tract (Chan et al., 2005; Cheung et al., 2002).  The production of 
these cytokines in the context of a virus highly resistant to their actions leads 
to increased immunopathology in the lung as the inflammatory response 
causes damage to the lung tissue while attempting to clear the virus.  The 
induction of cytokine production from infected macrophages (Cheung et al., 
2002; Zhou et al., 2006) leads to further influx of inflammatory mediators into 
the tissue and continues to exacerbate the condition, ultimately leading to the 
severe symptoms observed. 
  
The potential for this highly pathogenic virus to recombine with one capable of 
efficient human to human transmission and the increasing incidence of human 
infection makes the emergence of an H5N1 pandemic a serious threat. 
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1.4 Experimental Influenza Virus Infections in Mice 
 
Several different strains of virus have been utilised in experimental mouse 
models of influenza virus infection.  Perhaps the most commonly studied are 
the mouse adapted H1N1 strains A/WSN/33 (WSN) and A/PR/8/34 (PR8), 
both of which result in severe disease.  However, two milder H3N2 strains, 
BJx109 and HKx31, are also frequently used as mice generally recover from 
these infections.  Importantly, these viruses share their internal genes with 




In 1939 and 1940, two authors published the generation of variant strains of 
the Wilson-Smith virus (A/WS/33) which had been adapted to stably induce 
neurological symptoms in mice.  The first of these strains was generated by 
serial passage in embryonic chick chorioallantoic tissue followed by 
intracerebral inoculation in mice, resulting in neurological symptoms by 
passage 12 (Stuart-Harris, 1939), and became known as ‘A/NWS/33’.  
  
Several other variants were established by Francis and Moore, by serial 
passage of the Wilson-Smith strain through embryonic chick brain tissue.  
Following the seventh passage in this tissue, the virus was inoculated 
intracerebrally into mice, and further serial passage performed until 
neurological symptoms were evident at passage 12, when the mice were 
euthanized.  A further variant was developed in this laboratory by serial 
passage through whole chick embryo cultures, which was the standard tissue 
culture technique for maintenance of influenza viruses at that time.  Again, 
following intracerebral inoculation and serial passage, this virus demonstrated 
the ability to induce neurological symptoms.  The neurotropic capacity of this 
virus was restricted to intracerebral inoculation, while infection by the 
intranasal route resulted in pulmonary infection with no evidence of 
neurological symptoms (Francis & Moore, 1940).  However, this virus has now 
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been shown to induce systemic infection and has been recovered from the 
brain following intranasal infection (Castrucci & Kawaoka, 1993).  This 
laboratory maintained virus became known as ‘A/WSN/33’ (WSN) and has 
been widely used for infection studies in mice. 
 
The NA protein of WSN has been identified as being responsible for the 
neurotropism of this virus (Goto et al., 2001), and also enables WSN to utilise 
the ubiquitous protease plasmin to cleave its HA in the absence of trypsin 
(Goto & Kawaoka, 1998).  This increases the pathogenicity and tropism of 
WSN, as the virus does not contain a polybasic cleavage site in its 
haemagglutin protein, the presence of which is typical of highly pathogenic 
viruses and allows cleavage by ubiquitous cellular proteases such as furin (Gao 




The PR8 strain of virus was derived from a human isolate in Puerto Rico in 
1934 (Francis, 1934).  This isolate was serially passaged in ferrets, followed by 
passage in mice and further maintenance in chick embryo tissue culture 
medium, during which time the virus retained its infectivity for mice and 
ferrets, resulting in pulmonary disease (Francis & Magill, 1935).  PR8 has 
subsequently been shown to be highly pathogenic to mice, inducing excessive 
inflammation in the lung and death within seven days of infection (Hennet et 
al., 1992). 
 
1.4.3 HKx31 and BJx109 
 
As antigenic drift alters the surface proteins of circulating seasonal influenza 
viruses, the annual influenza vaccine must be updated.  However, circulating 
strains are generally inefficient at replicating in tissue culture and so high 
yielding reassortants, which combine the efficient tissue culture replicative 
capacity of PR8 with the antigenic determinants of seasonal influenza strains, 
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are necessary for generation of vaccine strains.  Embryonated chicken eggs are 
coinfected with the seasonal virus and the laboratory strain PR8, resulting in 
recombinant viruses.  The recombinant virus with the highest 
haemagglutination titre in the presence of anti-PR8 rabbit antisera is selected 
for further passage through chicken eggs.  This is repeated for three passages 
before antigenic determination of the high growth reassortant virus.  Further 
egg passage is carried out, followed by antigenic characterisation to ensure 
stable phenotype of the virus before inclusion in the vaccine (described by 
Robertson et al., 1992). 
 
This technique was successfully pioneered by Dr. E. Kilbourne, generating the 
HKx31 virus by recombination between PR8 and A/Aichi/2/68 (Kilbourne et 
al., 1971).  Similarly, BJx109 is a high yielding reassortant virus expressing 
the internal genes of PR8 and the surface proteins of the seasonal strain 
A/Beijing/353/89, generated for inclusion in the 1991-1992 vaccine 
(Robertson et al., 1992). 
 
Despite the high growth capacity, and the ability to replicate in mice, these 
viruses are not as pathogenic as their PR8 parent (Tate et al., 2011), which has 
been associated with the differential abilities of these viruses to infect 
macrophages (Reading et al., 2000) and resist the actions of surfactants and 
collectins (Reading et al., 1997). 
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1.5 Pathogenesis of Influenza A Virus 
 
Various viral proteins have been implicated in the pathogenicity of influenza 
viruses, with H5N1 viruses being especially well documented for their ability to 
cause dysregulation of the immune system.  Intensive inflammation of the 
airways and lungs leading to severe and irreversible pathology is characteristic 




Highly pathogenic avian influenza (HPAI) H5N1 viruses have been divided into 
two groups based on their pathogenicity in mice.  Group one viruses cause 
lethal systemic infection in mice and contain a multibasic cleavage site making 
HA susceptible to cellular proteases such as furin and PC6 (Gao et al., 1999).  
It has been suggested that this is responsible for allowing the virus to spread 
beyond the respiratory tract and become cleaved into HA1 and HA2 subunits 
in many different cell types.  Similarly, despite the absence of the polybasic 
cleavage site, WSN has demonstrated extrapulmonary tropism including 
neurovirulence, associated with the ability to bind and sequester plasminogen, 
enabling this virus to utilise plasmin to cleave its HA (Goto & Kawaoka, 1998).  
 
The second group of HPAI viruses are non lethal in mice and remain localised 
in the respiratory tract (Gao et al., 1999).  It was thought that lack of a 
multibasic cleavage site seen in group one viruses restricts the tropism of these 
viruses to respiratory cells containing specific proteases.  However, some non-
lethal viruses placed in group 2 possess multi-basic cleavage sites in their HA, 
indicating that lethality in mammals is a polygenic trait.  However, both groups 
of viruses cause systemic, lethal infection in chickens.  Furthermore, this 
classification applies only to isolates from the 1997 outbreak of H5N1. 
 
Single gene reassortant virus studies allowed further investigation of the role of 
HA in H5N1 virulence.  HA from group two viruses were found to contain either 
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serine or isoleucine at position 227, but were still non-lethal regardless of 
residue at this position.  However, introduction of these HA genes onto a group 
one virus background led to differing properties.  The HA containing isoleucine 
at position 227 successfully attenuated the pathogenicity of the group one 
virus.  The presence of serine however, did not confer any protection and 
infected mice succumbed to the infection (Hatta et al., 2001).  This shows that 
although amino acid sequence is an important factor in determining 
attenuation of virulence, this is complicated by the presence of other virulence 
factors within a viral strain. 
 
1.5.2 Non Structural Protein 1 
 
The NS1 protein has been heavily implicated in the pathogenesis of H5N1 and 
other influenza virus strains (Figure 1.2).  It confers resistance against the 
anti-viral activity of IFNs and TNFα, while interfering with production of these 
cytokines from infected cells.  It has been shown that recombinant viruses 
expressing the NS1 gene from H5N1 on an H1N1 background led to increased 
production of TNFα from infected cells (Cheung et al., 2002; Lipatov et al., 
2005).  However, pre-treatment with IFN or TNFα, which inhibits replication of 
other influenza A viruses, had no effect on replication of H5N1 virus.  Seo et al 
showed that the NS1 from lethal H5N1 has a point mutation at position 92.  All 
human strains have aspartic acid (D) at this position.  Those derived from the 
1997 H5N1, an avian virus, encode glutamic acid (E) at position 92.  PR8 H1N1 
virus was given only the NS1 from either H5N1/1997 (E at position 92), 
H5N1/2001 (D at position 92) or a revertant of H5N1/1997 (D at position 92).  
The viruses encoding D at NS1 position 92 were attenuated, while the 
remaining virus was pathogenic.  Furthermore, NS1 of H5N1 imbued WSN 
H1N1 virus with the capacity to induce high levels of TNFα, suggesting that 
this gene is involved in dysregulation of the cytokine response (Cheung et al., 
2002).  This single amino acid change has also been identified as responsible 
for  viral  resistance  to  cytokines  (Seo et al., 2002).  This work,  however, was  
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Figure 1.2  NS1 interacts with cellular defence pathways 
The viral protein NS1 interacts and inhibits many pathways involved in cellular 
recognition and response to influenza virus, including blocking IFNs at both pre and 
post-transcriptional levels, inhibiting inflammasome dependent cleavage of caspase 
1 and binding to viral RNA or host proteins to prevent recognition of the viral genome 
and thereby facilitates host immune evasion by a multitude of mechanisms.   
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carried out in porcine lung cells using pre-treatment with swine cytokines 
rather than a human lung epithelial cell line.  A recent study has 
demonstrated that in human lung explants, H5N1 and seasonal H1N1 viruses 
are in fact susceptible to the actions of IFNs following pre-treatment, despite 
efficiently inhibiting post-infection IFN signalling.  This indicates that although 
these viruses can subvert induction of the host immune response, they are not 
inherently resistant to the actions of IFNs (Jia et al., 2010).   
 
It was thought that the ability of the NS1 protein to bind to double stranded 
RNA resulted in sequestration of the viral genome from cellular defences such 
as PKR and 2’-5’-oligoadenylatesynthetase (OAS; Wright et al., 2006).  
However, while the RNA binding region of NS1 appears to be vital in protecting 
the virus from the degrading effects of OAS-induced RNAseL (Min & Krug, 
2006), this function of the NS1 protein does not seem to be involved in evasion 
of the PKR pathway.  It is now apparent that NS1 can bind to the N terminal 
region of PKR, inhibiting the conformational change induced by binding of 
double stranded RNA (Li et al., 2006; Min et al., 2007).  NS1 also binds to RIG-I 
(Mibayashi et al., 2007; Pichlmair et al., 2006), further impairing induction of 
the host IFN and anti-viral response.  NS1 mediated impairment of PKR, OAS 
and RIG-I results in downstream inhibition of transcription factors such as 
IRF3 and NFκB, ultimately preventing transcription of IFNs and effective 
establishment of the antiviral state (Figure 1.2). 
 
In addition to its role in pre-transcriptional impairment of the IFN response, 
NS1 also mediates post-transcriptional mechanisms of IFN blockade (Figure 
1.2).  NS1 can inhibit processing and maturation of cellular mRNAs by 
interacting with host polyadenylation machinery, Cleavage and Polyadenylation 
Specificity Factor (CPSF) 30 and PolyA Binding Protein II, resulting in 
inhibition of CPSF30 binding to cellular mRNAs and therefore impaired 
processing (Nemeroff et al., 1995).  Because the virus does not utilise these 
proteins for polyadenylation, viral mRNAs are unaffected.  NS1 is also 
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responsible for selective translation of viral mRNAs at the expense of cellular 
mRNAs, in addition to reducing the quantity of mature cellular mRNAs 
produced.  This occurs by interactions between NS1, the 5’ UTR of viral mRNAs 
and host cell protein complexes involved in targeting mRNAs to sites of 
increased translation.  NS1 interacts with subunits of the cellular cap-binding 
complex, eIF4GI and PABPI, as well as with hStaufen, which is involved in 
transportation of mRNAs to the polysome, resulting in selective enhancement 
of viral mRNA translation (Aragon et al., 2000; Burgui et al., 2003; Falcon et 
al., 1999). 
 
The NLRP3 inflammasome plays a role in the immune response to influenza A 
virus, resulting in activation of caspase-1, IL-1β and IL-18.  Inflammasome 
activation has been identified as a vital component in the development of 
functional innate and adaptive responses to influenza A viruses (Allen et al., 
2009; Ichinohe et al., 2009; Thomas et al., 2009).  However, the RNA binding 
domain of NS1 has been found to inhibit caspase-1 activation and therefore 
prevent cleavage of functional IL-1β and IL-18 from their pro- forms (Stasakova 
et al., 2005), further impairing the host response to infection. 
 
Deletion of NS1 by reverse genetics has further confirmed the role of this 
protein in escape from the host antiviral response.  The delNS1 mutant virus 
(generated on a PR8 H1N1 background) cannot grow in IFN competent systems 
(Egorov et al., 1998; Garcia-Sastre et al., 1998), in part due to recognition of 
viral RNA by PKR in the absence of NS1, and subsequent inhibition of viral 
protein synthesis (Bergmann et al., 2000).  However, this virus can replicate 
efficiently in IFN deficient cells, therefore showing that NS1 is required not for 
replication but for interaction and subversion of the host IFN response 
(Salvatore et al., 2002).  IFNα-regulated genes are effectively inhibited by wild 
type H1N1 virus due to NS1 mediated inhibition of NFκB activation, but the 
delNS1 mutant fails to do this (Wang et al., 2000) and so is reduced in its 
ability to subvert host IFN responses.  Furthermore, the NS1 protein may 
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effectively ‘buy time’ for viral replication by inhibiting induction of the 
inflammatory burst.  Infection with the delNS1 virus resulted in rapid 
induction of inflammatory responses in C57Bl/6 mice, while this was delayed 
by up to 48 hours before the host antiviral response was initiated following 
infection with wildtype virus (Moltedo et al., 2009). 
 
NS1 has also been shown to interact with the p85β subunit of PI3K (Hale et al., 
2006).  This interaction seems to be important for viral growth but the 
downstream effects on this diverse signalling pathway are as yet unclear.  It is 
likely however, that this interaction modulates apoptosis, prolonging survival 
of infected cells (Hale et al., 2006).  However, it has recently been shown that 
failure of mutant NS1 to bind PI3K did not result in increased apoptosis 
(Jackson et al., 2010) and so the role of this particular interaction remains 
undetermined. 
 
Despite interacting with the PI3K pathway, NS1 may play a role in induction of 
apoptosis of host immune cells, although this is not well defined.  Again, the 
delNS1 mutant was utilised to investigate the involvement of NS1 in 
macrophage apoptosis.  delNS1 viruses induce rapid apoptosis in infected cells 
(Zhirnov et al., 2002), possibly due to the inability of this mutant virus to 
inhibit IFN-mediated events.  However, the wildtype virus shows delayed 
apoptosis, indicating that NS1 protects the infected cell from undergoing 
immediate apoptosis and therefore prolonging the time for viral replication.  
Conversely, in the absence of other viral proteins NS1 has been shown to be 
sufficient to induce apoptosis in cells (Schultz-Cherry et al., 2001) further 




Studies of the two groups of H5N1 viruses with differential lethality in mice 
have led to the identification of PB2 as a virulence factor for this virus.  
Introduction of PB2 from a non-lethal H5N1 virus onto a lethal virus 
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background led to attenuation of the lethal virus.  However, introduction of 
PB2 from a lethal H5N1 virus onto a mild background required expression of 
serine at position 227 of the HA protein to confer lethality, while the same PB2 
gene on the non lethal background containing isoleucine at this position of the 
HA protein did not lead to death of the animals (Hatta et al., 2001).  Taken 
together, this illustrates the complexity of interplay between influenza virus 
pathogenicity factors, as sequence specificity on a given gene segment in 
combination with distinct virulence factors can influence the phenotype of the 
virus. 
 
The amino acid sequence of PB2 has also been investigated with regards to 
pathogenicity.  Positions 627 and 701 have been implicated (Table 1.2).  Single 
gene reassortant viruses were again utilised to investigate the effect of amino 
acid polymorphisms at these locations.  H5N1 viruses lethal in mice, that 
usually contain lysine at position 627 were attenuated by the presence of 
glutamic acid at this residue – normally seen in non-lethal virus PB2.  
Conversely, the milder viruses could be rendered lethal by substitution of 
glutamic acid for lysine (Gao et al., 1999; Hatta et al., 2001).  Similarly, at 
position 701, substitution of asparagine for aspartic acid leads to attenuation 
of lethal viruses, while the reciprocal substitution enables non fatal viruses to 
become lethal (Li et al., 2005).  As asparagine is found mostly in human 
viruses, it may be a requirement for making the jump from birds to humans.  
It is highly likely, therefore, that PB2 may play a role in host tropism. 
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Gene Background Amino Acid  Outcome 
PB2 Lethal Lys@627 Death 
PB2 Lethal Glu@627 Survival/attenuation 
PB2 Non Lethal Lys@627 Death 
PB2 Non Lethal Glu@627 Survival 
    
PB2 Lethal Asp@701 Death 
PB2 Lethal Asn@701 Survival/attenuation 
PB2 Non Lethal Asn@701 Survival 
PB2 Non Lethal Asp@701 Death 
Table 1.2  Pathogenic polymorphisms in PB2 
Amino acids at positions 627 and 701 are important determinants of PB2 pathogenicity.  
Insertion of Glu instead of Lys at position 627 leads to attenuation of lethal virus, while the 
opposite combination makes milder virus lethal.  Insertion of Asn instead of Asp at position 
701 leads to attenuation of lethal virus, while the opposite combination makes milder virus 
lethal. 
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The PB1 gene segment has been found to be of avian origin in pandemic 
strains of influenza virus (Zamarin et al., 2006).  The avian PB1 gene expresses 
an alternative open reading frame which encodes a protein termed PB1-F2, 
which is frequently lost or truncated during long term adaptation in humans 
(McAuley et al., 2010a).  The presence of this avian-derived factor in pandemic 
strains identifies it as a potential pathogenicity factor in influenza A virus 
infection.  
 
Although initially implicated in induction of apoptosis in macrophages (Chen et 
al., 2001), it now appears to play a pleiotropic role in influenza virus 
pathogenicity.  PB1-F2 contains a C terminal mitochondrial localisation 
sequence, resulting in translocation to this organelle, where it disrupts 
membrane potential and induces apoptosis dependent on components of the 
permeability transition pore complex, VDAC1 and ANT3 (Zamarin et al., 2005) 
and the pro-apoptotic proteins Bax and Bak (McAuley et al., 2010a).  This may 
lead to immunosuppression (Chen et al., 2001), reduced viral clearance and 
increased opportunity for viral replication (Zamarin et al., 2006).  A recent 
study, however, has indicated that the pro-apoptotic function of PB1-F2 may 
be virus strain and cell type specific, with the most commonly studied PR8-
derived PB1-F2 inducing apoptosis in both macrophage and lung epithelial cell 
lines.  The 1918 PB1-F2 demonstrated the ability to induce apoptosis in 
macrophages but not epithelial cells, while PB1-F2 from other viruses, 
including H5N1, failed to induce this phenomenon (McAuley et al., 2010a). 
 
Several groups have further investigated the potential function of this 
intriguing protein, implying a potential role in enhancing viral replication due 
to interactions of PB1-F2 with the viral polymerase complex (Mazur et al., 
2008).  This too appears to be strain and cell type specific with alteration of 
PR8 PB1-F2 leading to differential polymerase activity in A549 and 293T 
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epithelial cell lines but similar replication in vivo, while disruption of H5N1 and 
1918 PB1-F2 demonstrated decreased polymerase activity in both cell lines 
without affecting in vivo viral titres.  Furthermore, PB1-F2 from an H3N2 virus 
had no discernable effect on replication in vitro or in vivo (McAuley et al., 
2010b).  
 
The role of PB1-F2 may in fact be to regulate the inflammatory response.  Both 
C terminal peptides and full length PB1-F2 proteins from a PR8 and the 1918, 
1957 and 1968 pandemic strains of influenza virus resulted in excessive influx 
of macrophages and neutrophils, concomitant with onset of clinical symptoms 
following in vivo infection of mice (McAuley et al., 2010a).  Consistent with this, 
a recent study has indicated that a point mutation at position 66, altering 
asparagine to serine, results in enhanced pathogenesis independent of 
induction of apoptosis (Conenello et al., 2011).  The mutant was shown to 
depress the host IFN response, while elevating other proinflammatory 
cytokines, concomitant with increased innate immune cell infiltration early in 
infection.  This implies that the PB1-F2 protein may play a major role in 
modulation of the innate response.  Furthermore, the PB1-F2 has been found 
to interact with IPS-1, a downstream component of the RIG-I cascade, 
therefore the mitochondrial targeting of PB1-F2 may not be to induce apoptosis 
but rather to interfere with IFN induction, a function that is further enhanced 
in the presence of 66S (Varga et al., 2011). 
 
Recently, a third protein product from the PB1 gene segment has been 
identified.  Initiation of translation downstream of the PB1 protein results in a 
truncated PB1 related product designated N40 (Wise et al., 2009).  Although 
the function of this novel protein is yet to be elucidated, it is evident that 
expression is closely interlinked with that of PB1 and PB1-F2.  Disruption of 
the PB1-F2 open reading frame by specific mutations results in altered levels of 
N40 and PB1, while disruption of the N40 START codon leads to enhanced PB1 
during early infection (Wise et al., 2009).  Although several of the studies 
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detailed above have induced PB1-F2 mutations that are silent in both PB1 and 
N40 proteins (McAuley et al., 2010a; McAuley et al., 2010b), the effect of PB1-
F2 disruption must be carefully examined in light of the lack of independent 
protein expression from this gene segment.    
 
Prolonged circulation in the human population appears to favour truncation or 
non-functional mutation of PB1-F2 as observed in seasonal human H3N2 and 
post 1950 H1N1 isolates (McAuley et al., 2010a).  As previously discussed, the 
prototype 2009 pandemic H1N1 virus possesses a human PB1 gene segment 
without a PB1-F2 protein due to multiple STOP codons within this open 
reading frame.  Furthermore, the naturally occurring 2009 variant virus 
encoding a truncated PB1-F2 with leucine at position 12 showed some 
increased pathogenicity but was not lethal in experimentally infected animals 
(Ozawa et al., 2011).  It is therefore likely that PB1-F2 is essential for efficient 
replication in the avian host, but dispensable in human infection resulting in 




1.6 Immune Detection of Influenza Virus 
 
1.6.1 Toll-Like Receptors 
 
Influenza virus is recognised by infected cells in several ways.  Double and 
single stranded viral RNA is recognised by the intracellular toll-like receptors 
(TLR) 3 and 7 respectively and both have been implicated in detection of 
influenza virus infection (Figure 1.3).  
  
TLR7 signals via the MyD88 adaptor protein, resulting in NFκB activation and 
expression of proinflammatory cytokines.  This receptor also employs an 
alternative signalling pathway in plasmacytoid dendritic cells, via IRF7 
activation, leading to IFNα production (reviewed by Kawai & Akira, 2010).  Mice  
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Figure 1.3  Signalling cascades following influenza virus infection 
Infection with influenza virus is recognised with many different pattern recognition receptors, resulting 
in signalling cascades and expression of IFNs and proinflammatory cytokines, ultimately inducing an 
antiviral state. 
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lacking TLR7 or MyD88 have been shown to be deficient in their capacity to 
mount an effective IFNα response following infection both in vitro and in vivo, 
while exposure to purified single stranded genomic viral RNA was sufficient to 
induce this response from wildtype plasmacytoid dendritic cells (Diebold et al., 
2004; Lund et al., 2004).   
 
TLR3 recognises double stranded RNA and has been implicated in detection of 
many viral infections.  This is the only TLR that does not utilise the MyD88 
pathway, signalling instead via TRIF and IRF3 which results in production of 
IFNβ (reviewed by Kawai & Akira, 2010).  Surprisingly, mice deficient in TLR3 
expression demonstrate ameliorated disease following infection with influenza 
virus, exhibiting prolonged survival and decreased inflammatory cytokine 
expression in the lung (Le Goffic et al., 2006).  However, this was at the 
expense of viral clearance and ultimately all mice succumbed to infection.  
However, influenza virus does not appear to generate detectable double 
stranded RNA (Pichlmair et al., 2006).  This suggests that the presence of 
double stranded RNA may be extremely transient, sufficient to activate TLR3 
but not be detectable by assay.  Alternatively, NS1 incompetent intermediates 
may be released from dying infected cells, resulting in fragments of double 
stranded RNA which may activate this TLR.  However, the lack of readily 
detectable double stranded RNA indicates that recognition of single stranded 




In addition to endosomal TLRs, the cytoplasmic protein RIG-I has been 
implicated in detection of influenza virus RNA (Figure 1.3).  This receptor has 
been shown to detect transcribed viral RNA in vitro (Kato et al., 2006) and 
single stranded viral genomes expressing 5’-phosphates and secondary 
structure in vivo (Pichlmair et al., 2006; Rehwinkel et al., 2010).  Following 
binding of RNA, RIG-I induces IFNβ expression via IPS-1 and IRF3 (Mibayashi 
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et al., 2007).  The influenza virus protein NS1 has been shown to play a role in 
inhibition of the IFNβ response to viral RNA, not by sequestering of viral RNA 
as previously proposed, but by binding to RIG-I and inhibiting activation of 
downstream transcription factors (Mibayashi et al., 2007; Pichlmair et al., 
2006; Talon et al., 2000).   
 
Although both TLR and RIG-I pathways independently induce antiviral 
cytokine responses, only partial redundancy exists.  Functional signalling via 





Induction of IL-1β and IL-18 following influenza virus infection is an important 
aspect of the immune response and occurs through activation of the 
inflammasome (Figure 1.2).  Following activation by a two signal mechanism 
(Pang & Iwasaki, 2011), this cytoplasmic complex of proteins functions to 
activate caspase 1 which in turn cleaves pro-IL-1β and pro-IL-18 to their active 
forms (Stasakova et al., 2005).  Although some authors have indicated that 
genomic influenza virus RNA is sufficient for inflammasome activation, 
implicating TLR signalling as signal 1 (Thomas et al., 2009), others have shown 
that a second signal in the form of lysosome products and reactive oxygen 
species are also vital (Allen et al., 2009).  The function of the M2 ion channel 
protein has also been implicated as signal 2 (Pang & Iwasaki, 2011).  Mice 
genetically deficient in inflammasome components NOD-like receptor protein 3, 
its adaptor molecule ASC, or caspase 1 are unable to activate IL-1β or IL-18, 
resulting in increased morbidity associated with impaired neutrophil and 
monocyte recruitment (Allen et al., 2009; Thomas et al., 2009), with another 
group indicating impaired T cell responses (Ichinohe et al., 2009).  
Emphasising the importance of inflammasome activation in the antiviral 
response, the RNA binding properties of the NS1 protein interferes with 
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inflammasome activation of caspase 1, resulting in impaired IL-1β and IL-18 
responses (Stasakova et al., 2005).   
 
1.6.4 Mx Protein 
 
The anti-viral protein Mx1, which is nuclear in mice but cytoplasmic in 
humans and known as MxA, may play a key role in protection from influenza 
viruses.  Initially identified as a gene product that imbued a strain of 
laboratory mice with resistance to lethal influenza virus infection (reviewed by 
Haller et al., 2007), transfection of this protein into Mx1-/- mice conferred 
resistance to influenza virus infection, even in the absence of IFNs (Staeheli et 
al., 1986).  It now appears that this IFN-induced protein may target the viral 
nuclear protein, and by means as yet still unclear, interfere with viral RNA 
transcription (Dittmann et al., 2008).  Furthermore, Dittmann and colleagues 
demonstrated that Mx confers protection in a strain dependent manner, with 
avian influenza viruses showing greater susceptibility to the inhibitory effects 
of this protein than those of human origin.  Of interest was the finding that the 
highly pathogenic H5N1 virus was susceptible to the actions of the human Mx 
protein, while the 1918 H1N1 influenza virus was almost completely resistant 
(Dittmann et al., 2008).  This suggests a possible role for Mx in protection from 
avian influenza viruses and may offer further insight into the inability of H5N1 
to efficiently transmit within the human population. 
 
1.6.5 PKR and OAS 
 
Following initiation of the IFN response, two further cytoplasmic proteins are 
known to play a role in antiviral defence.  PKR, a serine-threonine kinase, 
inhibits viral protein synthesis by phosphorylating the transcription initiation 
factor eIF-2 (Murphy et al., 2008).  PKR function is inhibited by NS1, allowing 
the virus to replicate effectively within the IFN competent cell (Bergmann et al., 
2000; Li et al., 2006; Min et al., 2007).  
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Similarly to PKR, OAS is expressed following IFN stimulation.  This protein 
functions to activate RNAse L which degrades viral RNA, destroying the virus 
(Murphy et al., 2008).  However, the presence of NS1 protein once again 
counteracts this cellular defence mechanism.  NS1 binding of viral RNA has 
been shown to be vital for inhibiting RNAse L activity and protecting the viral 
genome from degradation (Min & Krug, 2006). 
 
Despite the many fold roles of the NS1 protein in protecting the virus from host 
cell defences, the virulence of a particular strain is closely related to its ability 
to dysregulate the ensuing immune response following infection.  
 
 
1.7 Dysregulation of the Host Immune System 
 
1.7.1 Cytokine Responses 
 
Infection with influenza A virus leads to increased production of 
proinflammatory cytokines, an immediate result of the host IFN response to 
generate an antiviral microenvironment and limit viral replication.  The 
infection is usually cleared within a few days and the respiratory tract recovers 
from inflammation.  However, viruses such as H5N1 (Chan et al., 2005; 
Cheung et al., 2002) and the 1918 H1N1 (Kobasa et al., 2004) induce dramatic 
increases in proinflammatory cytokines from epithelial and immune cells, 
leading to debilitating and often irreversible pathology in the lung.  In addition 
to the elevated levels of cytokines observed, H5N1 also appears to be resistant 
to the effects of these (Seo et al., 2002). 
 
H5N1 has been shown to induce elevated levels of many proinflammatory 
cytokines as well as chemoattractants (), and is a more potent inducer of these 
cytokines than other human influenza viruses (Cheung et al., 2002).  However, 
this is not a feature exclusive to the H5N1 viruses.  Experimental infection of 
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mice with the H1N1 strain PR8 results in severe disease characterised by 
excessive inflammatory infiltration into the lungs, coupled with uncontrolled 
expression of cytokines such as IL-1, IL-6, TNFα and IFNγ (Hennet et al., 1992).  
The temporally distinct cellular infiltration and cytokine expression observed 
provide early evidence of what is now thought of as a ‘cytokine storm’ following 
infection with highly pathogenic strains of influenza virus, such as H5N1 
(Chan et al., 2005; Cheung et al., 2002).  Furthermore, patients succumbing to 
fatal H5N1 infection demonstrated more extreme cytokinaemia than those who 
survived (de Jong et al., 2006). 
 
Production of TNFα by infected respiratory epithelial cells and alveolar 
macrophages is an early response to viral infection.  This activates 
macrophages to produce IFNβ, further TNFα, chemoattractants MIP-1α/β, 
MCP-1 and RANTES, as well as inducing chemokine expression from epithelial 
cells (Herold et al., 2006).  In turn, this leads to influx of inflammatory cells 
such as neutrophils as well as B and T cells.  The ability of highly pathogenic 
influenza viruses to induce high levels of cytokine production exacerbates the 
inflammatory response to infection leading to uncontrolled inflammation and 
immunopathology. 
 
1.7.2 B and T Cell Response 
 
CD8+ T cells are important mediators of viral clearance, although depletion of 
this subset does not impair clearance (Eichelberger et al., 1991) indicating that 
other mechanisms such as antibody mediated clearance can compensate for 
the absence of these cells (Scherle et al., 1992).  Clearance appears to be 
dependent on the presence of TH1 CD4+ T cells (Graham et al., 1994; Moran et 
al., 1999), as depletion of both T cell subsets results in excessive viral load and 
death (Eichelberger et al., 1991; Scherle et al., 1992).  B cell production of 
neutralising IgG isotypes has been shown to confer protection against 
influenza driven immunopathology in the lung (Palladino et al., 1995) while IgA 
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Table 1.3  Cytokines induced during influenza virus infection. 
Highly pathogenic influenza virus infection results in upregulation of cytokines and hemokines from 
immune and epithelial cells. 
Cytokine Role Sources 
TNFα Mediator of inflammatory response 
Induces cytokine production from various cells 
Activated mφ & lymphocytes 
IFNα/β Antiviral, inhibits cell proliferation 
Regulates MHC I expression 
Lymphocytes, mφ & epithelial cells 
IL-1β Acts on lymphocytes & monocytes 
Induces fever & other acute responses 
Many including lymphocytes, mφ & 
NK cells 
IL-4 Alternatively activates mφ 
Induces IgG, IgE & class switching  
T lymphocytes 
IL-6 Stimulates antibody production 
Regulates inflammatory responses 
T lymphocytes & monocytes 
IL-10 Inhibits proinflammatory cytokine production Mφ & lymphocytes 
IL-12 Induces IFNγ from T & NK cells Activated mφ, monocytes & B 
lymphocytes 
RANTES Attracts lymphocytes T lymphocytes & mφ 
MIP-1α/β Attracts lymphocytes Lymphocytes, mφ & neutrophils 
MCP-1 Attracts and activates monocytes Monocytes & T lymphocytes 
IP-10 Attracts Th1 lymphocytes & monocytes Monocytes & T lymphocytes 
TRAIL Induces apoptosis in tumour cells Mφ & lymphocytes 
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facilitates protection in the upper respiratory tract (Renegar et al., 2004). 
 
Neutralising antibodies have been isolated from H5N1 survivors, passive 
immunisation with which resulted in lower viral titres in the lungs of infected 
mice (Simmons et al., 2007), while vaccination of mice with a mild H5N1 plus 
alum led to cross reactive protective antibody response to challenge with a 
lethal H5N1 strain (Lu et al., 1999).  Furthermore, immunisation with plasmid-
expressed HA from the 1918 H1N1 virus resulted in potent B and T cell 
responses, while T cell depletion studies indicated that protection was antibody 
mediated (Kong et al., 2006). 
 
Although H5N1 viruses have demonstrated the ability to induce apoptosis in 
immune cells, this appears to be specific to the pathogenic group one viruses.  
Tumpey and colleagues showed that infection with reassortant group one 
H5N1 led to depletion of circulating lymphocytes by 80%, as well as fewer T 
cells in the lung, compared with group two viruses.  This was due in part to 
lower levels of chemokine MIP-1α and increased apoptosis in the lung and 
spleen (Tumpey et al., 2000).   
 
It has been suggested that a frustrated CD8+ T cell response may contribute to 
the cytokine storm observed during infection (reviewed by La Gruta et al., 
2007; Moskophidis & Kioussis, 1998).  When virus titres are low, CTL function 
effectively to clear the infection.  However, when titres are elevated, the CTL 
response struggles to function properly, resulting in more and more cytokines 
being produced, while very little virus is cleared. This further exacerbates the 
inflammation in the lung.  The speed of viral replication has also been 
implicated in dysregulation of the T cell response to influenza virus.  It has 
been suggested that rapid replication induces high levels of IL-12p40, which in 
turn upregulates FasL on dendritic cells in the lymph nodes.  This results in 
Fas:FasL mediated apoptosis of T cells circulating through the lymph node and 
subsequent depletion of CTL following highly pathogenic, or high dose virus 
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infection.  Lower doses of virus, or slower replication fails to induce this 
dramatic increase in FasL and therefore an efficient CTL response is mounted 
(Legge & Braciale, 2005).  This is further implied, as infection with a high dose 
of PR8 results in influx of monocytes and neutrophils but decreased T cell 
derived IL-10 (Sun et al., 2009). 
 
1.7.3 Macrophages and Apoptosis 
 
Macrophages have been shown to be both essential to clearance of influenza 
virus but also to contribute to immunopathology in the lung.  Inhibition of 
macrophage recruitment either by disruption of the CCR2 gene or 
pharmaceutical antagonism of this receptor resulted in ameliorated pathology 
and improved survival following infection with PR8 virus (Herold et al., 2008; 
Lin et al., 2011).  However, others have shown that alveolar macrophages are 
essential for limiting disease severity following infection with the low 
pathogenic strain of influenza virus BJx109 (Tate et al., 2010c). 
 
Macrophages are known to absorb virus to their surface and release it to infect 
neighbouring cells (Wells et al., 1978) as well as to phagocytose virions, but it 
appears unlikely that macrophages become productively infected (Rodgers & 
Mims, 1981).   The ability of influenza virus to infect macrophages appears to 
be strain dependent, resulting in differential cytokine production and related 
immunopathology (Reading et al., 2010).  Reading and colleagues have 
indicated that the ability of the two closely related viruses PR8 and BJx109 to 
cause such different severity of disease is a direct result of the ability to infect 
macrophages (Reading et al., 2010).  BJx109 efficiently infects murine 
macrophages and therefore is readily internalised into the cell where it 
undergoes abortive infection, essentially limiting the amount of free virus 
available to cause infection and damage to the lung epithelium (Tate et al., 
2010b).  Conversely, PR8 poorly infects macrophages, allowing free virus to 
infect epithelial cells, resulting in a more severe disease (Tate et al., 2010c).  
This has been attributed to the glycosylation pattern and also the SA 
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preference of the virus, with PR8 being poorly glycosylated and binding 
preferentially to α2,3SA, while BJx109 has several glycosylation sites on the 
HA and NA proteins and a preference for α2,6SA (Tate et al., 2010a; Tate et al., 
2010c).  This means that BJx109, but not PR8, efficiently binds to SA and 
lectin domains of receptors such as the macrophage mannose receptor 
(CD206) (Upham et al., 2010), facilitating efficient uptake into the endosomal 
compartment in macrophages.   
 
In addition to the ability of H5N1 viruses to induce higher cytokine production 
from macrophages than do other human influenza A viruses, these viruses 
appear to actively replicate within human macrophages (Cheung et al., 2002; 
Mok et al., 2007; Perrone et al., 2008).  Infection with H5N1 has also been 
observed to delay apoptosis of infected cells (Mok et al., 2007), perhaps as a 
means of allowing a longer window for viral replication.  However, this is in 
contention with reports that suggest H5N1 effectively induces apoptosis in 
immune cells (Tumpey et al., 2000).  
  
Virus-induced TRAIL expression from macrophages has been implicated in 
enhanced pathology and damage to epithelial cells following infection with 
highly pathogenic influenza but not milder strains (Herold et al., 2008). Zhou 
and colleagues also showed that increased expression of TRAIL from 
macrophages leads to apoptosis of Jurkat T cells, suggesting the possibility of 
TNFα regulated apoptosis in functional T cells in vivo via macrophage 
produced TRAIL (Zhou et al., 2006).  This study also showed that human H1N1 
was more efficient at inducing apoptosis of T cells than the avian virus, 
suggesting that although apoptosis may be a mechanism by which H5N1 
ultimately affects the immune system, it is delayed in comparison with human 
viruses. 
 
Production of RANTES (CCL5) by macrophages has been shown to protect 
these cells from apoptosis as CCL5-/- mice showed decreased viral clearance 
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alongside increased macrophage apoptosis, despite demonstrating functional 
lymphocyte recruitment (Tyner et al., 2005).  This indicates that macrophages 








Macrophages, dendritic cells and neutrophils all derive from the same 
progenitor cell in the bone marrow, with this common monoblast 
differentiating into a monocyte which enters the circulation and finally 
migrates into tissues to become a resident macrophage (van Furth & Cohn, 
1968).  Monocytes strongly express adhesion molecules on their surface, which 
facilitate extravasation into the tissues.  α integrins CD11b and CD11c interact 
with the β integrin CD18 to form adhesion molecules.  These integrins bind to 
members of the intercellular adhesion molecule (ICAM) family expressed on 
endothelial cells, among others, enabling the macrophage to adhere to the 
endothelial layer and exit the blood stream (Dustin et al., 1986; Rothlein et al., 
1986).  
 
Macrophages are responsive to various growth factors in vivo that influence 
differentiation and survival of this cell type.  M-CSF (Stanley et al., 1978) and 
IL-34 (Lin et al., 2008) stimulate proliferation and survival of macrophages 
through interactions with the M-CSF receptor, CSF-1R, although they are 
thought to bind to differing regions (Garceau et al., 2010).  GM-CSF gives rise 
to granulocytes as well as macrophages, and acts through a distinct receptor 
which shares its β chain with the IL-3 receptor (Kitamura et al., 1991).  
Interestingly, some populations of tissue macrophages, such as alveolar 
macrophages are dependent on GM-CSF for function, but not for 
differentiation and survival (Paine et al., 2001).  Further to the requirement for 
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M-CSF to support survival and proliferation of macrophages, at concentrations 
that promote maximal proliferation, macrophages actively degrade M-CSF, 
limiting the proliferative capacity of  this growth factor by removing it from the 
microenvironment (Tushinski et al., 1982).  M-CSF has also been shown to be 
proinflammatory in vitro, priming responses to LPS, while suppressing the 
response to other TLR ligands such as CpG (Sweet et al., 2002).  Conversely, 
other studies have demonstrated outgrowth of an IL-12lowIL-10high regulatory 
type macrophage in the presence of M-CSF, while GM-CSF resulted in classical 
IL-12high macrophages (Fleetwood et al., 2007). 
   
1.8.2 Role in Immune System 
 
Macrophages are highly efficient professional phagocytes and antigen 
presenting cells.  They detect, engulf, degrade and present microbial antigen to 
cells of the adaptive immunity.  They have enormous phagocytic capacity and 
play a vital role in clearance of debris during infection and homeostasis.  
Differentiation between apoptotic cell turnover and clearance of infection is 
vital to prevent inappropriate inflammatory responses.  Phagocytosis occurs by 
attachment of a particle to the macrophage via a range of receptors, followed 
by internalisation and degradation through sequential endosomes.  Phagocytic 
receptors include complement receptors (CR), Fc receptors (FcR), mannose 
receptors CD206 and DC-SIGN, CD14, scavenger receptor A (SR-A) in the 
mouse, and SR-A and B in man (Aderem & Underhill, 1999).  The receptor(s) 
involved in internalisation dictate the inflammatory response to phagocytosis.  
Ligation of FcR, for example, leads to release of TNFα, while CR-mediated 
phagocytosis does not (Stein & Gordon, 1991; Wright & Silverstein, 1983).  
However, more recently, macrophages undergoing FcγR ligation have been 
demonstrated to direct TH2 polarisation of the immune response, dependent on 
macrophage derived IL-10 (Anderson & Mosser, 2002).  Recognition of 
mannosylated moieties by CD206 results in production of proinflammatory 
cytokines including TNFα and IL-12 (Garner et al., 1994; Shibata et al., 1997; 
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Yamamoto et al., 1997), while uptake of apoptotic cells via CD14 (Devitt et al., 
1998) actively inhibits release of LPS-induced inflammatory mediators from 
macrophages (Fadok et al., 1998; Meagher et al., 1992).  This discrimination 
allows clearance of apoptotic cells without further induction of inflammatory 
mediators, allowing resolution of inflammation and preventing inappropriate 
tissue damage. 
 
Macrophages are a vital component of the innate immunity, being one of the 
first defences encountered by invading pathogens.  Early detection of infection 
by macrophages results in rapid release of cytokines, driving the adaptive 
immunity into polarised responses.  Although initially thought to be poor 
antigen presenting cells relative to dendritic cells, there is much evidence to 
suggest the contrary.  In recent years the distinctions between macrophages 
and dendritic cells have become blurred, with both cell types performing 
overlapping roles and expressing the same surface markers (reviewed by 
Hume, 2008).  Macrophages have demonstrated the ability to present both 
endogenous and exogenous antigen in association with MHC I and MHC II 
respectively to CD4+ and CD8+ T cells during primary responses (Desmedt et 
al., 1998; Pozzi et al., 2005).  In addition to this, macrophages possess the 
ability to cross present antigen to T cells; following uptake of exogenous 
antigen which by the normal pathway would be presented in complex with 
MHC II, macrophages can process and present this in complex with MHC I 
molecules, thereby presenting exogenous antigen directly to CD8+ cells 
(Kovacsovics-Bankowski et al., 1993; Kovacsovics-Bankowski & Rock, 1994). 
 
Further to their capacity to stimulate T cells following antigen capture, 
macrophages appear to be capable of priming B cell responses by capturing 
and presenting native protein to B cells migrating through the subcapsular 
sinus (reviewed by Martinez-Pomares & Gordon, 2007).  The macrophage 
surface marker sialoadhesin can bind to the soluble form of the mannose 
receptor CD206, which in turn binds the mannosylated moieties on the surface 
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of pathogens (Junt et al., 2007; Martinez-Pomares et al., 1999).  This allows 
macrophages to catch lymph-borne particulate antigen and present it to 
passing B cells, which slow their passage through the subcapsular sinus and 
form prolonged interactions with macrophages as they proceed deeper into the 
follicle (Carrasco & Batista, 2007). 
 
Although initially thought to drive TH1 responses due to their efficient 
production of IL-12, macrophages are now known to demonstrate a much more 
complex spectrum of activation phenotypes, resulting in priming of a range of 
immune responses (Figure 1.4).  
 
1.8.3 Classical Activation 
 
Macrophages have long been known to become activated and increase their 
anti-microbial capacity and cytokine output following stimulation with IFNγ 
and LPS or TNFα.  Proinflammatory ‘classically’ activated macrophages 
produce an array of cytokines and inflammatory mediators including IFNγ, IL-
12, TNFα, IL-1β and nitric oxide, which mount a rapid assault on intracellular 
pathogens and prime T cells for a TH1 response (Edwards et al., 2006; Nathan 
et al., 1983).  This activation state therefore contributes to type 1 
inflammation, characterised by IL-12, IFNγ, TNFα and neutrophilia. 
 
It was originally postulated that two activating signals are required by the 
macrophage to become classically activated.  These are usually IFNγ and TNFα. 
IFNγ is derived from either CD4+ T helper cells, natural killer cells, or in an 
autocrine manner from macrophages themselves in response to pathogen 
(Fultz et al., 1993), while TNFα is induced by TLR ligands such as LPS, and 
then co-operates with IFNγ to amplify the classical response.  However, some 
TLR ligands are capable of inducing IFNβ which, in the presence of TNFα, can 
substitute for IFNγ signalling to induce classical activation of macrophages 
(reviewed by Mosser & Edwards, 2008). 
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Figure 1.4  Macrophages influence development of T cell subsets 
Macrophages activated by differing stimuli influence the development of TH1 or TH2 T cells, which in 
turn further promote outgrowth of classical or alternatively activated macrophages. 
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Classical activation results in production of proinflammatory cytokines, 
polarisation of CD4+ T cells into TH1 cells leading to activation of CTLs, and 
recruitment of neutrophils and macrophages to the site of infection.  Inducible 
nitric oxide synthetase (iNOS) and IL-12 production are hallmark 
characteristics of classical activation, providing protection against intracellular 
pathogens such as Leishmania, Listeria and Mycobacteria spp.  Generation of 
nitric oxide by classically activated macrophages following infection plays such 
a vital role in protection, that iNOS-/- animals demonstrate reduced survival 
following infection with such pathogens (MacMicking et al., 1997; Wei et al., 
1995), while pharmaceutical inhibition of iNOS results in exacerbated disease 
in many infections ranging from intracellular bacteria and fungal infections to 
extracellular helminthic parasites (reviewed by MacMicking et al., 1997).  
Furthermore, iNOS and nitric oxide have been shown to inhibit replication by 
coxsackie, vaccinia, ectromelia and herpes simplex viruses (Croen, 1993; 
Karupiah et al., 1993; Zaragoza et al., 1997).  However, iNOS has been 
implicated in pathological developments in neurological disease such as Borna 
disease and rabies viruses, as well as experimental herpes simplex virus 
encephalitis (Akaike et al., 1996; Fujii et al., 1999; Koprowski et al., 1993; 
Zheng et al., 1993). Similarly, iNOS contributes to the pathogenesis of 
influenza virus, with ameliorated disease severity demonstrable following 
inhibition of iNOS metabolism or production (Aldridge et al., 2009; Karupiah et 
al., 1998).  
 
This highlights an important aspect of classical macrophage activation.  Such 
efficient antimicrobial killing must be tightly controlled to prevent excessive 
inflammation and tissue damage.  IL-10 is upregulated following the 
respiratory burst induced by LPS stimulation of macrophages (Chang et al., 
2007; Wanidworanun & Strober, 1993), resulting in a decrease in 
proinflammatory cytokine production, as well as inhibiting its own expression 
by induction of the suppressor of cytokine signalling protein, SOCS3 (O'Shea & 
Murray, 2008). 
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1.8.4 Alternative Activation 
 
Many studies have demonstrated that inbred strains of mice demonstrate TH1 
or TH2 skewing of their immune responses, a system which has been used to 
dissect the roles played by these polarised T cell subsets in infection 
(Buchmuller-Rouiller & Mauel, 1986; Heinzel et al., 1989; Mosmann et al., 
1986; Schijns et al., 1994; Watanabe et al., 2004).  Similarly, these inbred mice 
also demonstrate differential macrophage activation, with the TH1 C57Bl/6 
mouse demonstrating classical macrophages, while the TH2 BALB/c mouse 
shows an alternative macrophage phenotype (Mills et al., 2000; Pradel et al., 
2009). 
   
The initial ‘alternatively’ activated macrophage was demonstrated in response 
to IL-4 stimulation (Stein et al., 1992), which resulted in upregulation of 
CD206, while incubation with IFNγ downregulated this marker.  Subsequently, 
alternatively activated macrophages have been indentified following infection 
with parasitic worms (Anthony et al., 2006; Chakkalath & Titus, 1994; Herbert 
et al., 2004; Loke et al., 2002), after sterile surgery (Loke et al., 2007) and 
during allergic airway inflammation and fibrosis (Hancock et al., 1998; Kim et 
al., 2008; Liu et al., 2004; Prasse et al., 2007), indicating a role in type 2 
inflammation, characterised by eosinophilia and expression of TH2 cytokines 
IL-4, IL-5 and IL-13.   
 
Originally thought of as a linear polarisation, with classical and alternatively 
activated macrophages opposing each other, it is now apparent that a 
spectrum of macrophage activation states exists (reviewed by Mosser & 
Edwards, 2008).  Differences within the ‘alternatively’ activated population 
have been identified depending on the stimulus given.  IL-4 and IL-13 share a 
common receptor chain, IL-4Rα (Hilton et al., 1996), and induce alternative 
activation by signalling through this receptor (reviewed by Gordon, 2003).  
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Other activation groups are apparent following exposure to IL-5, IL-10 and 
immune complexes (Edwards et al., 2006; Gerber & Mosser, 2001; Mantovani 
et al., 2004; Stumpo et al., 2003).  Macrophages activated with these stimuli 
are distinct from the prototypical classical macrophage, but are also distinct 
from one another, albeit with partially overlapping characteristics.  This is 
exemplified by the range of genes induced following macrophage activation, 
with 75% of the genes induced by IL-10 being distinct from those upregulated 
by IFNγ stimulation.  57% of the IL-10 induced genes are also shared by IL-5 
activation.  However, only 18% of upregulated genes are common to both IL-10 
and IL-4 activation, demonstrating the stimulus dependent diversity within the 
‘alternatively activated’ macrophage (Stumpo et al., 2003).  Thus, non classical 
macrophages have now been further divided into groups which represent 
immunoregulatory and tissue remodelling effector macrophages (Edwards et 
al., 2006; Mantovani et al., 2004).  Expression of IL-10 and IL-12 has been 
used to distinguish between these groups of macrophages.  Classically 
activated macrophages are generally IL-12high IL-10low, while regulatory 
macrophages express more IL-10 than IL-12.  True alternatively activated 
macrophages are those activated with IL-4, and are strong producers of 
arginase, while classically activated macrophages predominantly express iNOS 
over arginase (Edwards et al., 2006).   
 
Furthermore, newly characterised cytokines are being ascribed roles in various 
aspects of alternative activation, most notably IL-21 and IL-33. IL-33 
synergises with IL-13 to induce IL-5 expression and enhance alternative 
activation and eosinophilia, thereby contributing to TH2 mediated airway 
inflammation (Kurowska-Stolarska et al., 2008; Kurowska-Stolarska et al., 
2009).  IL-21 is produced by TH2 cells and enhances alternative activation of 
macrophages by inducing expression of the shared IL-4 and IL-13 receptor 
chain while also downregulating expression of the soluble IL-13 decoy receptor, 
ultimately exacerbating fibrosis and granulomatous inflammation (Pesce et al., 
2006). 
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The defining characteristic of alternative activation is differential metabolism of 
L-arginine, which further underscores the role played by such macrophages in 
tissue remodelling and repair.  Alternatively activated macrophages produce 
arginase, leading to metabolism of L-arginine into proline and contributing to 
collagen deposition (Hesse et al., 2001), while classical macrophages produce 
nitric oxide by means of iNOS.  Although both enzymes may be induced by the 
same stimuli (Johann et al., 2007), arginase is capable of outcompeting iNOS 
for substrate (Gobert et al., 2004; Green et al., 1990; Johann et al., 2007). 
While poorly antimicrobial to intracellular pathogens due to lack of nitric oxide 
(Modolell et al., 1995), it has now been shown that alternatively activated 
macrophages are essential for protection against parasites.  However, this can 
be due to differing mechanisms.   
 
Infection with Leishmania major drives TH2 responses as a method of evading 
the host-protective inflammatory response.  iNOS mediates leishmaniacidal 
activity of macrophages during the obligate intracellular amastigote stage of 
leishmaniasis (Chakkalath & Titus, 1994; Liew et al., 1990).  Inhibition of 
iNOS, IL-12 or IFNγ results in fatal infection (Mattner et al., 1996; Stenger et 
al., 1996; Wei et al., 1995), while treatment of susceptible TH2 skewed strains 
of mice, such as BALB/c, with exogenous IFNγ renders them resistant to this 
parasite (Buchmuller-Rouiller & Mauel, 1986; Green et al., 1990).   
 
Schistosoma mansoni also induces alternative activation and TH2 type 
responses, yet these appear to be host protective.  Schistosoma are 
extracellular trematodes, which lay eggs in the gastro-intestinal tract and 
lining of the mesenteric veins resulting in granulomatous inflammation and 
fibrosis.  This pathology is TH2 mediated and induction of a TH1 response is 
beneficial in reducing granuloma size and associated pathology (Hesse et al., 
2001).  However, adopting a TH1 response to adult worms results in 
uncontrolled inflammation and failure to expel eggs from the gut (Herbert et 
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al., 2004).  Alternatively activated macrophages are vital in modulating the 
immune response during schistosomiasis (Herbert et al., 2004), with IL-10 
expression being key in balancing the excessive TH1 inflammatory response 
with the pathologic fibrosis induced by schistosome eggs (Hoffmann et al., 
2000).   
 
While the antiparasitic alternatively activated macrophages evidently 
contribute to fibrosis and tissue repair following the damage inflicted by 
parasite migration during various stages of the life cycle, alternatively activated 
macrophages have also been implicated in the pathogenesis of allergic asthma 
and chronic airway inflammation.  Alveolar macrophages have been thought of 
as a suppressive population, or at the very least quiescent in their ability to 
mount an inflammatory response to the constitutive barrage of inhaled 
particles.  Several studies have demonstrated the deleterious effect of alveolar 
macrophage depletion resulting in exacerbated disease severity, prolonged 
immune responses and inflammation (Broug-Holub et al., 1997; Tate et al., 
2010c; Thepen et al., 1989).  However, others have indicated that this cell 
population is essential in protection from pathogens by mounting an IFNγ 
response, inhibition of which leads to inappropriate type 2 inflammation 
(Pribul et al., 2008; Tang et al., 2001).  These discrepancies may be related to 
the complex nature of macrophage interactions with pathogens, as 
macrophages presenting antigen via the MHC pathway commonly stimulate 
TH1 responses (Anderson & Mosser, 2002; Tang et al., 2001), while those 
taking up opsonised particles and apoptotic cells by phagocytosis drive TH2 
responses (Anderson & Mosser, 2002; Johann et al., 2007).  
 
Allergic lung inflammation has been associated with excessive eosinophil 
infiltration and production of IL-4, IL-5, IL-13 and IgE.  This was originally 
thought of as a TH2 mediated phenomenon, due to the fact that SCID mice do 
not develop airway hyperresponsiveness (AHR) (Corry et al., 1996).  This was 
confirmed by the observation that the TH2 biased BALB/c mouse develops 
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AHR, while the prototype TH1 mouse C57Bl/6 is protected (Kearley et al., 
2009).  This paradigm is complicated, however, by the involvement of IFNγ.  
Some studies demonstrate protective effects of this cytokine by inducing a TH1 
environment and therefore ameliorating the excessive type 2 response (Kearley 
et al., 2009; Yoshida et al., 2002).  IFNγR-/- mice show prolonged TH2 cytokines 
and eosinophilia following sensitisation with ovalbumin (OVA), a well 
characterised experimental inducer of allergic type inflammation in the mouse, 
while wildtype animals demonstrate complete resolution of the condition at the 
same timepoint.  This indicates a role for IFNγ in clearance and resolution of 
eosinophil-mediated inflammation (Coyle et al., 1996).  Conversely, others have 
suggested that IFNγ may exacerbate acute airway inflammation (Koch et al., 
2006), leading to non-eosinophilic inflammation and tissue damage 
(Grattendick et al., 2002). 
 
In addition to the TH1/TH2 paradigm leading to lung inflammation, the more 
recently documented TH17 phenotype has been heavily implicated in allergic 
asthma, with alveolar macrophages identified as the main source of IL-17 
within the asthmatic lung (Song et al., 2008).  Dependent on TGFβ and IL-6, 
and in humans, IL-1β and IL-23 for development, the TH17 phenotype is 
proinflammatory with expression of IL-17 and IL-21, which further induce an 
inflammatory cascade of CXCL chemokines and contribute to cellular influx 
and pathogenic inflammation (Basso et al., 2009).   
 
Alternatively activated macrophages play a role in mediating AHR and chronic 
inflammation in the lung.  Atopic patients have demonstrated higher numbers 
of IL-10+ monocytes that readily differentiate into alternatively activated 
macrophages in vitro, in addition to elevated alternatively activated 
macrophages in fibrotic regions of the lung (Prasse et al., 2007).  Furthermore, 
IL-33 has been shown to be increased in human asthma patients and play a 
role in inducing quiescent alveolar macrophages into alternative activation.  In 
the mouse, IL-33 signalling enhances alternative activation of macrophages 
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and results in IL-5 mediated lung inflammation due to increased eosinophilia 
(Kurowska-Stolarska et al., 2009). 
 
In addition to environmental stimuli, viral infections have been implicated in 
triggering development of AHR.  Macrophages have been ascribed a potential 
role in this type of airway inflammation by means of prolonged activation of  
invariant NKT cells during low level persistence of the viral infection resulting 
in iNKT:macrophage interactions and chronic IL-13 and IL-13 receptor 
expression on the macrophage, ultimately resulting in excessive mucus 
production and AHR (Kim et al., 2008).   
 
However, alveolar macrophages pulsed with OVA and therefore functioning as 
APC, have been shown to successfully inhibit allergic airway inflammation by 
counteracting the TH2 response (Tang et al., 2001; Vissers et al., 2005).  Taken 
together, macrophages play a complex role in development and resolution of 
airway inflammation, with induction of alternative activation playing a 
predominantly pathogenic role, despite the tissue reparative potential of this 
macrophage subset. 
 
Regulatory macrophages have been observed following clearance of apoptotic 
neutrophils, which results in TGFβ production from these macrophages and 
suppression of inflammatory mediators (Fadok et al., 1998).  Regulatory 
macrophages strongly express IL-10, but require two stimulatory signals for 
this to occur.  Apoptotic cells (Johann et al., 2007), exposure to prostaglandins 
(Strassmann et al., 1994) or immune complexes (Lentsch et al., 1997) in 
isolation is not sufficient to induce a regulatory macrophage phenotype, but in 
conjunction with a TLR ligand, IL-10 expression is initiated (Edwards et al., 
2006; Gerber & Mosser, 2001).   
 
This regulatory phenotype is likely to be vital in the resolution of inflammation. 
Phagocytosis of inflammatory neutrophils results in induction of pro-fibrotic 
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arginase (Johann et al., 2007) and release of TGFβ and prostaglandin E, which 
are known to inhibit inflammatory mediators and induce IL-10 expression 
(Fadok et al., 1998; Strassmann et al., 1994).  iNOS mRNA is destabilised and 
degraded, inhibiting production of nitric oxide (Vodovotz et al., 1993), while 
TNFα expression is downregulated due to inhibition of the transcription factor 
NFκB by stabilisation of IκK (Lentsch et al., 1997), in addition to the IL-10 
mediated induction of SOCS3 and associated suppression of inflammatory 
cytokine expression (O'Shea & Murray, 2008).  Furthermore, ligation of 
macrophage FcγR has been shown to induce a switch from TH1 to TH2, 
inducing preferential IL-10 production over IL-12 from the macrophage (Gerber 
& Mosser, 2001; Lentsch et al., 1997).  This response is rapid following 
receptor binding of immune complexes, suggesting that a beneficial 
inflammatory response is generated during the early phase of infection to 
maximise pathogen killing, during which time the humoral response is 
mounted.  The presence of immune complexes at the site of infection results in 
ligation of the macrophage FcγR and downregulation of the inflammatory 
response. 
 
Despite the differing gene expression induced by the various alternative stimuli 
and the differing roles played by non-classical macrophages, drawing 
distinctions between subsets is difficult due to the plastic nature of these cells.  
Macrophages are known to alter their phenotype depending on stimuli and 
combinations thereof (Stout et al., 2005), indicating that macrophage 
activation is in fact a dynamic phenomenon, rather than a commitment to a 
particular phenotype.  Nomenclature within the literature has also been 
somewhat misleading as some authors use the term ‘alternatively activated’ to 
describe macrophages stimulated with any stimuli other than IFNγ, while 
others have specified this term to refer only to IL-4/-13 stimulated cells.  For 
the purposes of the study detailed herein, the term ‘alternatively activated 
macrophage’ shall refer to IL-4 stimulated cells only. 
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1.9 IFNγ Receptor Deficient Mice 
 
1.9.1 IFNγ  
 
Interferon gamma (IFNγ) is the prototype TH1 cytokine, involved in 
inflammatory responses, activation of both the innate and acquired immunity, 
and protection from invading pathogens.  Although originally thought to be 
produced by T and natural killer cells, IFNγ is now also known to be released 
by macrophages (Di Marzio et al., 1994; Fultz et al., 1993).  This has led to a 
‘kickstart’ mechanism for macrophage activation to be proposed, whereby 
autocrine IFNγ activates macrophages to produce IL-12 and further IFNγ which 
results in escalation of macrophage activation and drives TH1 development 
from naive CD4+ T cells (Frucht et al., 2001).  IFNγ also plays a role in 
preventing TH2 responses by inhibiting IL-4 production from CD4+ T cells, and 
by altering T cell responsiveness to IFNγ.  This cytokine has been shown to 
have anti-proliferative effects on TH2 polarised CD4+ T cells, resulting in 
outgrowth of the TH1 population (Gajewski & Fitch, 1988).  
 
The major role of IFNγ is to activate macrophages, which then secrete large 
quantities of IL-12 resulting in TH1 differentiation of T cells, but also 
demonstrate enhanced anti-microbial activity in the macrophage itself.  IFNγ 
stimulation primes macrophages for upregulation of many proinflammatory 
mediators including IL-12, IL-18, iNOS and IFNγ itself, following a second 
stimulus such as TLR ligands or TNFα (Drapier et al., 1988; Lorsbach et al., 
1993).  T cells respond by producing further proinflammatory cytokines in 
addition to enhanced expression of surface receptors for IL-12, complement, 
antibody and both classes of MHC molecules (reviewed by Schroder et al., 
2004).  SOCS 1 & 3 are induced by IFNγ and limit the IFNγ response even in 
the absence of infection, thereby limiting inflammation (Song & Shuai, 1998). 
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In addition to inducing inflammation and activating the immune response, 
IFNγ has direct antiviral properties.  Although the type I IFNs are the most 
potent inducers of the antiviral state via the signalling cascade involving STATs 
1 & 2 ultimately resulting in activation of Interferon stimulated response 
elements (ISRE) in the promoter regions of IFN stimulated genes (ISG), IFNγ 
induces many of the same antiviral genes such as PKR and OAS (reviewed by 
Boehm et al., 1997).   PKR contains both ISRE and gamma activated sequence 
(GAS) elements in the promoter region and is therefore directly induced by IFNγ 
(Tanaka & Samuel, 1994), while OAS is induced by an indirect mechanism.   
 
IFNγ signals through phosphorylation of STAT1 homodimers following ligation 
of the IFNγR, resulting in activation of GAS elements in the promoters of ISGs 
(reviewed by Boehm et al., 1997).  One of the genes most strongly induced by 
IFNγ is Interferon regulatory factor 1 (IRF1), which binds to ISRE thereby 
inducing ISGs following exposure to IFNγ, resulting in indirect induction of 
ISGs such as OAS (Coccia et al., 1995).  Furthermore, IRF1 is a potent 
enhancer of IFNβ expression (Pine, 1992) and so many of the antiviral effects of 
IFNγ are indirect due to upregulation of type I IFN expression.  However, IFNγ 
also upregulates expression of the p48 subunit of the type I IFN transcription 
factor, Interferon-stimulated gene factor 3 (ISGF3).  Interaction of p48 with 
STAT1 homodimers results in direct IFNγ induced activation of ISRE (Bluyssen 
et al., 1995).  Furthermore, IFNγ induced IRF1 has been shown to be vital to 
induction of iNOS (Kamijo et al., 1994), which in addition to induction of PKR 
and OAS, further contributes to the antiviral effects of IFNγ.   
 
Despite its role in mounting a protective response to infection, IFNγ has been 
implicated in the pathogenesis of autoimmune disease due to its 
proinflammatory nature.  However, some polymorphisms in the IFNγ gene may 
be beneficial as a dampened inflammatory response may occur.  Evidence of 
this was found by assessment of IFNγ gene sequences in centenarian men and 
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women, indicating that polymorphisms leading to low IFNγ production may be 
associated with longevity (Lio et al., 2002). 
 
1.9.2 The IFNγ Receptor 
 
Ubiquitously expressed on the surface of all cells except red blood cells (Farrar 
& Schreiber, 1993), the IFNγ receptor comprises a homodimeric IFNγRα 
subunit, which binds IFNγ and then interacts with the signalling subunit, 
IFNγRβ, also a homodimer.   IFNγRα binds and internalises ligand, activating 
the Jak-STAT pathway.  Binding of IFNγ to this subunit leads to 
phosphorylation of Jak1 and 2, which in turn allows activation of latent STAT1 
by the IFNγRα (reviewd by Schroder et al., 2004).  Nuclear translocation then 
occurs with the IFNγRα being transported to the nucleus along with bound 
IFNγ and STAT1, while IFNγRβ is recycled to the cell surface (Larkin et al., 
2000).  Older studies indicate that IFNγRα may also be recycled to an 
intracellular pool of receptor subunits, allowing constitutive repopulation of the 
plasma membrane with ligand-binding receptor (Celada & Schreiber, 1987). 
 
IFNγRβ has been demonstrated to play a role in TH1 polarisation.  Following 
exposure to IFNγ, CD4+ T cells downregulate expression of the IFNγRβ chain, 
and therefore become unresponsive to the IFNγ-induced block on proliferation, 
resulting in expansion of the TH1 population (Bach et al., 1995).  The β chain 
has also been implicated in cell survival, with cells expressing high levels of 
IFNγRβ undergoing apoptosis in response to IFNγ, due to rapid STAT1 
activation resulting in high levels of IRF-1.  Low level expressing cells, such as 
T cells, are protected as they undergo more gradual accumulation of IRF-1, 
which is insufficient to trigger apoptosis (Bernabei et al., 2001). 
 
IFNγRα has five potential N-linked glycosylation sites (Farrar & Schreiber, 
1993).  Disruption of this glycosylation by treatment with enzymes such as 
neuraminidase, which destroys SA, renders IFNγRα incapable of binding 
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ligand, suggesting that glycosylation is essential for maintaining receptor 
conformation (Fischer et al., 1990). 
 
1.9.3 IFNγ and IFNγR Deficiency 
 
Despite the seemingly critical role played by IFNγ in development of protective 
TH1 responses, disruption of either the IFNγ or the IFNγRα gene (referred to 
herein as IFNγR-/-) does not lead to overt immunodeficiency.  Although more 
susceptible to some intracellular infections, IFNγR-/- mice develop normally 
with similar expression of CD3, 4, 8, MHC I and II and also IgM to wildtype 
Sv129 animals (Huang et al., 1993).  However, lack of IFNγ signalling in mice 
predisposes the host to more severe disease following infection with Listeria 
monocytogenes (Szalay et al., 1996), pseudorabies (Schijns et al., 1994), 
vaccinia and lymphochoriomeningitis (LCMV) viruses (Huang et al., 1993).  The 
virological studies, however, documented normal CTL responses to viral 
infections but reduced IgG2a compared to wildtype Sv129 mice.  Survival 
following infection with a low pathogenic strain of influenza virus (HKx31, 
H3N2) was not different in IFNγR-/- mice than in wildtype, with similar viral 
titres, CTL and antibody responses being documented (Price et al., 2000).  It 
has been indicated that the cell type in which the IFNγ signalling deficiency 
occurs is important in determining response to infection.  Reconstitution of 
LCMV-infected irradiated IFNγR-/- mice with wildtype CTL did not result in 
protection, but wildtype mice given IFNγR-/- haematopoetic cells displayed 
milder disease (Henrichsen et al., 2005).  This study suggested that induction 
of an IFNγ-mediated antiviral response in the parenchyma was essential in 
order to allow efficient cellular protection, while CTL could function 
independently of IFNγ. 
 
The Sv129 strain of mice, from which IFNγR-/- animals were generated, is a TH1 
predisposed strain as these mice do not express IL-4 from splenocytes 
stimulated with concavalin A (Schijns et al., 1994).  It appears that in the 
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absence of IFNγ signalling, production of IL-12 results in inhibition of IL-4 
expression and allows maintenance of a functional TH1 response to infection 
(Bach et al., 1995; Mattner et al., 1996; Schijns et al., 1995; Swihart et al., 
1995).  However, other studies have documented increased TH2 cytokines in 
IFNγR-/- animals (Gangadharan et al., 2008) despite the presence of IL-12 
(Szalay et al., 1996).  Other cytokines, including IFNα/β can evidently 
compensate for some functions of IFNγ (Muller et al., 1994), but not for all, as 
IFNγR-/- fail to upregulate nitric oxide following stimulation with TNFα, IFNα/β 
or LPS (Kamijo et al., 1993).  IFNγR deficiency in humans has been associated 
with increased severity of mycobacterial and herpes virus infections in 
childhood (Dorman et al., 1999), while defective IFNγ signalling can result in 
reduced neutrophil recruitment (Davies et al., 1982).   
 
Taken together, these studies indicate that disruption of IFNγ signalling results 
in a functional T cell response, a functional antibody response but with altered 
isotype proportions, but an impaired innate response with decreased 
neutrophil mobility and poor nitric oxide production, ultimately impairing the 
immune response to intracellular pathogens. 
 
 




Influenza viruses infect macrophages, altering the cytokine profile and leading 
to enhanced inflammation with a concomitant increase in immunopathology.  
This project aims to investigate the hypothesis that alternative activation of 
macrophages overcomes this scenario by inducing an anti-inflammatory, TH2-
like environment, thereby reducing immunopathology and maintaining organ 
function. 
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1.10.2 Research Questions 
 
To address this hypothesis, several research questions must be answered, both 
in vitro and in vivo.  The following questions need to be explored in vitro before 
any in vivo work can be undertaken. 
What are the phenotypes of “alternative” and “classical” 
macrophages in our hands? 
Can alternatively activated macrophages sustain influenza 
virus infection? 
Once infected, can such macrophages maintain their alternative 
phenotype? 
 
Once these queries have been addressed, the following in vivo questions will be 
explored. 
Does skewing of the immune system away from TH1 using IFNγ 
receptor deficient mice lead to protection from 
immunopathology? 
What effect does skewing of the immune system have on viral 
load and disease progression? 
 
Investigation of these questions will lead to a better understanding of the 
immunopathological processes involved in influenza virus infection, which is of 
utmost importance in development of novel therapeutics to this disease. 
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2 Materials and Methods 
 
2.1 Animals and Macrophage Isolation 
 
2.1.1 Isolation of Bone Marrow for in vitro Culture 
 
6-8 week old mice of wild type 129SvEv (Sv129) and BALB/c backgrounds, 
IFNγ receptor deficient mice on the 129SvEv background (IFNγR-/-) and IL-4 
receptor deficient mice on the BALB/c background (IL-4R-/-) were culled for 
macrophage isolation.  Both IFNγR-/- and IL-4R-/- mice were congenic as for 
both strains, the target genes were disrupted in embryonic stem cells which 
were then implanted into 3.5 day blastocysts.  Chimeric males were 
intercrossed with wildtype females, resulting in heterozygous F1 offspring.  
These were then intercrossed to obtain IFNγR-/- Sv129 (Huang et al., 1993) or 
IL-4R-/- BALB/c animals (Noben-Trauth et al., 1997), therefore findings may be 
directly compared between wildtype and mutant strains of mice.  Littermate 
controls were not used as mutant mice were from distinct but congenic lines. 
Femurs were removed, cleaned and flushed through with cold Rosewell Park 
Memorial Institute 1640 medium (RPMI; Gibco) supplemented with 10% foetal 
calf serum (Invitrogen), using a 25 gauge needle (Microlance) and 10mL syringe 
(Terumo) to remove the bone marrow.  Bone marrow was then centrifuged at 
8000g, washed again in supplemented RPMI and resuspended in 40mL 
complete macrophage medium, as detailed in section 2.2.4. 
 
2.1.2 In vivo Infections 
 
6-8 week old female mice of the Sv129 and IFNγR-/- genotypes were infected 
intranasally with influenza virus A/WSN/33 at a dose of 1x104 plaque forming 
units (pfu) per mouse.  Mice were weighed daily and culled at days 2, 4, 6 and 
8.  Lungs were harvested for virus assay and histological analysis.  Small 
pieces of lung were harvested from the most distal point of the left lobe, 
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consistent between all animals and placed in RNAlater (Qiagen) for RNA 
extraction.  These pieces were initially stored at 4oC to allow the RNAlater 
solution to penetrate the tissue, followed by longer term storage at -80oC.  
Collecting tissue from this region of the lung meant that changes in cytokine 
expression influencing the whole lung could be detected, whereas taking 
samples from closer to centre of the lung could be heavily influenced by the 
local presence of infiltrating cells and give a false indication of the extent of 
cytokine production throughout the entire organ. 
 
 
2.2 Tissue Culture 
 
2.2.1 Madine-Darby Canine Kidney Cells 
 
Madine-Darby Canine Kidney (MDCK) cells were cultured in tissue culture 
flasks (Nunc) in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco) 
supplemented with 10% foetal calf serum (Invitrogen), 100U/mL penicillin and 
streptomycin (Gibco) and 1% L-glutamine (Gibco).  Cells were passaged every 
four days by incubation with trypsin (Gibco) for 20 minutes, centrifuged at 
8000g and reseeded in DMEM. 
 
2.2.2 RAW macrophages 
 
RAW 264.7 cells, a murine leukaemic macrophage cell line was cultured in 
RPMI supplemented with 10% foetal calf serum, 100U/mL penicillin and 
streptomycin and 1% L-glutamine.  Cells were loosely adherent and passaged 
every four days by gentle scraping, followed by reseeding in new flasks.   
 
RAW cells were infected with A/WSN/33 virus at a multiplicity of 1 and used 
as positive controls for the staining methods detailed in section 2.8. 
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2.2.3 L929 fibroblasts 
 
L929 fibroblasts were cultured in RPMI supplemented as described in section 
2.2.2.  Cells were passaged every four days until a total volume of 2L 
supernatant was achieved.  This was then collected and pooled followed by 
centrifugation at 8000g to remove cellular debris, and stored at -20oC in 20mL 
volumes as a source of M-CSF.  L929 cells and supernatants were also tested 
for mycoplasma using a PCR-ELISA detection kit (Roche), as these fibroblasts 
are known to produce IFNα/β when infected with mycoplasma.  Cells and 
supernatants were pelleted by centrifugation, followed by lysis of the pellet.  
After neutralisation of the lysis buffer, extracts and controls were incubated 
with the kit PCR mix and run on the following program: 5 minutes at 95oC, 
followed by 40 cycles of 30s at 94oC, 30s at 62oC, 1 minute at 72oC with a final 
10 minute step at 72oC.  10µL of the PCR product was denatured using the kit 
denaturation reagent before addition of hybridisation reagent, transfer to 
ELISA plates and incubation in the dark with gentle agitation for 3 hours at 
37oC.  Anti-digoxigenin conjugated to peroxidase was added to wells and 
incubated in the dark for a further 30 minutes at room temperature before 
addition of 3,3’,5,5’-tetramethylbenzidine (TMB) and a final incubation period 
of 20 minutes in the dark at room temperature.  A sulphuric acid stop solution 
was added and absorbance determined at 450nm.  Negative controls should 
give <0.25Abs, while positive controls should be >1.2Abs.  If samples were 
>0.2Abs after subtraction of the negative control, then samples were 
considered mycoplasma positive.  However, all samples gave final absorbance 
of <0.2Abs, and so were considered mycoplasma free. 
 
2.2.4 Bone Marrow Derived Macrophages 
 
Isolated bone marrow was cultured in 10mm square bacteriological dishes 
(Sterilin) for 7 days in complete macrophage media, which contained RPMI 
supplemented with 10% foetal calf serum (Invitrogen), 100U/mL penicillin and 
streptomycin (Gibco), 1% L-glutamine (Gibco) and 50% L929 supernatant.  
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Cultures were initially set up by seeding cells from one femur in each plate.  
Bone marrow derived macrophages (BMDMφ) were passaged on day four by the 
following method: incubation with Dulbecco’s Phosphate Buffered Saline (D-
PBS; Gibco) for 5 minutes followed by detaching from the plastic by washing 
vigorously with D-PBS using an 18 gauge needle (Microlance) and syringe 
(Terumo) and centrifugation at 8000g.  Cells from each plate were then 
reseeded into two new plates in complete macrophage medium supplemented 
with 5mL original medium.  On day 7, BMDMφ were activated with either 
4ng/mL IL-4, or 1ng/mL IFNγ (Peprotech) in complete macrophage medium.  
Activated BMDMφ were infected at 16 hours post activation (day 8) by 
incubation with A/WSN/33 virus at a multiplicity of infection of 10 for 1 hour.  
Following this, inoculum was removed, the activating medium returned to the 
plates and culture continued for either 16 hours, or 48 hours to allow multiple 
rounds of viral replication.  BMDMφ were detached from the plastic, washed 
and centrifuged into pellets of 5x106 cells and supernatant collected, then 
stored at -20oC for future analysis. 
 
 
2.3 Virological Techniques 
 
2.3.1 Influenza Virus Preparation 
 
The mouse adapted influenza A virus strain A/WSN/33 (a gift from Dr D. 
Jackson, University of St Andrews, UK) was cultured on a monolayer of MDCK 
cells for 36 hours at a multiplicity of infection of 0.001.  The supernatant was 
then harvested and centrifuged at 8000g before being aliquotted into volumes 
of 100µL, 500µL and 1mL and stored at -80oC for future use.  Virus titre was 
determined by plaque assay on MDCK cells. 
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2.3.2 Plaque Assay 
 
Ten fold serial dilutions of virus were made in serum free DMEM and 400µL of 
dilutions 1x10-3 to 1x10-8 were plated in duplicate onto confluent MDCK 
monolayers in 6 well plates (Nunc).  The plates were incubated at 37oC for 1 
hour, rocking every 10 minutes to prevent the cells drying out and ensure even 
spread of inoculum.  Virus was removed by aspiration after 1 hour and cells 
overlaid with 2% agarose (Bioline) in serum free DMEM containing 2µg/mL N-
acetyl trypsin (Sigma).  Once the agarose had set, plates were inverted and 
incubated at 37oC for 3 days.  Cells were then fixed with 10% neutral buffered 
formalin (Surgipath), agarose plugs removed and monolayers stained with 
toluene blue (Appendix 2.3 Recipes) to visualise plaques.  Plaques were 
counted at two dilutions and the average taken, the higher dilution being 
converted into the lower, giving the plaque count in 400µL of the chosen 
dilution.  This was then multiplied by 2.5 to give plaque count/mL and finally 
multiplied by the appropriate dilution factor to give final viral titre in pfu/mL. 
 
2.3.3 Haemagglutination Assay 
 
Two fold dilutions of BMDMφ supernatant were made and 25µL diluted 
supernatant was added to 25µL 1% human red blood cells (RBC) in round 
bottom 96 well plates. Plates were incubated at 4oC overnight to allow virus to 
agglutinate the RBC.  Presence of virus particles was detected by inhibition of 
RBC pellet formation in the bottom of the well.  Serially diluted virus stock and 
media alone were used as positive and negative controls respectively. 
 
 
2.4 Flow Cytometry 
 
0.5x106 BMDMφ were aliquotted in 100µL phosphate buffered saline 
supplemented with bovine serum albumin (PBSA; Appendix 2.3 Recipes).  
These cells were labelled with rat anti-mouse primary antibodies listed in Table 
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2.1, washed twice with PBSA then stained with a secondary goat anti-rat 
antibody labelled with Alexafluor 647 (Molecular Probes) at a dilution of 
1:4000.  Two further PBSA washes were performed and cells fixed in 200µL 4% 
paraformaldehyde (PFA; Appendix 2.3 Recipes) for 20 minutes before addition 
of 300µL PBSA for analysis.  
 
 
Antibody Dilution Cell type Supplier Clone Isotype 
CD11b Neat Macrophage In house 5C6 IgG2b 
F4/80 1:100 Macrophage AbD Serotec Cl:A3-1 IgG2b 
CD206 1:200 Macrophage AbD Serotec MR5D3 IgG2a 
Table 2.1  Flow cytometry antibodies. 
Antibody dilutions and target cells for flow cytometry analysis of bone marrow derived macrophages 
 
 
CD206 labelled BMDMφ required fixing and permeablisation of the cell 
membrane prior to labelling.  This was carried out by washing cells twice with 
PBSA,  fixing for 10 minutes with 4% PFA followed by permeablising with 0.1% 
saponin (Sigma) in PBSA for 10 minutes.  Primary antibody was then diluted in 
permeablisation buffer (Appendix 2.3 Recipes) and incubated with the cells for 
30 minutes on ice, followed by washing with PBSA and incubation with 
secondary antibody, again diluted in permeabilsation buffer.  Two final washes 
with PBSA were carried out before the cells were resuspended in 500µL PBSA 
for analysis. 
 
The labelled cells were then analysed on a FACSCalibur system using 
CellQuest software (BD Biosciences).  Further analysis was also carried out 
using FlowJo software (TreeStar). 
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2.5 Enzyme Linked Immunosorbent Assay 
 
IL-12p40 and TGFβ levels in BMDMφ supernatant and lung homogenates were 
analysed by Enzyme Linked Immunosorbent Assay (ELISA).  TGFβ is found in 
both latent and activated forms, requiring cleavage to become active.  For this 
ELISA, samples were not subjected to cleavage as the amount of active TGFβ 
present was under investigation, not the total amount being synthesised.  This 
allowed detection of the extent of bioactive TGFβ present following influenza 
virus infection.  96 well ELISA plates (Immunolon) were coated with the 
appropriate capture antibody (RnD Systems), diluted in PBSA, for 16 hours at 
25oC.  Plates were then washed twice with PBS containing 0.05% Tween20 
(National Diagnostics) and blocked with PBSA for 1 hour, followed by two 
further washes.  Samples were plated in duplicate and incubated for 2 hours 
at room temperature, followed by two further washes and addition of the 
biotinylated detection antibody (RnD Systems).  Plates were incubated for 2 
hours at room temperature and washed again before addition of streptavidin-
linked horseradish peroxidise (RnD Systems) for 20 minutes in the dark.  After 
three washes, TMB substrate solution (RnD Systems) diluted in 100mM 
sodium acetate, (Sigma) containing 2µL 30% hydrogen peroxide (Sigma), was 
added to the wells for 20 minutes in the dark.  Finally, the reaction was 
terminated using 2M sulphuric acid (BDH).  Absorbance was measured at 




2.6 Inducible Nitric Oxide Synthetase Bioassay 
 
Active inducible nitric oxide synthetase (iNOS) was investigated using the 
Greiss reagent bioassay, which results in production of nitrite and a colour 
change from colourless to pink in the presence of enzyme.  100µL Greiss 
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reagent (Appendix 2.3 Recipes) was added to 100µL BMDMφ supernatant or 
100µL sodium nitrite standard (Sigma) and absorbance read at 540nm. 
 
 
2.7 Arginase-1 Bioassay 
 
Bioactive Arginase-1 was measured in its ability to convert L-Arginine to urea 
as follows.  1x105 BMDMφ were plated onto 96 well flat bottomed plates (Nunc), 
washed with PBS and lysed with 0.1% Triton-X (Sigma).  The lysate was then 
removed to sterile eppendorfs.  After addition of 100µL 25mM Tris-HCl and 
20µL 10mM MnCl2, tubes were incubated at 56oC for 10 minutes.  100µL of 
each sample was transferred to fresh eppendorfs and incubated with 100µL 
0.5M L-Arginine for 2 hours.  During this time a standard dilution series of 
urea was made.  Following the incubation step, 800µL sulphuric/phosphoric 
acid solution (Appendix 2.3 Recipes) was added along with 40µL 
isonitropropiophenone, mixed by vortexing and incubated at 95oC for 30 
minutes.  Once cooled, samples and standards were plated in a 96 well plate 







1x105 infected BMDMφ were cultured on 8 well chamber slides (BD Falcon), 
medium aspirated and cells washed with PBS.  All incubations were performed 
for 30 minutes at room temperature, and antibodies were used at 
concentrations detailed in Table 2.2.  BMDMφ were fixed with 4% PFA before 
blocking with Cas block (Invitrogen).   Slides were incubated with polyclonal 
goat anti-influenza antibody (AbD Serotec; Table 2.2), or polyclonal sheep anti-
NS1 antibody (a gift from Dr. D. Jackson, University of St Andrews, UK) 
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followed by washing twice with PBS.  Rabbit anti-goat/sheep Alexafluor 488 
labelled secondary antibody (Molecular Probes), along with DAPI (Invitrogen) 
was added again followed by two wash steps.  The chamber portion of the slide 
was then removed, the slides mounted in mowiol (Appendix 2.3 Recipes) and 
sealed with nail polish.  Slides were stored in the dark at 4oC. 
 
 
Target Host Dilution Supplier Clone 
Influenza virus Goat 1:200 AbD Serotec Polyclonal 
NS1 Sheep 1:200 Dr D. Jackson Polyclonal 
Mouse F4/80 Rat 1:100 AbD Serotec A3-1 
Mouse Ly6G Rat 1:100 Biolegend 1A8 
Sheep/Goat IgG - Alexafluor 488 Rabbit 1:1000 Invitrogen Polyclonal 
Rat IgG - Alexafluor 594 Rabbit 1:1000 Invitrogen Polyclonal 
DAPI - 1:1000 - - 
Rat IgG - Horseradish peroxidase Goat 1:100 Invitrogen Polyclonal 
Table 2.2  Immunohistochemistry antibodies. 
Host and target species and dilutions of antibodies used for immunohistochemistry staining of 
sections and cells. 
 
 
2.8.2 Dual immunofluorescent stain 
 
Virus positive macrophages were detected by dual immunofluorescent staining 
for the macrophage marker F4/80 and influenza antigens.  Lungs were inflated 
and coated with OCT compound (VWR) and frozen rapidly in isopentane over 
dry ice.  Sections were prepared on coated slides and stored at -80oC.  
Incubations were performed for 30 minutes at room temperature, unless 
otherwise stated, and antibodies were used at the concentrations detailed in 
Table 2.2.  At time of staining, sections were fixed in acetone for 10 minutes, 
followed by washing briefly in PBS and blocking with Cas block.  Incubation 
with polyclonal goat anti-influenza antibody was followed by washing with PBS 
and addition of the second primary antibody, rat anti-F4/80 (AbD Serotec).  
Subsequently, sections were incubated with a cocktail of Alexafluor-linked 
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secondary antibodies (Table 2.2), allowing detection of both antigens and 
counterstain with DAPI to be performed in a single incubation.  Sections were 
then washed thoroughly and mounted with mowiol, sealed with nail polish and 




Paraffin wax embedded lung sections were stained for neutrophil marker Ly6G 
Biolegend), or virus antigens, followed by detection with DAB substrate.  
Briefly, sections were dewaxed in xylene (BDH) followed by rehydration in 
increasing concentrations of alcohol.   Slides were then placed in a sodium 
citrate antigen retrieval solution (Appendix 2.3 Recipes) and microwaved in a 
pressure cooker for 20 minutes to break crosslinking of antigens caused by the 
paraffin wax embedding process.   Slides were cooled in running tap water 
before being blocked with Cas block for 30 minutes and washed twice with TBS 
containing 0.05% Tween 20 (Appendix 2.3 Recipes).  Sections were incubated 
with primary goat anti-influenza, or rat anti-Ly6G (Biolegend) antibody (Table 
2.2) for 2 hours at room temperature, followed by two washes and blocking of 
endogenous peroxidases by incubation with H2O2:methanol (Appendix 2.3 
Recipes) for 5 minutes.  Species specific horseradish peroxidase labelled 
secondary antibody (AbD Serotec;Table 2.2) was added for 1 hour at room 
temperature followed by washing.   Sections were then incubated with 
diaminobenzidine substrate solution (DAB; Sigma) for 10 minutes followed by 
two further washing steps.  Slides were mounted in Vectamount (Vector) 
permanent mounting medium and stored at room temperature. 
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2.9 RNA Extraction 
 
2.9.1 RNA Extraction from BMDMφ 
 
RNA was extracted from cell samples using a RNeasy Mini Kit (Qiagen) as per 
the manufacturer’s instructions.  Briefly, pellets of 5x106 BMDMφ were 
disrupted by addition of 350µL RLT Buffer (lysis buffer, containing β-
mercaptoethanol) followed by addition of 350µL 70% ethanol.  The 
homogenised lysate was then mixed by pipetting, placed in a spin column and 
centrifuged at 8000g for 15 seconds.  700µL RW1 Buffer (first wash buffer) was 
then added to the column and centrifuged, followed by two washes of 500µL 
RPE (second wash buffer, containing ethanol).  30-50µL nuclease free water 
was then added directly to the membrane in the spin column and centrifuged 
at 8000g to elute RNA.  RNA concentration was determined using a 
spectrophotometer and quality of RNA estimated by running 2µL on a 1% 
agarose gel to visualise 18S and 28S ribosomal RNA bands. 
 
2.9.2 RNA Extraction from Whole Lungs 
 
Lung pieces in RNAlater were removed from -80oC and placed in sterile 
eppendorfs on dry ice.  100µL RLT buffer was added and lungs ground using a 
plastic pestle (Anachem) until completely homogenised.  600µL RLT buffer was 
added, the homogenate placed in a Qiashredder column (Qiagen) and 
centrifuged at 8000g for two minutes.  700µL 70% ethanol was added to the 
effluent from the Qiashredder and RNA extraction continued as described 
above. 
 
Chapter 2  Materials and Methods 
                                                                                                                                            
75 
 
2.10 DNase Treatment and Reverse Transcription 
 
1000 or 2000ng RNA was DNase treated with 1µL DNA-free (Ambion) plus 1µL 
buffer and incubated at 37oC for 30 minutes.  1µL inactivation reagent 
(Ambion) was then added and incubated at room temperature for two minutes 
before brief centrifugation to pellet the inactivation reagent.  Reverse 
transcription using the Superscript III system (Invitrogen) was then performed.  
DNase treated RNA was incubated at 65oC with 50ng random primers 
(Invitrogen) or 0.2µM oligodT (Ambion) and 0.5mM dNTPs (Roche) for five 
minutes followed by one minute on ice.  Superscipt III enzyme, 5x first strand 
buffer, DTT and RNaseOUT (all Invitrogen) were added and the following 
heating cycle performed: 25oC for five minutes; 50oC for 60mins; 70oC for 
15mins.  cDNA was stored at -20oC. 
 
 
2.11 Gene Cloning 
 
Primers were designed as listed in Table 2.3 using NetPrimer and Primer3 
software.  Specificity was confirmed by performing a search on NCBI 
Nucleotide BLAST. The genes detailed in Table 2.3 were amplified with a high 
fidelity DNA polymerase (Finnzyme) and cloned using a Zero Blunt II Topo PCR 
Cloning Kit (Invitrogen) and Beta 10 competent cells (New England Biolabs). 
Briefly, 1µL amplified product was incubated at room temperature with 1µL 
pCR Blunt II TOPO plasmid along with salt solution and water for 10 minutes.  
Following this, the plasmid/product mixture was added to a tube of Beta 10 
cells, mixed gently and incubated on ice for 10 minutes.  Heat shocking was 
carried out at 42oC for 30 seconds and the cells replaced on ice.  250µL SOC 
medium (Invitrogen) was added to the tube of cells and shaken for 1 hour at 
37oC.  Cells were then streaked onto kanamycin plates (Appendix 2.3 Recipes), 
incubated overnight and colonies picked for further analysis.  
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Several clones were also purchased from GeneService and are detailed in Table 
2.4. These were streaked onto plates containing appropriate antibiotic and 
single colonies picked for analysis. 
 
Cloned products were purified using a Miniprep DNA Purification Kit (Qiagen).  
Briefly, picked colonies were amplified in 5mL kanamycin or ampicillin 
medium (Appendix 2.3 Recipes) and incubated shaking overnight at 37oC.  
Amplified cultures were pelleted, supernatant removed and the pellet 
resuspended in Buffer P1 (resuspension buffer).  Cells were transferred to 
microfuge tubes where 250µL Buffer P2 (alkali lysis buffer) was added with 
gentle mixing, followed by addition of 350µL Buffer N3 (neutralisation buffer).  
Lysates were centrifuged at 12,000g for 10 minutes and supernatants applied 
to a QiaPrep spin column.  Columns were centrifuged, effluent discarded and 
column washed with Buffer PB (binding buffer).  Effluent was again discarded 
and a second wash step performed using Buffer PE (wash buffer), followed by 
further centrifugation to remove effluent and residual buffer.  Bound DNA was 
eluted by addition of 50µL water directly to the membrane of the column and 
spinning for one minute.Products were sequenced, linearised with restriction 
enzymes (Promega), listed in Table 2.4, or with HinDIII for all Blunt Topo 
plasmids, and used as template DNA for qPCR. 
 
Template DNA for the influenza A virus gene M1 was generated in the same 
manner by Mr Ian Bennet. 
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Gene Forward Reverse Region Accession No 
Arg-1 ggaacccagagagagcatga ggagaaaggacacaggttgc 87-547 NM_007482 
CD206 caccagagcccacaacaac ctggtggattgtcttgtgga 2003-2494 NM_008625 
CNX ttagttgaccagtctgttg cctttcatcccaatcttcag 694-803 L23865 
IL-10 gcttctattctaaggctggc ctgggggatgacagtagg 949-1148 NM_010548 
iNOS atgctaatgcgaaaggtca tttggtgtggtgtaggac       1744-2563 NM_010927 
SDHA gctcctactgatgaaacctg aactcaatcccttacagcaa 2017- 2189 NM_023281 
TNFa gggattatggctcagggtc ggctggctctgtgaggaagg 979-1277 NM_013693 
Table 2.3  Primers for cloning of genes of interest. 
Primers were designed using the freely available programs Primer3 and NetPrimer then checked for 





Gene Accession No Plasmid Linearised Antibiotic 
FIZZ BC029248 pCMV SPORT6 HinDIII Amp 
IL-1b BC011437 pCMV SPORT6 EcoRI Amp 
IL-6 BC132458 pCR Blunt TOPO HinDIII Kan/Amp 
IL-12p40 BC103608 pCR4-TOPO NotI Kan 
Table 2.4  Details of purchased clones. 
Clones were purchased from Gene Service Ltd and grown on plates containing antibiotic before 
pickingof individual colonies, overnight culture and DNA purification alongside in-house cloned 
products.  Amp, Ampicillin; Kan, Kanamycin. 
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2.12 Quantitative Polymerase Chain Reaction 
 
2.12.1 Generation of standard curves 
 
Standard curves were generated from the purified template DNA of each gene 
of interest by calculating the number of gene copies per µL (Equation 2.1) and 








2.12.2 Optimisation of reaction conditions 
 
Primers were designed for each gene of interest as previously described and are 
detailed in Table 2.5.  Reaction conditions for SybrGreen qPCR (SybrGreen, 
Biogene; PCR reagents, Roche) were optimised by first using a constant 
concentration of MgCl2 and altering the primer concentration.  Once optimal 
primer concentration had been established, MgCl2 concentration was titrated 
for each set of primers.  Annealing temperature was also altered based on the 
melt temperatures of the primers.  A trial standard curve was then performed 
to ensure that all conditions were successfully optimised.  This will be 
discussed fully in Chapter 3.  Reaction conditions for each gene of interest are 
detailed in Table 2.6. 
 
2.12.3 Analysis and Normalisation of Quantitative RT-PCR data 
 
Two housekeeping genes were used to normalise the genes of interest.  A panel 
of primers for 12 genes (Quantace) was tested, and will be discussed in 
Chapter 3.  The two genes with most stable expression were selected; calnexin 
(CNX) and succinate dehydrogenase A (SDHA).  Primers were designed, again 
Copies/µL = 6.02x1023 x concentration {g/µL}  
                          Total vector size {bp} x 660 
 
Equation 2.1  Calculation of gene copy number per µL cloned plasmid 
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using NetPrimer and Primer3 software (Table 2.5), product was amplified by 
high fidelity PCR, purified by Qiagen Miniprep, cloned as described in 2.11 and 
reaction conditions optimised. 
 
Relative expression of genes between samples and non activated controls was 
calculated using Genex software (MulitD Analyses), based on Equation 2.2, 
taking efficiency of the reaction and expression of housekeeping genes into 
consideration.  Relative expressions were then plotted using Prism Graphpad 
software (GraphPad Software) or R (R-project.org). 
 




     (1+ERef)
Ct Ref




     (1+ERef)
Ct Ref










2.13 Statistical Analysis 
 
Data is presented as mean ± standard error of the mean (SEM), or as box and 
whisker plots representing the median, 25th and 75th percentile, minimum and 
maximum values.  Outliers have been included in the statistical analysis and 
plotted as single points outwith the whiskers of the main data set.  Histograms 
were plotted using Prism 4.0 for Windows (GraphPad). Analysis of variance 
(ANOVA) was performed using the statistical package R (R-project.org), which 
was also used to display box and whisker plots.  Statistical significance was 
graded as * P<0.05, ** P<0.005, *** P<0.0005. 
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Gene Forward Reverse 
CNX tta gtt gac cag tct gtt g    cct ttc atc cca atc ttc ag 
SDHA gct cct act gat gaa acc tg aac tca atc cct tac agc aa 
Arg-1 ggc ctt tgt tga tgt ccc ta    atg ctt cca act gcc aga ct 
CD206 tga acc caa atg tcc aga aa ctc gta atc agc ctc caa atc 
FIZZ act ggg tgt gct tgt ggc ttt gcc t agc agg gta aat ggg caa ta 
IL-1b cga caa aat acc tgt ggc ct gag gca agg agg aaa aca ca 
IL-6 gta cca tag cta cct gga gt gga gag cat tgg aaa ttg g 
IL-10 ctt tgc tat ggt gtc ctt tca atc tcc ctg gtt tct ctt cc 
IL-12p40  gga agc acg gca gca gaa ta ttg agg gag aag tag gaa tgg 
iNOS  tgc tac tga gac agg gaa g gac agt ctc cat tcc caa 
TNFa cac cac cat caa gga ctc aa   gac aga ggc aac ctg acc ac   
Influenza M1 ctc tct atc gtc ccg tca gg gag cgt gaa cac aaa tcc ta 
Table 2.5  qPCR primers (All MWG Eurofins) 
 
Gene Forward Reverse MgCl Anneal 
CNX 400nm  400nm 3.0mM 62oC 
SDHA 400nm  400nm  2.5mM 62 oC 
Arg-1 400nm  400nm 3.0mM 62 oC 
CD206 400nm   400nm 3.0mM 62 oC 
FIZZ 400nm 400nm 2.5mM 66 oC 
IL-1β 300nm 300nm 2.5mM 62 oC 
IL-6 400nm 400nm 2.5mM 62 oC 
IL-10 500nm  500nm  2.5mM 62 oC 
IL-12p40  400nm 400nm 2.5mM 62 oC 
iNOS  400nm  500nm 3.0mM 62 oC 
TNFα 400nm  500nm  3.0mM 65 oC 
Influenza M1 400nm 500nm 2.5mM 62 oC 
Table 2.6  Optimised qPCR conditions 
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Appendix 2.1   Suppliers 
 
AbD Serotec MorphoSys UK Ltd, Endeavour house, 
Langford Business Park, Langford Lane, 
Kidlington, Oxford, OX5 1GE, UK 
     www.abdserotec.com 
 
Ambion Applied Biosystems/Ambion, 2130 Woodward 
St., Austin, TX 78744-1832, USA 
     www.ambion.com 
 
Anachem Anachem House, 1 & 2 Titan Court, Laport 
Way, Luton, LU4 8EF, UK 
     www.anachem.co.uk 
 
BD Biosciences  21 Between Towns Rd, Cowley, Oxford, OX4 
3LY, UK 
     www.bdbeurope.com 
 
BDH      Supplied by VWR 
     www.vwr.com 
 
Bioline 16 The Edge Business Centre, Humber Rd, 
London, NW2 6EW, UK 
     www.bioline.com 
 
Biogene BioGene House, 6 The Business Centre, 
Harvard Way, Kimbolton, Cambs, PE28 0NJ, 
UK 
     www.biogene.com 
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BioLegend UK Ltd Munro House, Trafalgar Way. Bar 
Hill,Cambridge, CB23 8SQ, UK 
www.biolegend.com/uk 
 
Eurofins MWG Operon  Anzingerstr. 7a, 85560 Ebersberg, Germany 
     www.eurofinsdna.com 
 
Finnzyme     Keilaranta 16 A, 02150 Espoo, Finland  
www.finnzymes.com 
 
Fisher Scientific Bishop Meadow Rd, Loughborough, 
Leicestershire, LE11 5RG, UK 
     www.fishersci.com 
 
GeneService Ltd  Source BioScience, Units 24 & 25, William 
James House, Cowley Road, Cambridge, CB4 
0WU, UK 
     www.geneservice.co.uk 
 
Gibco      Supplied by Invitrogen 
     www.invitrogen.com 
 
GraphPad Software Inc. 2236 Avenida de la Playa, La Jolla, CA 92037 
USA 
     www.graphpad.com 
 
Immunolon     Supplied by VWR 
     www.vwr.com 
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Invitrogen     3 Fountain Drive, Inchinnan Business Park, 
     Paisley,PA4 9RF, UK 
     www.invitrogen.com 
 
Microlance       Supplied by SLS 
     www.scientificlabs.co.uk 
 
Molecular Probes Inc   29851 Willow Creek Rd, Eugene, OR 
(Invitrogen)    97402, USA 
     www.invitrogen.com 
 
MultiD Analyses    Odinsgatan 28, SE-411 03, Göteborg, Sweden 
     www.multid.se 
 
National Diagnostics   Supplied by Fisher Scientific 
     www.fishersci.com 
 
New England Biolabs  75-77 Knowl Piece, Wilbury Way, Hitchin, 
Herts SG4 0TY, UK 
     www.neb.com 
 
Nunc      Supplied by SLS 
www.scientificlabs.co.uk 
 
PeproTech  PeproTech House, 29 Margravine Rd, London, 
W6 8LL, UK 
     www.peprotechec.com 
 
Promega Delta House, Southampton Science Park, 
Enterprise Rd, Southampton SO16 7NS, UK 
     www.promega.com 
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Qiagen  Qiagen House, Fleming Way, Crawley, West 
Sussex, RH10 9NQ, UK 
     www.qiagen.com 
 
Quantace Rowlandson House, 289-293 Ballards Lane, 
Finchley, London N12 8NP, UK 
     www.quantace.com 
 
R-project    The R Foundation for Statstical Computing 
www.r-project.org 
 
RnD Systems  19 Barton Lane, Abingdon Science Park, 
Abingdon, Oxford, OX14 3NB  
     www.rndsystems.com 
 
Roche Charles Avenue, Burgess Hill , West Sussex , 
RH15 9RY, UK 
     www.roche.com 
 
Scientific Laboratory   Orchard House, The Square, Hessle, East 
Supplies (SLS)   Riding of Yorkshire, HU13 0AE, UK  
     www.scientificlabs.co.uk 
   
Sigma Aldrich The Old Brickyard, New Road, Gillingham, 
Dorset, SP8 4XT, UK 
     www.sigmaaldrich.com 
 
Sterilin     Supplied by SLS 
     www.scientificlabs.co.uk 
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Surgipath    Venture Park, Stirling Way, Bretton,  
     Peterborough, Cambridgeshire, PE3 8YD, UK 
     www.surgipath.com 
 
Thermo Scientific Pierce Biotechnology, PO Box 117, 3747 N. 
Merdian Rd, Rockford, IL 61105, USA 
     www.thermoscientific.com 
 
Tree Star Inc.   340 A Street #101, Ashland, OR 97520, USA 
     www.treestar.com 
 
Vector Laboratories   3 Accent Park, Bakewell Rd, Orton, 
Southgate, Peterborough, PE2 6XS, UK 
     www.vectorlabs.com 
 
VWR  Hunter Boulevard, Magna Park, Lutterworth, 
Leicestershire, LE17 4XN, UK 
     www.vwr.com 
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Appendix 2.2   Equipment 
 
Automatic pipettor   Express, Falcon 
 
Balances    Fine:   AE163, Mettler 
     Medium:  EK-200G, AND 
 
Centrifuges    TJ-6, Beckman 
     1-15P, Sigma 
     113, Sigma 
 
Flow cytometer   FACSCalibur, Becton Dickinson 
 
Gel documentation system FluorChem HD2, Alpha Innotech 
 
Gel electophoresis system  Mini-Sub Cell GT, Bio-Rad 
 
Haemocytometer   SLS 
 
Heating Block   Dri-Block, Techne 
 
Histology camera   AxioCam MRc, Zeiss 
 
Humidity chamber   Sandrest 
 
Incubators    25oC:   4536, Forma Scientific 
     37oC humidified:  MCO-20AIC, Sanyo 
 
Microbiological safety   Envair 
cabinets (Class II) 
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Microscopes    Axioskop 2 Plus, Zeiss 
     Observer D1, Zeiss 
 
Microwave    NN-E442W, Panasonic 
 
PCR machine   T3 Thermocycler, Biometra 
 
pH meter    CD500, WPA 
 
Pipettes    Pipetman, Gilson 
 
Plate reader    Modulus Microplate, Turner Biosystems 
 
Pressure cooker    Tendercook, Nordic Ware 
 
Real time PCR machine  R-3000 Rotorgene, Corbett 
 
Refrigeration     4oC:     Silverline, LEC; PL167GWA, Proline 
     -20oC:   Scandinova 
     -80oC: U410 Premium, New Brunswick  
       Scientific 
 
Spectrophotometer   ND-1000, NanoDrop 
 
Stirrer    Stuart Scientific 
 
Waterbath     Grant Instruments 
 
Vortex     Whirlimixer, FSA Laboratory Supplies 
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Appendix 2.3   Recipes 
 
Greiss Reagent   5.8% (v/v) H3PO4 




Kanamycin agar   LB medium 
     1.5% (w/v) bacto-agar 
     30µg/mL kanamycin 
 
Kanamycin medium  LB medium 
     30µg/mL kanamycin 
 
LB medium (pH7.4)   1% (w/v) tryptone 
     0.5% (w/v) yeast extract 
     1% (w/v) NaCl 
 
Paraformaldehyde  (pH7.4) PBS 
     4% (v/v) paraformaldehyde  
     1% (v/v) 1M NaOH 
 
PBS pH 7.4    137mM NaCl 
     2.7mM KCl 
     4.3mM Na2HPO4 
     1.4mM KH2PO4 
 
PBSA     PBS 
     1% (w/v) bovine serum albumin 
     0.1% (w/v) sodium azide 
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Permeablisation buffer  PBSA 
     0.1% (w/v) saponin 
 
Peroxidase block   TBS 
     70% (v/v) methanol 
     3% (v/v) H2O2 
 
Mowiol    1% (w/v) Mowiol 4-88               
25% (v/v) Glycerol                    
50% (v/) 0.2N TrisHCl pH8.5       
 
Sodium citrate antigen   10mM Na3C6H5O7.2H2O 
retrieval buffer (pH 6.0)  0.05% (v/v) Tween 20   
 
Sulphuric/phosphoric acid 10% (v/v) H2SO4  
30% (v/v) H3PO4  
 
TBS (pH7.4)    0.8% (w/v) NaCl2 
     0.05% (w/v) KCl 
     0.3 % (w/v) Trisma base 
 
Toluene Blue    1% (w/v) Toluene Blue  
     5% (v/v) methanol to dissolve 
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Bone marrow derived macrophages (BMDMφ) were initially cultured as 
described by several authors (Qin et al., 2007; Turnbull et al., 2006), on tissue 
culture plastics in DMEM or RPMI, supplemented with 100U/ml penicillin and 
streptomycin, 1% L-Glutamine, 10% foetal calf serum  and recombinant 
macrophage colony stimulatory factor (rM-CSF).  According to the literature, 
cells were then removed from plastic with versene and downstream analysis or 
manipulation performed.  However, it rapidly became evident that this method 
of culture was inappropriate, if not completely unsuccessful.  Retrieval of 
BMDMφ from tissue culture plastic using either versene or trypsin proved 
extremely difficult, with loss of the majority of viable cells, rendering further 
analysis impossible.  Both plastic and growth medium required adjustment in 
order to obtain viable cultures of BMDMφ in sufficient numbers for further 
analysis. 
 
Tissue culture plastic 
 
After limited success in establishing macrophage cultures using published 
methods, advice was sought from Dr Dave Sester and Prof. David Hume at the 
Roslin Institute, both of whom have considerable experience in macrophage 
culture and manipulation.  It was recommended that BMDMφ  be grown on 
bacteriological dishes (Sterillin) as the tissue culture coating on Nunc brand 
plastics leads to extremely strong adherence of BMDMφ and removal of viable 
cells in large numbers is highly unlikely.  As such, BMDMφ were then grown in 
uncoated 100mm square dishes and removed easily by washing with 
magnesium, calcium free PBS using a needle and syringe.  Following 
optimisation of the growth medium, this allowed harvest of large quantities of 
Chapter 2  Materials and Methods 
                                                                                                                                            
91 
 
viable cells, which were then either reseeded for activation and infection, or 
harvested for FACS analysis or RNA extraction.  
 
Growth medium optimisation 
 
M-CSF is an essential growth factor required for outgrowth and maintenance of 
macrophage cultures (Metcalf, 1986; Tushinski et al., 1982).  rM-CSF is 
available from several suppliers, with R&D Systems and Peprotech being the 
most commonly used.  As such, rM-CSF was purchased from Peprotech and 
titrated on freshly extracted bone marrow, starting with the manufacturer’s 
recommended concentration of 1ng/ml.  However, even at 10ng/ml, BMDMφ 
were sparse on the plate, with no evidence of proliferation and many floating 
cells.  rM-CSF purchased from R&D Systems was titrated in the same manner, 
yielding similar results (Figure 2.1a).  This was not an inherent inability of 
bone marrow cells to respond to cytokine, as substantial BMDMφ outgrowth 
was observed in response to ‘in house’ rM-CSF, a kind gift from Prof. David 
Hume for use as a positive control.  As it was evident that commercial rM-CSF 
was ineffective at inducing macrophage outgrowth from bone marrow, at least 
at financially viable concentrations, an alternative source of growth factor was 
sought.   
 
The murine fibroblast cell line, L929, is known to be a potent producer of M-
CSF (Ladner et al., 1988) and media supplemented with L929 supernatant has 
been frequently used in the past to grow macrophages.  However, the inherent 
difficulty with this approach is the soup of cytokines and growth factors that 
are likely to be present in the supernatant, detailed analysis of which has 
never been published.  However, macrophages would be exposed to a complex 
cytokine milieu in situ, rather than M-CSF in isolation and therefore, by 
comparing activated samples with controls exposed to supplemented medium 
only, this source of M-CSF was deemed appropriate and may bear some 
physiological relevance to the in vivo cytokine environment experienced by res- 
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Figure 2.1  Titration of commercial and in house M-CSF. 
RPMI media was supplemented with 10% foetal calf serum, 1% L-Glutamine and 100U/mL penicillin 
and streptomycin, along with a) commercially available rM-CSF from Peprotech or R&D Systems at 1, 
5 or 10ng/ml.  rM-CSF from the Roslin Institute was used at 1x concentration as a positive control 
(dotted line). b) RPMI was supplemented with 3, 10, 25 or 50% supernatant harvested from L929 
murine fibroblast cells. 
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ident tissue macrophages.  As such, RPMI supplemented with L929 
supernatant was titrated (Figure 2.1b).  Strong outgrowth of BMDMφ was 
achieved with concentrations of supplemented media above 10% v/v.  
However, given the difficulties experienced establishing this system, the 
highest concentration of 50% L929 supernatant v/v was selected as optimal 




Several unsuccessful attempts were made to stain for the macrophage marker 
F4/80 on paraffin wax embedded material.  These tissues are unsuitable for 
fluorescent staining due to high levels of autofluorescence caused by this 
manner of processing.  Therefore, colorimetric stains were investigated.  As the 
lungs were inflated with 10% neutral buffered formalin, antigen retrieval was 
required to break cross linking of surface antigens.  Citrate buffer at pH 6.0 
was used for heat induced antigen retrieval, both by microwaving and by 
heating more gently in a water bath at 90oC.  As it was likely that F4/80 may 
be a fragile surface antigen, the process of dewaxing and rehydration through 
sequential alcohols may have caused damage which prevented the antibody 
from binding.  Therefore, rehydration through decreasing concentrations of 
acetone was attempted.  However, only very weakly positive antigen was 
detected.  This was of no use as it would be overshadowed by strong viral 
staining when attempting to perform the dual stain.  A biotinylated antibody 
was employed to add an amplification step to the protocol, but this too proved 
ineffective. 
 
It was then decided to repeat the animal experiments and inflate lungs with 
OCT compound, followed by fast freezing and cutting of frozen sections.  This 
effectively bypassed the damage caused by paraffin wax embedding and 
subsequent downstream processing, allowing staining with fluorescent 
antibodies.  This resulted in strong positive staining with the biotinylated 
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F4/80 antibody, but also some non specific staining in the secondary antibody 
control slide.  Further investigation indicated the presence of endogenous 
biotin activity in these sections.  Attempts were made to block this with 
streptavidin solutions, but these large complexes also appeared to sterically 
hinder specific binding of antibody to the macrophages, which were also likely 
to possess endogenous biotin activity.  A rat anti-mouse F4/80 antibody, 
which was previously shown to specifically detect macrophages by flow 
cytometry, was successfully employed on these frozen sections in conjunction 
with goat anti-rat Alexafluor 488.  The ability of this antibody to detect 
macrophages by flow cytometry, and the strong staining obtained when used 
against RAW macrophages indicated that this antibody was highly specific for 
macrophages.  Furthermore, when positive staining was compared to cell 
morphology, it appeared that this antibody successfully detected any 
macrophages present within the sections examined. 
 
Once specificity of both the anti-macrophage and anti-influenza antibodies had 
been established, attempts were made to perform a dual stain for these 
markers.  However, further problems ensued due to conflicting species 
specificities of secondary antibodies conjugated to particular Alexafluors that 
could be visualised by the confocal microscope.  The goat anti-influenza virus 
was detected with a rabbit anti-goat Alexafluor 488, while the confocal 
microscope could visualise Alexafluors 488 and 546 in addition to the DAPI 
counterstain.  However, it was not possible to purchase an Alexfluor 546 
conjugated antibody without species conflictions and so a rabbit anti-rat 
Alexafluor 594 was purchased.  Dr Trudi Gillespie at the IMPACT confocal 
facility was able to image this Alexafluor using a far red laser which gave a 
visible but less intense red emission, therefore enabling the dual stain for virus 
and macrophages within lung tissue to be performed.  Although it may have 
been possible to purchase an anti-influenza virus antibody raised in an 
alternative species, at the time of development, the influenza virus stain was 
extremely reliable and so there was less inclination to change this unless 
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absolutely necessary.  Furthermore, purchasing an anti-rat secondary 
antibody would benefit the laboratory as a whole more than altering the 
influenza stain, as many of the primaries used are raised in rat, in addition to 
saving on the cost involved in purchasing 3 new antibodies rather than the 
anti-rat Alexafluor only. 
 
The results of failed immunohistochemistry experiments were assessed by 






Selection of reference genes 
 
Appropriate reference genes were required for normalisation of qPCR data.  
Appropriate reference genes should be stably expressed across the range of 
tissue types and infection or treatment models under investigation to provide a 
reliable standard to normalise RNA concentration against.  The program 
NormFinder (available through Genex software) was utilised to select two 
housekeeping genes with the most stable expression across a panel of 
activated BMDMφ.  To do this, a standard curve for each of a panel of 
housekeeping genes (Table 2.7) was generated and a panel of samples run 
(Table 2.8).   
 
Standard curves for each housekeeping gene were set up using high fidelity 
PCR products from genomic DNA, generated with PFU polymerase (NEB) and 
the primer pairs supplied in the Quantace Normalisation Gene Panel.  These 
products were then gel purified using a Qiagen Gel Purification Kit.  
Concentration of the products was assessed using a Nanodrop 
spectrophotometer and copy number per microlitre calculated (Equation 2.1).  
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This DNA was then used in serial dilution for generation of standard curves, 
under the conditions recommended by the manufacturer (Table 2.9). 
 
NormFinder then calculated the variability between samples, based on the 
point at which each crossed the threshold set in the standard curve, allowing 
selection of the most stably expressed genes as reference genes (Figure 2.2).  
The two genes with most stable expression were CNX and SDHA, and so these 
were carried forward as reference genes.  
 
Optimisation of genes of interest 
 
For each gene to be analysed, primer and MgCl2 concentrations were 
optimised, along with annealing temperature to ensure optimal reaction 
conditions.  iNOS is detailed here as a worked example of the optimisation 
procedure applied to each gene.  Primer sequences for all genes are listed in 
Table 2.5. 
 
Initially a panel of primer concentrations were tested with a constant 
concentration of MgCl2 (2.5mM) in a 20µL reaction volume (Table 2.10).  The 
optimal combination of forward and reverse primer concentrations was that 
which gave highest product yield with a narrow single peaked melt curve.  
Figure 2.3a depicts the product yield, showing that all concentrations of 
primers give a similar yield of product.  However, some combinations result in 
fluorescent intensity achieving 100% at an earlier cycle, and therefore the most 
efficient was selected as the optimum combination of primer concentrations.  
For iNOS, this was 400nM forward, 500nM reverse primer (Figure 2.3e).  A 
single peak was observed when the products were melted (Figure 2.3c), 
demonstrating that these primers were specific, and generated a single 
product.  However, there was a small shoulder to the left of this melt curve due 
to suboptimal primer concentrations.  When conditions are fully optimised, 
this shoulder will no longer be present.  
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SSDHA Succinate dehydrogenase complex, subunit A 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase  
G ACTIN Gamma actin, cytoplasmic  
RN18s 18S Ribsomal RNA 
PGK Phosphoglycerate kinase 1  
UBQC Ubiquitin C  
RPL13A Ribosomal protein L13a  
B2MG Beta-2 microglobulin E 
Table 2.7  Panel of qPCR reference genes 





Tissue Timepoint Activation 
BMDMφ Day 7 M-CSF 
BMDMφ Day 8 M-CSF + IFNγ 
BMDMφ Day 8 M-CSF + IL-4 
BMDMφ Day 8 M-CSF + IL-13 
BMDMφ Day 6 M-CSF 
BMDMφ Day 7 M-CSF + IFNγ 
BMDMφ Day 7 M-CSF + IL-4 





Step Temp Time 
Enzyme activation  95°C  10min 
Anneal 95°C  15sec 
Extend 55°C 20sec 
Denature  72°C  20sec 
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Figure 2.2  NormFinder analysis of reference gene expression across cell panel. 
Standard deviation of Ct values are assessed across the range of cells tested and those genes with 
least variation are selected as reference genes with most stable expression. 
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Table 2.10  Primer concentration matrix.  



















Table 2.11  MgCl2 concentration optimisation.  
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Figure 2.3  qPCR optimisation for iNOS. 
Primer concentration was optimised, by assessment of a) product yield and c) melt curve, followed 
by selection of the combination of concentrations that gave highest product yield with a clean melt 
curve (e).  MgCl2 was then assessed in the same manner (b, d & f).  A standard curve was performed 
(g) resulting in an efficient reaction under these conditions (h). 
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Once optimal primer concentration had been established, MgCl2 concentration 
was addressed.  Increasing MgCl2 concentration enhances specific binding.  
Primers had been carefully designed to minimise primer dimer and cross 
dimers, so only a narrow range of MgCl2 concentrations were assessed (Table 
2.11). 
 
MgCl2 was optimised in the presence of the previously established primer 
concentration, again with product yield and melt curve being assessed.  In the 
case of iNOS, and the majority of genes investigated, a concentration of 3.0mM 
(Figure 2.3f) most rapidly achieved 100% fluorescence (Figure 2.3b) with a 
single peaked melt curve (Figure 2.3d).  The melt curve shoulder observed in 
Figure 2.3c was absent following primer optimisation (Figure 2.3e), indicating 
appropriate primer concentrations had indeed been selected.  Finally, a 
standard curve was performed to ensure an efficient reaction could be obtained 
under the newly optimised conditions (Figure 2.3g&h). 
 
Primer pairs for each gene of interest were subjected to this optimisation 
process, in addition to which, annealing temperature was altered if necessary.  
Fully optimised conditions are detailed in Table 2.6.  Despite detecting the 
template used for generation of a standard curve, the initial set of IL-12p40 
primers failed to detect product in samples and so these primers were 
redesigned using Primer3 and NetPrimer software, resulting in successful 
detection of IL-12p40 in samples. 
 
Optimisation of cDNA dilutions 
 
Establishment of a suitable dilution of cDNA was required to ensure the most 
reliable results were obtained.  If the cDNA used is too concentrated or too 
dilute, this can affect the quality of the reaction.  This must be balanced 
against finding a suitable dilution to give sufficient quantities of cDNA to 
complete reactions for all genes of interest. 
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cDNA was generated from BMDMφ exposed to M-CSF alone, IFNγ or IL-4 in 
vitro, along with mock and virus infected lung homogenates.   Samples were 
pooled by activation group before undergoing serial dilution, beginning at 1:10 
and continuing to 1:50.  A standard curve for each gene of interest was 
generated from the cloned template material as described in Chapter 2.12.1 to 
obtain a threshold to apply to the pooled samples. The serial dilutions of cDNA 
were run under the appropriate conditions for each gene as described in Table 
2.6 and the point at which each dilution crossed the threshold (Ct value) was 
plotted against dilution (Figure 2.4).  A suitable common dilution (1:20) was 




Statistical analysis was performed using the software package R (R Foundation 
for Statistical Computing).  Linear mixed effect models were applied to assess 
differences in mean relative gene expression between activation and infection 
groups, as well as between Sv129 and IFNγR-/- backgrounds for survival, 
infection rates and relative gene expression.    
  
This type of model incorporates what are described as ‘fixed’ and ‘random’ 
effects.  A fixed effect is a variable which alters the mean of a group, allowing 
comparisons between groups, or in other words, generates informative data, for 
example cytokine treatment.  A random effect is one which influences the 
variation within a dataset and is generally uninformative.  For example, mice 
within the same treatment group will have some variation but the difference 
between individual mice within a group is not of interest when investigating 
the differences between treatment groups.  However, although not inherently of 
interest, this effect must still be taken into account (Crawley, 2007). 
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Figure 2.4  Selection of optimal cDNA concentration. 
Samples were pooled by activation group and diluted prior to performing Q-PCR for genes of interest.  
Lowest common dilution within the straightest portion of the graph for each gene was selected 
(1:20). 
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In this section, development of the model will be outlined fully, using in vitro 
generated relative gene expression data for iNOS at the 48 hour timepoint 
(Chapter 4.2.1) as a worked example of this statistical analysis method.  This 
shall begin with an introduction to the factors under investigation, followed by 
basic analysis of each factor in turn. Finally, all factors will be incorporated 
together, taking reverse transcription efficiency (RT) and repeated measures 
from the same animal (mouse effect) into account in the final full model.  
Statistics presented in results chapters are those generated from the full linear 
mixed effect model. 
 
Factors under investigation 
 
The experiments performed aimed to establish whether activation with IFNγ or 
IL-4 led to different responses to infection with influenza virus A/WSN/33, and 
whether this was different between the two strains of mice being studied.  In 
order to do this, bone marrow from each mouse was split into six groups;  
M-CSF alone  
M-CSF + IFNγ  
M-CSF + IL-4  
M-CSF + WSN  
M-CSF + IFNγ + WSN 
M-CSF + IL-4 + WSN   
Therefore each individual animal appeared in every group, introducing 
repeated measures to the sampling process.  This allowed comparison of the 
same mice for differing cytokine treatments and infection (fixed effects) but also 
meant that the inherent variations between individual mice (random effect) 
must be taken into account, ie accounting for a mouse that may be a 
consistently low cytokine producer, but follows the same trend as the rest of 
the population sampled. 
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It was also important to discover whether any interactions existed between the 
factors under investigation, for example is response to virus in one strain of 
mouse dependent on cytokine treatment? Interactions will be discussed in 
subsequent sections.  
 
Therefore the factors under investigation were strain of mouse, cytokine 
treatment and infection status, each of which yielding informative data that 
affects the mean of each group, and so were treated as fixed effects.  However, 
these factors were additionally influenced by differing reverse transcription 
efficiencies (RT effect), which also had to be taken into account as a fixed 
effect.  As previously described, the repeated measures from individual mice 
introduced random variation into the dataset and therefore mouse effect was 
treated as a random effect, and ultimately led to use of linear mixed effect 
models for this analysis (Crawley, 2007).    
 
Single factor analysis 
 
In order for the data to be analysed successfully, it was first compiled into one 
spreadsheet, with each factor heading a column.  The dataset was created, 
manipulated to order the factors, exclude missing values and named (eg Data 
1).  Data were expressed as gene expression relative to the M-CSF alone control 
group, so this group had already been taken into account prior to analysis and 
was therefore excluded from the analysis.  This approach allowed for initial 
investigation of each factor in isolation, prior to assessment of any other effects 
or interactions. 
 
A one way ANOVA was performed for each factor (RT, Figure 2.5a; strain, 
Figure 2.5b; cytokine treatment, Figure 2.5c; infection status, Figure 2.5d) and 
the distribution of the residuals was checked for normality and followed by log 
transformation if necessary.  This was required for the iNOS example described 
here.  Each one way ANOVA generated an output indicating whether there was 
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a statistical difference between groups independent of any other factor.  For 
example, there was a significant difference between Sv129 and IFNγR-/- 
BMDMφ in their ability to express iNOS (p<0.0001) irrespective of infection or 
cytokine treatment (Figure 2.5e, Figure 2.5b). 
 
As each factor was assessed in isolation by one way ANOVA, the influence of 
one factor on another was not addressed and required further investigation.  
There were clear differences between reverse transcription reactions, with 
batch 3 demonstrating a higher median than the previous two (Figure 2.5a).   
 
The variation in RT would influence the remaining factors under investigation 
unless taken into account prior to further analysis and so must be 
incorporated as a fixed effect.  Mouse effect was not included at this stage of 
the analysis.  
 
Integration of reverse transcription as a fixed effect 
 
In order to allow comparison between samples reverse transcribed at different 
times, RT effect was taken into account as a fixed effect, prior to assessing the 
other factors.  To do this, a new dataset was created from the residuals of the 
RT factor column following the initial ANOVA.  A residual is the difference 
between an individual sample value and the mean value of the group.  
Therefore, the residuals carried forward into the next stage of the analysis 
represent the variation in the data that remains after correcting for RT effect. 
 
The residuals were plotted on a boxplot, followed by ANOVA for the remaining 
factors taking RT into account.  This means that the effect of strain on iNOS 
expression could be interpreted, having already taken into account the effect of 
RT (Figure 2.6a & b).  The output obtained demonstrated that although there 
was a significant difference between reverse transcriptions (p<0.001; Figure 
2.6c, ‘RT’), there was also a significant difference between Sv129 and IFNγR-/-  
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e       summary(aov(log10iNOS~Strain,data=Data1) 
 
     Df    P     
       Strain        1     <0.0001*** 
       Residuals     119      
 
Figure 2.5  Factors under investigation. 
Reverse transcription batch (a); strain of mouse (b); cytokine treatment (c) and infection status (d) 
were plotted independently of each other, demonstrating differences in mRNA expression within 
each factor, but not taking into account the influences of the other factors.  
e) Example of R command and readout for ANOVA  for mouse strain data.  R was given the summary 
of ANOVA command (aov) which resulted in the output detailing a significant difference in iNOS 





Chapter 2  Materials and Methods 











Df P     
RT           2   <0.001 
Strain       1   <0.0001
Residuals    117
a b
Figure 2.6  Example of data for mouse strain, taking RT effect into account. 
a)  ANOVA of strain in Data1 prior to accounting for RT effect, as plotted in Fig 2.5b 
b)  Residuals following ANOVA of RT factor were used to plot differences in iNOS mRNA expression 
between strains of mice, taking RT effect into account. 
c)  ANOVA of iNOS mRNA expression between strains of mice, taking RT effect into account, indicates 
a significant difference between Sv129 and IFNγR-/- BMDMφ. 
Chapter 2  Materials and Methods 
                                                                                                                                            
109 
 
BMDMφ in their ability to express iNOS irrespective of cytokine treatment or 
infection (p<0.0001; Figure 2.6c, ‘Strain’).  Genetic background of the BMDMφ 
was significant prior to taking RT into account (Figure 2.5e & Figure 2.6a), but 
by incorporating RT as a fixed effect in this manner, the effect of this variable 
was removed when assessing the effect of the remaining variables, allowing 
more accurate interpretation of the data. 
 
Single cytokine analysis 
 
Having integrated RT effect into the model as a fixed effect, further analysis of 
the remaining factors was undertaken to determine the effect of cytokine 
treatment and infection on the two strains of mice.  This involved splitting the 
original dataset, Data 1, into subsets for the two cytokines under investigation, 
IFNγ and IL-4.  The remaining factors, namely strain and infection status, 
within each subset were assessed and any interaction between these factors 
was investigated (Figure 2.7a).  This demonstrated that, as expected, genetic 
background of the BMDMφ led to a significant difference in iNOS expression 
following stimulation with IFNγ, having taken RT into account (p<0.0001; 
Figure 2.7a, ‘Strain’).  It was also apparent that there was no significant 
difference between mock and infected BMDMφ in iNOS expression following 
IFNγ stimulation, or in other words, infection failed to significantly upregulate 
iNOS expression over that observed in response to IFNγ alone (p=0.67; Figure 
2.7a, ‘MockInf’). 
 
Analysis of interactions between factors answers the following question: is 
response to virus influenced by genetic background, following exposure to IFNγ 
or IL-4? If there was a significant interaction between strain and infection 
status for the IFNγ stimulated subset, this would indicate that the relationship 
between mock and infected Sv129 BMDMφ for iNOS expression was different to 
the relationship between mock and infected IFNγR-/- counterparts, in the 
presence of IFNγ.  If the interaction between strain and infection status was not 
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significant, then this suggests that both strains respond in a similar manner to 
infection with regards to iNOS expression following stimulation with IFNγ.  
What was actually observed was that neither strain significantly upregulated 
iNOS expression in response to infection over that seen for IFNγ alone, 
therefore there was no interaction between strain and infection (p=0.29; Figure 
2.7a, Strain:MockInf), but that IFNγR-/- BMDMφ showed significantly lower 
iNOS expression than their wildtype counterparts (p<0.0001, Figure 2.7a 
‘Strain’ & c).  The interaction was excluded and the model repeated to ensure 
that the interaction did not mask factor effects (Figure 2.7b).  Exclusion of the 
interaction did not alter the degree of significance observed. 
 
Integration of mouse as a random effect 
 
As yet, individual mouse effect had not been taken into account, and so was 
incorporated into the model as a random effect.  This was because each 
individual mouse was present in every group, giving rise to repeated measures.  
The differences between individual mice were not of interest for comparisons 
between groups but must be accounted for due to the variation they 
introduced into the dataset.  Most statistical models assume independence of 
data but as repeated measures are present in this dataset, this assumption is 
incorrect.  Therefore, the repeated measures must be explicitly incorporated 
into the analysis by means of the linear mixed effect model.  The full model was 
run for each cytokine subset, taking RT effect into account as a fixed effect and 
mouse effect into account as a random effect, along with assessment of 
interactions between the remaining factors (Figure 2.8) although only the IFNγ 
stimulated subset is discussed here. 
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Df    P     
RT               2    0.05   
Strain           1   <0.0001  
MockInf          1     0.67     
Strain:MockInf   1     0.29     







Df    P     
RT             2    <0.05    
Strain         1   <0.0001  
MockInf        1     0.67     
Residuals     56   
c 
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Figure 2.7  ANOVA for IFNγ-activated subset for mouse strain and infection status. 
a)  ANOVA for the IFNγ stimulated subset of data demonstrated a significant difference between 
Sv129 and IFNγR-/- mice in response to IFNγ, but not in response to infection.  There was no 
significant interaction between infection status and strain of mouse. 
b)  Excluding the interaction from the analysis did not alter the degree of significance observed 
previously for the factors investigated. 
c)  Relative iNOS expression minus RT effect demonstrating differences between Sv129 and IFNγR-/-
BMDMφ following stimulation with IFNγ (p<0.0001) and that neither strain significantly upregulate 
expression upon infection (p=0.67). o, outlier.  
As both strains respond in the same manner to infection, ie by failing to further upregulate iNOS 
expression, there is no significant interaction between strain and infection status (p=0.29). 
Chapter 2  Materials and Methods 
                                                                                                                                            
113 
 
This analysis demonstrated that iNOS mRNA expression was significantly 
different in Sv129 BMDMφ compared to IFNγR-/- BMDMφ upon activation with 
IFNγ, as would be expected (p<0.0001; Figure 2.8a, ‘Strain’).  Furthermore, this 
analysis also showed that there was no significant difference in iNOS mRNA 
expression between mock and virus infected BMDMφ in the presence of IFNγ 
(p=0.52; Figure 2.8a, ‘MockInf’), and that there was no interaction between the 
two factors (p=0.49; Figure 2.8a, ‘MockInf:Strain’).  
 
However, this did not allow investigation of differences between strains 
following polarisation and infection, ie, to answer the question ‘is there a 
difference between classically and alternatively activated infected IFNγR-/- 
BMDMφ and wildtype counterparts?’ required further analysis. 
 
Full mixed effect model 
 
Finally, the dataset was once again assessed as a whole to investigate 
interactions between cytokine treatment and mouse strain, or cytokine 
treatment and infection status, with both RT and mouse effect taken into 
account (Figure 2.9).  As previously indicated (Figure 2.5) there were significant 
differences in iNOS mRNA expression between mock and virus infected 
BMDMφ, ie overall, the mean iNOS expression for infected cells (classical and 
alternatively activated BMDMφ of both strains together) was significantly 
higher than for uninfected cells (p<0.01; Figure 2.9a ‘MockInf’).  There were 
also significant differences between Sv129 and IFNγR-/- BMDMφ (p<0.0001; 
Figure 2.9a, ‘Strain’), and between IFNγ and IL-4 activated BMDMφ (p<0.0001; 
Figure 2.9a, ‘Ck’), independently of any other factor, as plotted in Figure 2.5. 
Obviously this was not particularly useful as genetic background and 
activation group must be separated, and so interactions between these factors 
were investigated.  As previously discussed, there was no interaction between 
strain and infection in the presence of IFNγ.  However, significant interactions 
were evident between infection status and cytokine treatment (p=0.001; Figure 
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Df   P 
RT                  2    0.09 
MockInf             1    0.52 
Strain              1    <0.0001 






DF  P 
RT                2    0.10 
MockInf           1    0.52 






Df   P 
RT                  2    <0.01 
MockInf             1    <0.01 
Strain              1    <0.05 






DF  P 
RT                2    <0.01 
MockInf           1    0.01 
Strain            1    0.05 
Figure 2.8  Inclusion of mouse as random effect. 
Mouse effect was integrated into the model as a random effect using the mixed effect model 
command ‘lme’ (a), which did not alter the significance of results obtained in Fig. 3.7.  Exclusion of 
the interaction between infection status and mouse strain (b) did not affect the significance of the 
factors investigated.  The model was repeated for the IL-4 stimulated subset (c & d). 
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Figure 2.9a, ‘MockInf:Ck’), or in other words, initial cytokine treatment of 
BMDMφ had a significant effect on response to virus infection in both strains.  
Similarly, mouse strain and cytokine treatment showed a significant 
interaction (p<0.0001; Figure 2.9a ‘Strain:Ck’), or rather that response of 
BMDMφ to cytokine was influenced by genetic background. 
 
Taken together, these interactions indicate that IFNγR-/- BMDMφ respond 
differently with regards to iNOS expression than do Sv129 cells in the presence 
of IFNγ, but not IL-4 (Figure 2.9a; ‘Strain:Ck’ & b) and that although IFNγ 
treated IFNγR-/- BMDMφ show lower iNOS expression than their wildtype 
counterparts (p<0.0001; Figure 2.9a, ‘Strain’ & Figure 2.9b), infection does not 
significantly further increase expression in either strain (p=0.49; Figure 2.8a, 
‘MockInf:Strain’ & Figure 2.9b).  However, in the presence of IL-4, both strains 
demonstrate upregulated iNOS expression following infection (p<0.05; Figure 
2.8c ‘Strain’ & Figure 2.9b), but as this meant that both strains responded in a 
similar manner to virus, there was again no interaction between strain and 
infection status with regards to iNOS expression (p=0.64, Figure 2.8c, 
‘MockInf:Strain’). The final interaction to be interpreted was that of infection 
status and cytokine, or in other words, does inital cytokine treatment affect 
response to virus?  This interaction was statistically significant (p=0.001; 
Figure 2.9a, ‘MockInf:Ck’), indicating that iNOS expression is different between 
classical and alternatively activated BMDMφ following infection. 
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                 Df  P 
RT                  2      0.05 
MockInf             1      0.01 
Strain              1      <0.0001 
Ck                  1      <0.0001 
MockInf:Strain      1      0.40 
MockInf:Ck          1      0.001 


































Figure 2.9  Full mixed effect model for in vitro iNOS mRNA expression. 
a)  Full mixed effect model, taking RT and mouse effects into account as a fixed and random effect 
respectively, followed by investigation of factors as fixed effects and interactions between factors. 
b)  Boxplot output of whole data for in vitro iNOS mRNA expression, demonstrating differential iNOS 
expression in a factor dependent manner.  o, outlier. 
This data is discussed fully in the context of other genes in Chapter 4. 
b 
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In terms of statistical interpretation with regards to iNOS expression, virus 
infected IFNγ stimulated BMDMφ are not different from mock infected IFNγ 
stimulated BMDMφ, but virus infected IL-4 stimulated BMDMφ are different 
from mock infected IL-4 stimulated BMDMφ, indicated by the significant 
‘MockInf:Ck’ interaction.  IFNγR-/- BMDMφ do not respond to IFNγ treatment, 
while Sv129 do but both strains respond similarly to IL-4, and so the 
‘Strain:Ck’ interaction is significant.  Infected BMDMφ of either strain do not 
respond differently to mock BMDMφ in the presence of either cytokine, which 
was established within single cytokine subsets where the ‘MockInf:Strain’ 
interaction is not significant.   However, as the ‘MockInf:Ck’ and ‘Strain:Ck’ 
interactions are significant, this shows that Sv129 and IFNγR-/- BMDMφ 
respond differently to cytokine treatment and that cytokine treatment 
influences response to infection, so it can therefore be inferred that there is a 
difference in iNOS expression between classically and alternatively activated 
Sv129 BMDMφ and identically treated IFNγR-/- counterparts following infection. 
 
Exclusion of the non-significant interaction (MockInf:Strain) did not affect the 
significance of any other.  These data will be presented fully, in their proper 
context in Chapter 4. 
 
This procedure was applied to all genes investigated both in vitro and in vivo, 
while a slightly modified method excluding RT effect was applied to the survival 
and infection data in Chapter 5.1.1. 
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3 In vitro infection of bone marrow derived macrophages 
 
Infection with influenza virus leads to a classical proinflammatory response 
from macrophages and other cells of the immune system, resulting in elevated 
levels of inflammatory mediators which can be detrimental to the host, 
resulting in cytokine storms and organ failure.  It has previously been shown 
that reducing infiltration of dendritic cells and macrophages during influenza 
infection leads to ameliorated disease (Aldridge et al., 2009; Herold et al., 
2008), most likely due to lower levels of inflammatory mediators such as iNOS 
and TNFα in the lung.  It has also been shown that the TH1 or TH2 bias of 
C57Bl/6 and BALB/c mice respectively results in differing responses to some 
pathogens.  A TH2 response is essential for expulsion of helminth worms in the 
BALB/c mouse (Else et al., 1994), but the ability of C57Bl/6 mice to mount an 
efficient local inflammatory response affords protection from bacterial infection 
and sepsis (Watanabe et al., 2004).  
 
Disruption of genes encoding receptors for key mediators which influence the 
TH1 or TH2 bias of the immune system, IFNγ and IL-4 respectively, results in a 
skewed cytokine response.  This project sought to identify the role that altering 
the cytokine profile produced by macrophages has on influenza virus infection.  
These preliminary experiments aim to establish and optimise the experimental 
conditions and procedures that will be used to profile the response of BMDMφ 
from 129SvEv (Sv129), IFNγR-/-, BALB/c and IL-4R-/- mice to influenza virus by 
investigating BMDMφ responses from a small number of animals.  As such, no 
statistical analysis will be carried out. 
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3.1 Characterisation of polarised bone marrow derived 
macrophages 
 
Macrophages have been experimentally infected with influenza virus in vitro, 
with differing efficiency depending on the strain of virus (Tate et al., 2010c) and 
the manner of macrophage isolation (Rodgers & Mims, 1981).  However, the 
macrophage response to influenza virus in the Sv129 strain of mice has not 
been previously reported in the literature.  Similarly, infection of IFNγR-/- 
macrophages on this genetic background requires characterisation in vitro.   
 
3.1.1 Characterisation of the bone marrow derived macrophage 
population 
 
Macrophages were generated from Sv129 mouse bone marrow as described in 
Chapter 2.2.4.  After 7 days culture with M-CSF, mature BMDMφ were 
characterised by flow cytometry (Figure 3.1).  BMDMφ were assessed for 
macrophage markers F4/80 and CD11b, isotype controls and secondary 
antibody alone were included to control for non-specific binding and 
fluorescence.  Greater than 90% of cells stained positive for F4/80 and CD11b 
(Table 3.1), confirming that culture of bone marrow cells with M-CSF for 7 days 
gives rise to a population of macrophages. 
 
3.1.2 Generation of classical and alternatively activated 
macrophages 
 
Sv129 BMDMφ were harvested, counted and reseeded followed by culture with 
activating cytokines for 16 hours as described in Chapter 2.2.4.  Figure 3.2 
depicts the experimental procedure followed for generation and infection of 
polarised macrophages.  Both IFNγ and IL-4 were titrated to determine the 
optimal activating concentration to achieve polarised BMDMφ (Figure 3.3).   
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Table 3.1  Flow cytometric analysis of 7 day BMDMφ.  





Marker Percentage Positive 
 Sv129 IFNγR-/- 
Secondary Control   0.32   0.60 
F4/80 99.25 91.34 
CD11b 95.21 93.96 
Figure 3.1  Flow cytometric analysis of 7 day BMDMφ. 
Sv129 (a&c) and IFNγR-/- (b&d) BMDMφ were assessed for expression of surface markers indicative 
of macrophage lineage, along with isotype fluorescent controls. 
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Figure 3.2  Experimental procedure 
Bone marrow was harvested from femurs and cultured in the presence of M-CSF for 7 days.  Cells 
were then split and incubated with activating cytokine for 16 hours to generate polarised 
macrophage subsets.  These were then either characterised directly, or infected with influenza virus 
at an MOI of 10 for 16 or 48 hours before characterisation.  For optimisation of infection conditions, 
macrophages were infected following 7 days culture in M-CSF but prior to polarisation (red hatched 
arrow) 
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Figure 3.3  Titration of activating cytokines IFNγ and IL-4. 
mRNA expression of iNOS & TNFα (classical activation) and Arg-1 & CD206 (alternative activation) 
were assessed by qPCR at increasing concentrations of IFNγ and IL-4.  Samples were normalized 
against BMDMφ stimulated with M-CSF alone.  Gene expression was normalized against two 
housekeeping genes, CNX and SDHA. n=1 
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mRNA expression of iNOS and TNFα, indicative of classical activation, along 
with Arg-1 and CD206, alternative activation markers, was quantified by qPCR 
to assess polarisation.  Incubation with all concentrations of IFNγ for 16 hours 
led to elevated iNOS and TNFα, but not Arg-1 or CD206 mRNA expression.  
Conversely, activation with IL-4 resulted in elevated Arg-1 and CD206 mRNA, 
but low expression of the two classical markers.  This confirmed the generation 
of polarised macrophages following incubation with either IFNγ or IL-4.  
Concentrations of 1ng/mL IFNγ and 4ng/mL IL-4 were selected to complete a 
timecourse to establish the optimal incubation period for polarisation of Sv129 
BMDMφ. 
 
Polarised phenotypes were established rapidly upon incubation of BMDMφ with 
activating cytokine.  As early as 1 hour post activation, iNOS and TNFα mRNA 
was upregulated in response to IFNγ (Figure 3.4), while IL-4 activated 
macrophages showed upregulation of alternative markers Arg-1 and CD206 
mRNA, but not iNOS or TNFα. 
   
Interestingly, IL-10 mRNA expression was upregulated at early timepoints after 
IL-4 activation, peaking at 8 hours followed by subsequent decline.  However, 
upon activation with IFNγ, expression of this mRNA was low at 8 hours but 
increased until 24 hours, in contrast to the response seen to IL-4.  This 
suggests that IL-10 expression is upregulated upon prolonged exposure to 
proinflammatory stimulus, in order to return the inflammatory 
microenvironment to homeostasis.  In response to IL-4, however, IL-10 is 
induced early, amplifying the overall TH2 microenvironment, but expression 
subsequently wanes in the absence of further stimulation. 
 
IL-12p40 was not detected by qPCR, but was successfully detected by ELISA 
(Figure 3.5).  IL-12p40 concentration increased with time in response to IFNγ 
but not to IL-4, confirming that IL-4 does not drive expression of this classical 
TH1 cytokine.  TGFβ, however, was detectable at 1  hour  post  activation,  but  
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Figure 3.4  Timecourse of activating 
cytokines IFNγ and IL-4. 
Sv129 BMDMφ were incubated with 
1ng/mL IFNγ or 4ng/mL for up to 
24hrs followed by qPCR analysis of 
classical and alternative marker 
mRNA expression.  Normalisation of 
samples was carried out as 
described in Fig. 4.2. ND = not 
detected. n=1 
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Figure 3.5  ELISA detection of IL-12p40 and TGFβ.  
Sv129 supernatants were harvested and assessed for presence of IL-12p40 and TGFβ
by ELISA.  Optical density was read at 450nm, corrected at 540nm and concentration 
extrapolated from a standard curve. n=1 
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downregulated by both IFNγ and IL-4 to undetectable levels at all later 
timepoints. 
 
Based on these data, an incubation period of 16 hours was selected as this 
timepoint gave a marked difference in all markers observed, with the exception 
of TGFβ. 
 
3.1.3 Polarisation of IFNγR-/- bone marrow derived macrophages 
 
In order to determine whether IFNγR-/- BMDMφ could be polarised, 7 day 
mature BMDMφ from IFNγR-/- mice were incubated with 1ng/mL IFNγ or 
4ng/mL IL-4 for 16 hours, alongside Sv129 BMDMφ.  iNOS and Arg-1 
bioassays were performed to determine successful polarisation (Figure 3.6). 
 
As expected, Sv129 BMDMφ were successfully polarised by activation with IFNγ 
and IL-4, confirming the earlier qPCR data (Figure 3.3).  The IFNγR-/- BMDMφ 
activated with IL-4 showed upregulated Arg-1 activity, consistent with 
alternative activation.  However, incubation of IFNγR-/- BMDMφ with IFNγ failed 
to induce iNOS activity, with similar levels observed for both IFNγ and IL-4 
stimulation.  This confirms that IFNγR-/- BMDMφ are unable to respond to IFNγ 
and so fail to become classically activated. 
 
3.1.4 Characterisation of the mRNA expression profile of polarised 
BMDMφ 
 
In order to further investigate the capacity of IFNγR-/- BMDMφ to become 
polarised, a panel of genes indicative of classical or alternative activation was 
assessed by qPCR, at 16 hours post activation for Sv129 and IFNγR-/- BMDMφ.  
Proinflammatory markers iNOS, TNFα, IL-6 and IL-1β were measured, along  
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Figure 3.6  Bioassays for iNOS and Arg-1 activity. 
Sv129 and IFNγR-/- polarised BMDMφ were assayed for differential iNOS and Arg-1 activity.  Optical 
density was read at 450nm and corrected at 540nm, concentrations were extrapolated from a 
standard curve. n=3 per strain. 
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Sv129
IFNγR-/-
Figure 3.7  mRNA expression profile of polarised BMDMφ.  
16 hr polarised Sv129 and IFNγR-/- BMDMφ were assessed for expression of a panel of genes 
indicative of classical or alternative activation by qPCR, and normalised against housekeeping genes 
CNX and SDHA, followed by normalisation against M-CSF controls to obtain relative expression of 
each gene. n=1 per strain. 
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with markers of alternative activation Arg-1, CD206, FIZZ and IL-10 (Figure 
3.7).  IFNγ stimulation of Sv129 BMDMφ (Figure 3.7, solid red bar) showed 
higher expression of iNOS, TNFα, IL-1β and IL-6 mRNA than their IL-4 
stimulated counterparts (Figure 3.7, solid green bar).  However, these 
increases were only slightly upregulated from baseline, demonstrating less 
than a 2 fold increase in expression (Figure 3.7, solid line).  The response to IL-
4 was more robust in this instance, with the classical markers being 
downregulated and Arg-1, CD206 and FIZZ mRNA all strongly increased.  IL-10 
was the exception, with neither IFNγ or IL-4 having a strong effect.  However, it 
should be noted that these data are from a preliminary experiment, where n=1 
and thus require further experiments to confirm these findings.   
  
As expected, IFNγR-/- BMDMφ failed to upregulate any of the classical genes in 
response to IFNγ (Figure 3.7, hatched red bar).  However, expression of iNOS, 
IL-6 and FIZZ mRNA was quite strongly downregulated relative to M-CSF 
alone.  This was surprising, but may be due to an anomaly within the single 
mouse investigated during establishment of the techniques in this section.  IL-
4 (Figure 3.7, hatched green bar) induced successful upregulation of Arg-1, 
CD206 and FIZZ mRNA, but failed to upregulate IL-10.  IL-10 induced by 
IFNα/β following TLR stimulation results in upregulation of SOCS 3 and 
subsequent control of inflammatory cytokine signalling, thereby limiting the 
inflammatory cascade and restoring homeostasis (reviewed by O'Shea & 
Murray, 2008).  The lack of proinflammatory gene expression may be the 
reason for poor IL-10 expression, as the cytokine microenvironment is not 
strongly dysregulated following exposure of IFNγR-/- BMDMφ to IFNγ. 
 
Interestingly, in the absence of IFNγ mediated inhibition, IFNγR-/- BMDMφ 
appear to upregulate CD206, while their wildtype Sv129 counterparts 
downregulate this receptor. 
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Taken together, these data suggest that IFNγR-/- are impaired in their capacity 
to mount a classical proinflammatory response, but can be successfully driven 
into an alternatively activated state.   
 
3.2 Preliminary infection of polarised BMDMφ with influenza virus 
 
Previous studies have experimentally infected macrophages with varying 
efficiencies depending on strain of influenza virus and method of macrophage 
isolation.  Reading and colleagues have demonstrated infection of alveolar and 
peritoneal macrophages differed between virulent and avirulent influenza 
strains (Reading et al., 2000; Tate et al., 2011), while Rodgers and Mims 
showed differing infectivity between alveolar and peritoneal macrophages, but 
no differences between virus strains (Rodgers & Mims, 1981).  It was therefore 
important to establish the optimal infection conditions with the virus to be 
used prior to attempting infection of polarised macrophages. 
 
3.2.1 Optimisation of A/WSN/33 virus infection 
 
The mouse adapted strain of influenza A virus, A/WSN/33 (WSN) was used to 
infect BMDMφ.  This virus was initially titrated on MDCK cells in a standard 
plaque assay as described in Chapter 2.3.2, to determine the concentration of 
virus in plaque forming units in this cell type.  This virus stock was then used 
to infect BMDMφ at varying multiplicities of infection (MOI) to establish the 
optimal viral dose to induce cytopathic effect.  In vivo experiments within our 
laboratory have previously shown BALB/c mice to be more susceptible to 
infection with this virus than Sv129 (Y. Ligertwood, personal communication) 
and so the virus was titrated on BMDMφ from both BALB/c and Sv129 mice.  
  
Seven day mature, non-activated BMDMφ were infected with WSN (Figure 3.2, 
red hatched arrow).  Infections were carried out on glass chamber slides and 
stained at 48 hours post infection. 
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The virus was titrated at MOI of 1 (Figure 3.8a&e), 5 (Figure 3.8b&f), 10 (Figure 
3.8c&g) and 15(Figure 3.8d&h) for Sv129 (Figure 3.8a-d) and BALB/c BMDMφ 
(Figure 3.8e-h).  MOI of 1 gave rise to very low levels of infection (Figure 
3.8a&e), while higher MOI resulted in more efficient infection.   
 
MOI of 10 was selected for further infections as this resulted in a robust 
infection in BMDMφ from both strains of mice.  A timecourse was then 
performed to determine the optimal duration of infection prior to harvesting 
BMDMφ for analysis.  Sv129 BMDMφ were generated and infected as previously 
described then harvested for cytospins at 1, 8, 16 and 24 hours post infection.  
These cytospins were stained with polyclonal anti-influenza antibody, followed 
by visualisation with Alexafluor 488, as described in Chapter 2.8.1 (Figure 
3.9).  At 1 hour post infection, no staining was seen (Figure 3.9a).  However, by 
8 hours post infection, strong staining was observed in some cells (Figure 
3.9b).  The staining pattern altered between 8 and 16 hours to show low level 
staining in the majority of cells with some more intensely positive macrophages 
(Figure 3.9c) and was still apparent at 24 hours post infection (Figure 3.9d).  
The distribution of viral antigen also appeared to change throughout the 
course of this infection.  At 8 hours, the cytoplasm appeared to be staining 
most strongly, while by 16 and 24 hours post infection, the strongest staining 
was localised beneath the plasma membrane.  Given that a polyclonal anti-
influenza antibody was used, it is likely that antibody is predominantly binding 
to HA and NA.     
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Figure 3.8  Titration of A/WSN/33 on Sv129 and BALB/c BMDMφ. 
A/WSN/33 was titrated at MOI 1, 5, 10 & 15 on BMDMφ from Sv129 (a-d) and BALB/c (e-h) mice.  
BMDMφ were grown on glass chamber slides and stained with polyclonal anti-influenza antibody and 
Alexafluor 488, along with DAPI nuclear counterstain.  Mock infected BMDMφ were stained as 
controls.   
x5 magnification, representative of n=2 per strain 
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Figure 3.9  A/WSN/33 infection timecourse. 
Sv129 BMDMφ were infected with MOI 10 A/WSN/33 and harvested for cytospins at 1 (a), 8 (b), 16 
(c) and 24 (d) hours post infection followed by staining with a polyclonal anti-influenza A antibody 
and Alexafluor 488.  
x5 magnification, n=1 
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It has been previously reported that macrophages do not support productive 
infection (Rodgers & Mims, 1981).  This pattern of staining suggests that a 
proportion of BMDMφ become infected but do not release infectious virus, as 
an accumulation of viral antigen is detected at the plasma membrane and 
neighbouring cells express only low levels of staining.  It was also evident that 
the method of preparing infected cells for staining had an important impact on 
the extent of infection observed.  BMDMφ grown on chamber slides prior to 
fixation and staining showed stronger staining than those grown on plates and 
harvested for cytospin analysis.  One explanation for this may be mechanical 
destruction of fragile infected cells during the cytospin process.  Taking this 
into consideration, together with the staining obtained at 48 hours post 
infection during the virus titration, the timepoints of 16 and 48 hours post 
infection were selected for further investigation of the effects of influenza virus 
infection on BMDMφ grown on chamber slides. 
 
3.2.2 Characterisation of mRNA expression profile in infected 
polarised Sv129 and IFNγR-/- bone marrow derived 
macrophages 
 
Polarised Sv129 and IFNγR-/- BMDMφ were infected and harvested for RNA 
extraction at 48 hours post infection.  The mRNA expression profile was then 
examined by qPCR.  
  
As previously observed, IFNγ activation of Sv129 BMDMφ led to an 
upregulation of mRNA for proinflammatory markers iNOS, TNFα, IL-1β and IL-
6 (Figure 3.10, first solid red bar) relative to baseline expression levels in non-
activated, uninfected control BMDMφ (Figure 3.10, solid line).  IL-12p40 mRNA 
was also successfully detected by qPCR and was found to be elevated by IFNγ 
activation, consistent with the ELISA data (Figure 3.5). 
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Figure 3.10  mRNA expression analysis of infected polarised BMDMφ. 
Infected polarised Sv129 and IFNγR-/- BMDMφ were harvested at 48 hours post infection for RNA 
extraction and qPCR analysis.  Samples were normalised against mock infected BMDMφ stimulated 
with M-CSF alone and gene expression was normalised against housekeeping genes CNX and SDHA 
as previously described. n=4 per strain 
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Arg-1 mRNA was also increased in the IFNγ activated group (Figure 3.10, first 
solid red bar), but this was to a much lower level than iNOS, a 70 fold increase 
in Arg-1 versus a 2000 fold increase in iNOS, indicating that the BMDMφ 
response was predominantly classical in nature.  
  
Incubation with IL-4 (Figure 3.10, first solid green bar) led to an increase in 
Arg-1 and FIZZ mRNA, consistent with alternative activation, while CD206 
mRNA expression was unaltered.  Surprisingly, IL-6 and iNOS expression were 
also upregulated by IL-4 as well as by IFNγ.  IL-10 mRNA, however, was 
downregulated, perhaps due to absence of proinflammatory TNFα and IL-
12p40. 
 
Infection of classically activated Sv129 BMDMφ (Figure 3.10, second solid red 
bar) resulted in a further upregulation of TNFα, IL-12p40, IL-1β, IL-6 and IL-10 
mRNA expression.  iNOS mRNA expression remained high, and surprisingly, 
FIZZ mRNA was increased slightly when compared with IFNγ alone, but 
remained lower than baseline levels.  Arg-1 mRNA was also elevated from 
baseline, but to a lesser extent than in response to IFNγ alone, and again 
remained lower than iNOS in the infected group. 
 
Alternatively activated Sv129 BMDMφ also exhibited upregulation of iNOS, 
TNFα, IL-12p40 and IL-1β mRNA upon infection with WSN (Figure 3.10, 
second solid green bar).  This suggests that infection with virus is sufficiently 
proinflammatory to drive expression of classical markers despite the initial IL-4 
signal.  However, a mixed phenotype was observed in this population, as Arg-1 
and FIZZ mRNA expression remained at similar high levels to those observed 
with IL-4 alone (Figure 3.10, solid green bars).  IL-10 was also upregulated in 
the infected IL-4 stimulated group, consistent with the suggestion that as 
proinflammatory cytokines are induced, IL-10 expression increases in order to 
control this inflammatory response.  
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IFNγR-/- BMDMφ, consistent with previous data, showed no classical response 
to IFNγ (Figure 3.10, first hatched red bar).  However, BMDMφ from one mouse 
expressed elevated IL-6 mRNA, but this cytokine was undetectable in BMDMφ 
from the remaining three mice.  
  
Upon infection of IFNγ stimulated IFNγR-/- BMDMφ, mRNA for inflammatory 
markers iNOS, TNFα, IL-12p40 and IL-1β was upregulated, as was IL-6 
expression in all four mice (Figure 3.10, second hatched red bar), 
demonstrating that WSN is capable of driving a proinflammatory response even 
in the absence of IFNγ signalling.  FIZZ was also slightly upregulated, but 
remained below baseline, similar to wildtype Sv129 BMDMφ.  Interestingly, 
CD206 mRNA expression was strongly increased upon infection. 
 
IL-4 activation of IFNγR-/- BMDMφ increased expression of Arg-1 and FIZZ 
mRNA (Figure 3.10, first hatched green bar), with CD206 expression remaining 
similar between both IFNγ and IL-4 activated populations (Figure 3.10, first 
hatched red and green bars respectively).  An increase in inflammatory 
markers TNFα, IL-12p40, IL-1β and IL-6 was also observed and may be 
responsible for the elevated IL-10 expression in this population.  
  
Infection of the alternatively activated IFNγR-/- BMDMφ (Figure 3.10, second 
hatched green bar) showed decreased expression in all markers compared to 
IL-4 alone, with the exception of iNOS, which was upregulated upon infection, 
and CD206, which was also elevated.  Despite being lower than IL-4 
stimulation alone, TNFα mRNA levels were still higher than baseline, as were 
those for IL-6 and FIZZ.  The observation that Arg-1 mRNA expression is 
almost completely abrogated and FIZZ mRNA is reduced compared to IL-4 
activation alone suggests that IL-4 is incapable of maintaining a dominant 
effect on this strain of macrophage in the presence of WSN. 
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Similar to wildtype Sv129 BMDMφ, IFNγR-/- BMDMφ showed a mixed phenotype 
upon infection, with expression of both classical and alternative markers.  
Interestingly, CD206 was elevated in all IFNγR-/- populations assessed and 
showed the highest degree of upregulation in the infected groups.  This 
receptor has been implicated in attachment and entry of influenza virus to 
macrophages (Reading et al., 2000) and so this may be an influential factor in 
the pathogenesis of the virus in this strain of mouse. 
 
3.2.3 Characterisation of mRNA expression profile in infected 
polarised BALB/c and IL-4R-/- bone marrow derived 
macrophages 
 
As IFNγR-/- BMDMφ cannot become classically activated, it was of interest to 
compare the response to infection with BMDMφ that were inhibited in their 
ability to become alternatively activated.  As such, IL-4R-/- mice on the BALB/c 
background were utilised and BMDMφ from this strain of mice compared to 
wildtype BALB/c BMDMφ. 
 
BALB/c BMDMφ responded to IFNγ activation by upregulation of all classical 
markers (Figure 3.11, first solid red bar), although the increase in IL-1β and 
IL-6 was modest.  Arg-1 was also upregulated, but to a much lesser extent 
than iNOS, similar to that observed in Sv129 BMDMφ.  Together with the 
absence of FIZZ, the overall response to IFNγ appeared to be classical in 
nature. 
   
Conversely, activation with IL-4 resulted in upregulation of all alternative 
markers, including IL-10 and decreased expression of proinflammatory 
cytokines (Figure 3.11, first solid green bar), indicating successful alternative 
activation. 
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Figure 3.11  mRNA expression analysis of infected polarised BMDMφ. 
Infected polarised BALB/c and IL-4R-/- BMDMφ were harvested at 48 hours post infection for RNA 
extraction and qPCR analysis.  Samples were normalised against mock infected BMDMφ stimulated 
with M-CSF alone and gene expression was normalised against housekeeping genes CNX and SDHA 
as previously described. n=4 per strain 
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Infection of the classically activated population resulted in elevated expression 
of IL-10, TNFα, IL-1β and iNOS mRNA, although in the case of iNOS, this was 
to a lesser extent than IFNγ alone (Figure 3.11, second solid red bar).  
Surprisingly, Arg-1, CD206 and FIZZ mRNA expression was also strongly 
increased in response to IFNγ plus WSN.  This strain of mice is more TH2 
biased and so macrophages may adopt a ‘wound healing’ type role during 
challenge, hence explaining the observed elevation in Arg-1 and FIZZ 
expression.  Also unexpected was the decline in IL-12p40 mRNA expression.  
Along with the increase in IL-10 expression, it is suggestive of a less 
inflammatory response to virus than that seen in the Sv129 BMDMφ, despite 
priming with IFNγ. 
 
Alternatively activated BALB/c BMDMφ showed upregulation of iNOS and IL-6 
mRNA in response to infection (Figure 3.11, second solid green bar) but no 
increase in any other proinflammatory marker.  However, expression of 
alternative markers Arg-1 and CD206 was increased and high expression of 
FIZZ was maintained.  This suggests that, unlike Sv129 BMDMφ, this strain of 
macrophage may be more capable of maintaining a dominant alternative 
phenotype even in the presence of a strong proinflammatory stimulus such as 
influenza virus. 
 
IFNγ activation of IL-4R-/- resulted in a response indistinguishable from the 
wildtype BALB/c BMDMφ (Figure 3.11, first hatched red bar), as did infection 
of classical BMDMφ of this strain (Figure 3.11, second hatched red bar), with 
the exception of Arg-1 and FIZZ, which were markedly lower in the infected IL-
4R-/- BMDMφ than the wildtype BALB/c cells. 
 
Stimulation of IL-4R-/- BMDMφ with IL-4 failed to induce any response, 
evidenced by expression of baseline levels of every marker examined.  Upon 
infection, the IL-4R-/- retained their ‘non-activated’ baseline phenotype, with 
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very little change in mRNA expression (Figure 3.11, second hatched green bar).  
IL-1β and FIZZ showed slight upregulation in response to virus, but the 
increased iNOS and IL-6 observed in wildtype BALB/c BMDMφ was notably 
absent.  CD206, however, was strongly upregulated during infection consistent 
with BALB/c BMDMφ.   
 
3.3 Summary of results and discussion 
 
It has previously been documented that BALB/c and C57Bl/6 mice show 
markedly differing responses to stimuli such as LPS, whereby C57Bl/6 mice 
are able to produce high levels of iNOS, TNFα and IL-12, but BALB/c mice are 
impaired in their ability to do so (Watanabe et al., 2004).  Conversely, BALB/c 
mice have been shown to be higher producers of Arg-1 in response to IL-4 
stimulation (Pradel et al., 2009).  
  
The preliminary data presented herein suggest that BMDMφ on the Sv129 
background are primed towards inflammation, similar to the C57Bl/6 
background, and appear to be more TH1 oriented than their BALB/c 
counterparts.  Some degree of proinflammatory cytokine mRNA expression was 
driven by the virus upon infection of BMDMφ on the Sv129 background, even 
in the absence of IFNγ signalling.  In contrast to this, infection of IFNγ primed 
BALB/c and IL-4R-/- BMDMφ failed to drive expression of inflammatory 
markers. 
 
While sufficient to induce an alternatively activated phenotype from Sv129 and 
IFNγR-/- BMDMφ, IL-4 did not appear capable of maintaining this activation 
state upon infection with WSN.  Macrophages are known to alter their 
phenotype in response to sequential stimulation (Stout et al., 2005) and 
therefore it is perhaps not surprising that infection may lead to mixed 
expression of classical and alternative markers.  Infection did not achieve 
100% efficiency, even at an MOI of 10 in these BMDMφ populations, and so 
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infected cells may upregulate inflammatory genes while uninfected cells may 
remain alternatively activated.   
 
The data suggest that BALB/c BMDMφ were able to maintain an alternatively 
activated phenotype following IL-4 activation and virus infection, or in the 
absence of IL-4 signalling, BMDMφ maintained a non activated phenotype.  
However, similar to the IFNγR-/- BMDMφ, both BALB/c and IL-4R-/- 
macrophages demonstrated elevated CD206 mRNA expression following 
infection.  Whether this is a result of infection or of differing levels of 
endogenous interferon specific to each strain requires further investigation, 
but enhanced CD206 expression may be influential in the ability of WSN to 
infect BMDMφ. 
 
Influenza virus causes damaging immunopathology due to a highly reactive 
inflammatory response.  As IFNγR-/- BMDMφ seemed impaired in their ability to 
mount a functional inflammatory response compared to that observed in 
wildtype Sv129 BMDMφ, this strain was used to further investigate the effect of 
the inflammatory response on WSN infection of BMDMφ (Chapter 4), and 
continued in a whole mouse model (Chapter 6). 
   
The aim of this chapter was simply to establish the in vitro model systems to 
be used.  The number of replicates in these preliminary experiments was 
limited and therefore no definitive conclusions can be drawn from the data 
presented here.  However, techniques for culture, activation and infection of 
BMDMφ have been established here allowing the study of larger groups of mice 
in order to investigate the aims of the project in detail.  
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4 Infection of Sv129 and IFNγR-/- bone marrow derived 
macrophages 
 
4.1 Infectivity of A/WSN/33 for Sv129 and IFNγR-/- bone marrow 
derived macrophages 
 
As previously shown in Chapter 3, influenza virus A/WSN/33 can infect Sv129 
BMDMφ and elicit a cytokine response from both Sv129 and IFNγR-/- BMDMφ 
(Chapter 3.2.2.)  In this chapter, the effect that inhibiting IFNγ signalling could 
have on influenza virus infection of BMDMφ and on the characteristic 
inflammatory response was further investigated. 
 
4.1.1 Evaluation of A/WSN/33 infection of BMDMφ 
 
BMDMφ of both strains were generated, activated and infected as described in 
Chapter 2.2.4, on 8 well glass chamber slides or 100mm uncoated dishes.  
Macrophages were fixed and stained at 16 and 48 hours post infection with 
either anti-NS1 or polyclonal anti-influenza antibodies to determine the ability 
of WSN to infect BMDMφ as opposed to being detected as phagocytosed virions 
and infected debris.  NS1 is synthesised early in infection and so positive 
staining for this viral protein indicates active replication, while the anti-
influenza antibody may detect viral envelope proteins on phagocytosed 
particles in addition to any newly expressed viral proteins. 
 
Classically activated Sv129 BMDMφ demonstrated very strong NS1 staining in 
the cytoplasm at 16 hours (Figure 4.1a), which diminished by 48 hours, when 
the NS1 stain appeared condensed in nature and colocalised with the nuclear 
counterstain (Figure 4.1e).  This is consistent with early and abundant 
expression of NS1 followed by nuclear localisation but no new synthesis of this 
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Figure 4.1  Immunofluorescent staining for influenza virus in Sv129 BMDMφ. 
Classical (a,b,e&f) and alternatively activated (c,d,g&h) Sv129 BMDMφ were stained with an NS1 
(a,c,e&g) or polyclonal anti-influenza antibody (b,d,f&h), followed by detection with alexafluor 488 at 
either 16 (a-d) or 48 hours (e-f).   
x20 magnification, 2 fields of vision counted, data are representative of 3 independent experiments. 
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protein at later stages of non-productive infection.  Had replication been 
ongoing within the cell, NS1 would remain detectable in the cytoplasm at 48 
hours.  The anti-influenza antibody detected viral antigens at both 16 and 48 
hours (Figure 4.1b&f) but was strongest at 48 hours, consistent with an 
accumulation of viral proteins and particles. 
 
Infection of alternatively activated Sv129 BMDMφ showed weaker NS1 staining 
at 16 hours than classically activated BMDMφ, but stronger positivity with the 
anti-influenza antibody at this timepoint (Figure 4.1c&d).  NS1 staining at 48 
hours was sparse but appeared to be predominantly nuclear (Figure 4.1g), 
while the anti-influenza antibody staining remained strong (Figure 4.1h).  
These data demonstrate that classical and alternatively activated macrophages 
exhibit differing infection profiles. 
 
IFNγ and IL-4 stimulated IFNγR-/- BMDMφ were very similar in their staining 
patterns, with NS1 staining strongly in both at 16 hours (Figure 4.2a&c), and 
the anti-influenza antibody most strongly at the later timepoint (Figure 
4.2f&h).  Similar to their Sv129 counterparts, IL-4 stimulated IFNγR-/- BMDMφ 
appear to show stronger polyclonal staining at 16 hours than the IFNγ 
stimulated population (Figure 4.2b&d), along with slightly weaker NS1 
staining, although this was not as pronounced as in the wildtypes.  This 
further suggests differing kinetics of infection between activation groups. 
  
The percentage of cells becoming positive for viral protein by 48 hours was 
then quantified.  Sv129 BMDMφ showed a significantly higher percentage of 
cells staining positive for viral protein at 16 hours than IFNγR-/- macrophages 
(Figure 4.3a, p<0.05), but by 48 hours, both strains demonstrated similar 
levels of positivity (Figure 4.3b).   However, IL-4 stimulation led to greater 
numbers of positive staining cells in both Sv129 and IFNγR-/- BMDMφ (Figure 
4.3a&b, green bars), reaching statistical significance by 48 hours (p<0.05). 
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Figure 4.2  Immunofluorescent staining for influenza virus in IFNγR-/- BMDMφ. 
Classical (a,b,e&f) and alternatively activated (c,d,g&h) IFNγR-/- BMDMφ were stained with an NS1 
(a,c,e&g) or polyclonal anti-influenza antibody (b,d,f&h), followed by detection with Alexafluor 488 at 
either 16 (a-d) or 48 hours (e-f).  
x20 magnification, 2 fields of vision counted, data are representative of 3 independent experiments. 
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Figure 4.3  Percentage of polarised BMDMφ infected. 
Polarised Sv129 (n=3) and IFNγR-/- (n=3) were infected with MoI 10 WSN, stained with polyclonal 
anti-influenza A or NS1 antibody and the percentage of positive cells was calculated at 16 (a) and 48 
(b) hours post infection.  NS1 positive BMDMφ were counted at 16 hours, while cells positive for anti-
influenza antibody were counted at 48 hours.  2 fields of vision were counted. 
* indicates statistical significance between cytokine treatment (p<0.05) 
† indicates statistical significance between Sv129 and IFNγR-/- BMDMφ (p<0.05) 
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This observation suggests that wildtype Sv129 BMDMφ are permissive for rapid 
establishment of infection, with the alternatively activated group being most 
readily infected.  Classically activated BMDMφ did not demonstrate any further 
increase in staining for viral proteins at 48 hours, suggesting that IFNγ 
signalling prevents propagation of the infection, while the alternatively 
activated group show some increase in positive cell numbers by 48 hours.  It 
was also evident that fewer IFNγR-/- BMDMφ were positive for viral proteins 
early in infection, but by 48 hours reached levels similar to wildtype BMDMφ, 
suggesting that WSN encounters a restriction on either entry or early protein 
synthesis in IFNγR-/- BMDMφ.  However, this block is overcome and by 48 
hours, similar levels of viral proteins are observed in both Sv129 and IFNγR-/-. 
 
qPCR analysis of M1 expression at 48 hours post infection further emphasised 
the differing effect of IFNγ and IL-4 activation on WSN infection of BMDMφ. 
mRNA is synthesised in the infected cell so detection of this RNA species is 
indicative of active viral replication.  Quantification of M1 mRNA copy number, 
normalised against the housekeeping gene calnexin, showed the alternatively 
activated group of both strains to contain more M1 mRNA than their IFNγ 
stimulated counterparts (Figure 4.4, p<0.0005).  Together with the percentage 
positivity calculated from the immunofluorescent staining, it may be inferred 
that alternatively activated macrophages are more permissive for influenza 
virus infection than their classical counterparts.  
  
Despite lower levels of infection, IFNγR-/- BMDMφ also showed significantly 
poorer survival than the wildtype Sv129 cells (Figure 4.5, p<0.05 at 16 and 48 
hours ).  By 16 hours post infection, only 55% IFNγ stimulated IFNγR-/- BMDMφ 
remained viable by trypan blue exclusion assay, which is similar to survival 
rates of IFNγR-/- M-CSF only control BMDMφ following infection with WSN, 
while 90% of classically activated Sv129 BMDMφ were viable at this timepoint 
(Figure 4.5a, red bars).   
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Figure 4.4  Real-time PCR for Influenza M1 mRNA. 
M1 mRNA was assessed by qPCR at 48hrs post infection and copy number was normalised against 
strain matched infected controls activated with M-CSF alone.  Data are expressed as copy number 
per 103 copies of the housekeeping gene CNX to normalise for amount of input RNA, as it was 
unknown how many copies of the M1 mRNA were produced per input virus.  n=5 per strain. 
*** indicates statistical significance between cytokine treatments (p<0.0005) 
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Figure 4.5  Percentage of polarised BMDMφ surviving infection. 
BMDMφ were harvested and counted.  Survival of polarised Sv129 (solid bars) and IFNγR-/- (hatched 
bars) following infection with MoI 10 WSN was assessed by trypan blue exclusion assay at 16 (a) and 
48 hours (b), and normalised against strain matched mock infected polarised BMDMφ. n=3 per 
strain at 16 hrs, n=6 per strain at 48 hrs. 
* indicates statistical significance between cytokine treatments  
(* p<0.05, ** p<0.005) 
† indicates statistical significance between Sv129 and IFNγR-/- BMDMφ (p<0.05) 
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BMDMφ survival was further reduced by 48 hours (Figure 4.5b, red bars).  
BMDMφ derived from both strains showed significantly lower survival following 
infection of IL-4 activated macrophages compared to the IFNγ stimulated group 
(Figure 4.5a&b, green bars, p<0.05 & p<0.005 at 16 and 48 hours 
respectively), consistent with the higher rates of infection in these populations.  
The alternatively activated IFNγR-/- BMDMφ appeared to be most severely 
affected suggesting an interaction between strain and cytokine effect upon 
resilience to infection, but this did not achieve statistical significance (p=0.07).  
Taken together with the NS1 staining data, this suggests that IL-4 activation 
renders BMDMφ more permissive for WSN, allowing rapid progression of 
infection and ultimately resulting in more cell death in the alternatively 
activated population. 
 
4.1.2 Assessment of viral propagation in BMDMφ 
 
Despite the presence of NS1 being indicative of active infection, very little 
infectious virus was released into the supernatant of BMDMφ from either strain 
or activation group (Figure 4.6).  Supernatant was collected at 48 hours post 
infection and used to inoculate MDCK cells in a standard plaque assay as 
described in Chapter 2.3.2.  Slightly higher titres were retrieved from IFNγR-/- 
BMDMφ supernatant than from Sv129, but both were still markedly lower than 
the amount of input virus, (Figure 4.6, dashed line).  This is consistent with 
previous studies that found influenza virus infection to be non-productive in 
macrophages (Rodgers & Mims, 1981; Wells et al., 1978), despite being 
permissive for viral protein synthesis.  
  
It is possible that infection of macrophages with WSN results in production of 
replication defective viral particles, as it is evident that NS1 and other viral 
proteins are being produced, but little infectious virus released.  This was 
investigated by haemagglutination assay, whereby the presence of 
haemagglutinin-bearing  virions  causes agglutination of red blood cells regard- 
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Figure 4.6  Virus titre retrieved from BMDMφ supernatant. 
Serial dilutions of supernatants from polarised infected BMDMφ harvested at 48 hours post infection 
were assessed by plaque assay on MDCK cells.  Following incubation with the supernatants for 1 hr, 
MDCK cells were washed, overlaid with agarose and assessed for plaque formation after 72hrs.  The 
dotted line indicates input virus at an MoI of 10 used to infect the BMDMφ.  n=7 per strain 
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less of infectivity of the particles.  Defective particles were not detected in these 
experiments as incubation of BMDMφ supernatant with red blood cells did not 
result in haemagglutination (Figure 4.7).  Supernatants had been subjected to 
two prior freeze, thaw cycles and so it is possible that some particles may have 
been destroyed.  However, it is unlikely that high titres would be affected by 
several freeze thaw cycles, and haemagglutination would be observed in 
undiluted supernatant.  As this did not occur, it suggests that high numbers of 
defective particles are not released from BMDMφ and that influenza virus 
infection is truly abortive in this cell type.  
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Figure 4.7  Haemagglutination assay with supernatants from infected polarised BMDMφ 
Serial dilutions of supernatants from infected polarised BMDMφ harvested at 48 hour post infection 
were incubated with human red blood cells to assess presence of defective influenza virus particles.  
Diluted stock virus and serum free medium were used as positive and negative controls respectively 
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4.2 Cytokine response to influenza virus infection 
 
Further to the preliminary data presented in Chapter 3.2.2, the inflammatory 
response to influenza virus infection of Sv129 and IFNγR-/- was investigated.  
Again, qPCR was used to assess mRNA expression of key markers, along with 
ELISA and functional bioassays to assess the levels of protein being produced. 
 
4.2.1 mRNA expression profile in Sv129 and IFNγR-/- BMDMφ upon 
infection with A/WSN/33 
 
The cytokine response to WSN was investigated by infecting BMDMφ of both 
strains after activation with either IFNγ or IL-4, as described in Chapter 2.2.4, 
and extracting RNA at either 16 or 48 hours post infection, along with RNA 
from activated mock infected control BMDMφ.  RNA was reverse transcribed 
into cDNA and diluted 1 in 20 before being assessed for gene expression by 
qPCR.  The resulting data were analysed using Genex software and statistical 
analysis was carried out using the software package R, as described in 
Appendix 2.4.  R was also used to present the data.  Additionally, these data 
are summarised in Table 4.1 indicating up or downregulation in gene 
expression relative to strain matched BMDMφ cultured in M-CSF alone.  
Relative expression data in its full context along with statistical significance are 
presented in Figure 4.8 and Figure 4.9. 
 
In response to IFNγ, Sv129 BMDMφ demonstrated upregulated iNOS mRNA 
expression at both 16 and 48 hours (Figure 4.8a&b, 1st panel, 1st box).  
Expression remained high, but was not further enhanced by infection with 
WSN (Figure 4.8a&b, 1st panel, 2nd box).  As expected, IFNγ failed to induce 
significant iNOS expression from IFNγR-/- BMDMφ at either timepoint (Figure 
4.8a&b, 2nd panel, 1st box), indicating a significant difference between Sv129 
and IFNγR-/- BMDMφ (p<0.05 & p<0.0005 at 16 and 48hrs respectively).   
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16hr IFNγ IL-4 
Sv129 IFNγR-/- Sv129 IFNγR-/- 
Virus - + - + - + - + 







TNFα ↑ ↑ 
↑ 
↑ ↓ ↑ ↓ ↔ 
IL-12p40 ↑↑ ↑↑ ↔ ↔ ↔ ↑↑ ↑ ↑ 
IL-6 ND ↑↑ ND ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ 
Arg-1 
↑ 
↔ ↔ ↔ ↑ ↑ ↑ ↑ 
CD206 ↓ ↓ 
↑ 









FIZZ ND ↑↑ ND ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ 
48hr IFNγ IL-4 
Sv129 IFNγR-/- Sv129 IFNγR-/- 
Virus - + - + - + - + 
iNOS ↑↑ ↑↑ ↔ ↑ ↑ ↑↑ ↑ ↑↑ 
TNFα ↑ ↑ ↔ ↔ ↓ ↑ ↓ ↔ 
IL-12p40 ↑↑ ↑↑ ↑ ↑ ↔ ↑ ↔ ↔ 
IL-6 ↑↑ ↑↑ ↓ ↑ ↔ ↑ ↑↑ ↑ 
Arg-1 ↑ ↔ ↔ ↔ ↑ ↑ ↑ ↑ 
CD206 ↓ ↓ ↔ ↔ ↔ ↓ ↑ ↓ 
IL-10 ↑ ↑ ↔ ↔ ↔ ↑ ↓ ↔ 
FIZZ ↔ ↔ ↓ ↔ ↑↑ ↑↑ ↑↑ ↑↑ 
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Table 4.1  Summary of mRNA expression data. 
mRNA expression was assessed by qPCR, followed by normalisation against stably expressed 
housekeeping genes and expressed as fold change relative to mock infected control BMDMφ.  
Relative increases and decreases in expression following activation and infection of BMDMφ are 
summarised here for each gene of interest. 
 
ND, not detected;   
↔, No change from M-CSF only controls (baseline);   
↑ Marginal increase from baseline;   
↑, <100 fold increase from baseline expression;   
↑↑, >100 fold increase from baseline expression;   
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Figure 4.8  qPCR analysis of ‘classical’ gene expression. 
mRNA was extracted and reverse transcribed to cDNA followed by qPCR assessment of gene 
expression at 16 hrs (a, c, e, g) and 48 hrs (b, d, f, h). Each gene was normalised against a standard 
curve and each sample was normalised against two housekeeping genes to account for 
discrepancies in RNA concentration.  Each sample was then normalised against strain matched 
mock infected controls, activated with M-CSF only to obtain the fold change in mRNA expression 
relative to baseline levels.  Data are expressed as Log10 gene expression relative to controls.  n=3 
per strain at 16hrs, Sv129 n=22 & IFNγR-/- n=19 at 48hrs, except IL-6 where n=13 & n=10 for 
Sv129 &IFNγR-/- respectively. 
† indicates statistical significance between Sv129 and IFNγR-/- BMDMφ († p<0.05, †† p<0.005, ††† 
p<0.0005) 
 indicates statistical significance between mock and infected BMDMφ. Significance was graded as 
for †. 
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Infection of IFNγR-/- BMDMφ with WSN, however, led to a significant 
upregulation of iNOS expression at 16 hours (Figure 4.8a, 2nd panel, 2nd box, 
p<0.05).  This increase in expression was not maintained, however, and by 48 
hours levels were not significantly different from the IFNγ only group (Figure 
4.8b, 2nd panel, 2nd box). However, there was substantial variability in iNOS 
mRNA expression, indicating that a proportion of IFNγR-/- BMDMφ were driven 
to express iNOS mRNA following infection.  Despite the elevated iNOS 
expression observed early in infection, IFNγR-/- BMDMφ were significantly 
impaired in their classical response, regardless of infection (p<0.05 & p<0.0005 
at 16 and 48 hours respectively). 
 
IL-4 stimulation of both Sv129 and IFNγR-/- BMDMφ failed to induce significant 
iNOS expression (Figure 4.8a&b, 3rd & 4th panels, 1st box), but again, infection 
led to a significant increase at both timepoints (Figure 4.8a&b, 3rd & 4th panels, 
2nd box, p<0.05 & <0.005 at 16 and 48 hours respectively).  Additionally, 
IFNγR-/- BMDMφ expressed significantly less iNOS mRNA compared to wildtype 
counterparts at 48 hours, even in the presence of virus (p<0.05).  WSN 
infection appears to override the alternative activation induced by IL-4, causing 
iNOS mRNA to be expressed.  Infection with WSN is sufficiently 
proinflammatory to drive iNOS expression from IFNγR-/- BMDMφ, although this 
is impaired in the absence of IFNγ signalling.  
 
A similar pattern of expression was observed for TNFα, with Sv129 BMDMφ 
expressing elevated levels in response to IFNγ, which were further enhanced 
following infection with WSN (Figure 4.8c&d, 1st panel), and reached statistical 
significance at 48 hours (p=0.0005).  As expected, IFNγR-/- BMDMφ were 
significantly impaired in TNFα expression following exposure to IFNγ (Figure 
4.8c&d, 2nd panel, 1st box, p<0.05 & p<0.0005 at 16 and 48 hours 
respectively), but at 16 hours, demonstrated elevated TNFα expression 
following infection (Figure 4.8c, 2nd panel, 2nd box).  Similar to iNOS 
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expression, TNFα mRNA had returned to baseline expression by 48 hours in 
both mock and infected BMDMφ.   
 
IL-4 activation downregulated the TNFα response from both strains of 
macrophage, as expected (Figure 4.8c&d, 3rd & 4th panels, 1st box), but 
infection of IL-4 stimulated BMDMφ with WSN resulted in significantly elevated 
TNFα mRNA in both strains of BMDMφ when compared to mock infected 
alternatively activated macrophages (Figure 4.8c&d, 3rd & 4th panels, 2nd box, 
p<0.005 & p<0.0001 at 16 and 48 hours respectively).  This again 
demonstrates the ability of WSN to drive an inflammatory response in the 
presence of alternatively activating stimuli.  There was also a statistically 
significant interaction between infection and strain (p<0.05), demonstrating 
that although the virus is capable of driving a TNFα response from both strains 
of BMDMφ, this is impaired in the IFNγR-/- cells compared to wildtype Sv129 
BMDMφ.  
 
IL-12p40 mRNA expression was elevated in Sv129 BMDMφ in response to IFNγ.   
Following infection, no further increase was seen compared with IFNγ alone 
(Figure 4.8, e&f, 1st panel).  As expected, IFNγR-/- BMDMφ showed an impaired 
inflammatory response at both timepoints compared to wildtype counterparts 
(Figure 4.8e&f, 2nd panel, 1st box, p<0.0001 at 48 hours).  IL-12p40 mRNA was 
not detected in one mouse of each strain at 16 hours, despite this primer pair 
generating a standard curve with similar efficiency and limit of detection to 
primers for other genes of interest.  Therefore the difference between strains 
did not reach statistical significance at this timepoint. 
  
IL-4 stimulation failed to induce IL-12p40 mRNA expression from Sv129 
BMDMφ (Figure 4.8e&f, 3rd panel, 1st box), but induced variable expression of 
this mRNA in IFNγR-/- BMDMφ (Figure 4.8e&f, 4th panel, 1st box).  At 16 hours, 
these BMDMφ displayed slightly elevated IL-12p40 expression, and by 48 
hours substantial variation existed within this population.  However, upon 
Chapter 4                                                           Infection of Sv129 and IFNγR-/- BMDMφ 
                                                                                                                                            
164 
 
infection of alternatively activated macrophages, IL-12p40 expression remained 
low with the exception of Sv129 BMDMφ at 16 hours post infection, where 
expression was increased by the virus (Figure 4.8e, 3rd panel, 2nd box).  It was 
surprising to note that IL-12p40 was poorly induced by WSN, when both iNOS 
and TNFα were efficiently upregulated following infection.  However, these data 
are consistent with the preliminary mRNA expression data presented in 
Chapter 4.2.2, which showed a very modest increase in IL-12p40 mRNA 
expression following infection, and a variable response following IL-4 
stimulation of IFNγR-/- BMDMφ (Figure 3.10). 
 
IL-6 was strongly upregulated at 16 hours post infection by both strains of 
BMDMφ following infection with WSN but was undetectable in the mock 
infected IFNγ treated group (Figure 4.8g, 1st and 2nd panels).  Furthermore, 
BMDMφ from only one wildtype and two knockout mice activated with IL-4 
showed expression of this mRNA (Figure 4.8g, 3rd and 4th panels, 1st box).  
However, infected BMDMφ from both strains displayed greatly elevated IL-6 
mRNA expression, regardless of activating cytokine.  By 48 hours, IL-6 mRNA 
was detectable in all groups, but was highest in Sv129 BMDMφ (Figure 4.8h, 
1st panel, 1st box), although expression was highly variable.  Expression in this 
group was not increased following infection (Figure 4.8h, 1st panel, 2nd box), 
while IFNγR-/- BMDMφ were impaired in IL-6 mRNA expression in both mock 
and infected groups (Figure 4.8h, 2nd panel).  IL-4 stimulation led to 
upregulated IL-6 mRNA in both Sv129 and IFNγR-/- BMDMφ, with infection 
resulting in a modest  decrease in both strains (Figure 4.8h, 3rd & 4th panels).  
The considerable variation within these groups, however, prevented these 
alterations in expression level between mock and infected BMDMφ reaching 
statistical significance.   
 
Taken together, the ability of IFNγR-/- BMDMφ to mount a proinflammatory 
response to IFNγ stimulation is severely impaired, yet influenza virus is capable 
of inducing expression of proinflammatory mRNAs from IFNγR-/- BMDMφ and 
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from alternatively activated Sv129 BMDMφ.  However, this inflammatory mRNA 
expression is induced to a lower level in the knock out macrophages compared 
with their wildtype counterparts and therefore inhibition of IFNγ signalling may 
be important in vivo in dampening the detrimental inflammatory response that 
leads to severe immunopathology. 
 
As IFNγR-/- BMDMφ exhibited a less proinflammatory cytokine response to 
influenza virus, it was likely that they may express markers of alternative 
activation to a greater extent than the wildtype Sv129 BMDMφ.  This was also 
investigated by qPCR.  IL-4 activation induced significantly higher levels of Arg-
1 mRNA expression from both strains of BMDMφ at 16 and 48 hours, than did 
IFNγ (Figure 4.9a&b, all panels, 1st box, p<0.005 & p<0.0001 at 16 and 48 
hours respectively).  However, infection led to a slight decrease of this mRNA in 
all groups, reaching statistical significance at 48 hours post infection (Figure 
4.9b, all panels, 2nd box, p<0.005).  There appeared to be no difference between 
IFNγR-/- and Sv129 BMDMφ in their capacity to retain Arg-1 mRNA expression 
in the face of viral infection, despite the reduced expression of iNOS in IFNγR-/- 
macrophages. 
 
IL-4 stimulation significantly increased CD206 expression, compared with IFNγ 
in Sv129 BMDMφ at both 16 and 48 hours (Figure 4.9c&d, 1st & 3rd panels, 1st 
box, p<0.05 & p<0.005).  Additionally, CD206 mRNA was more strongly 
expressed in IFNγR-/- BMDMφ regardless of activating stimulus when compared 
with identically treated wildtype BMDMφ (Figure 4.9c&d, 2nd & 4th panels, 1st 
box, p=0.05, p<0.0001, IFNγ at 16 and 48 hrs respectively & p<0.05, IL-4 at 48 
hours).  However, upon infection, CD206 expression was markedly reduced in 
all groups investigated, significantly so in IL-4 stimulated BMDMφ at 48 hours 
(Figure 4.9d, 3rd & 4th panels, p<0.0001).  This contradicts the preliminary data 
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Figure 4.9  qPCR analysis of 'alternative' gene expression. 
As for Figure 4.8, RNA was extracted and reverse transcribed, followed by qPCR analysis.  Gene 
specific standard curves and two independent housekeeping genes were used to normalise the 
data, before fold change relative to non-activated, mock infected controls was calculated. 
Data are expressed as Log10 gene expression relative to controls.  n=3 per strain at 16hrs (a, c, e, 
g), Sv129 n=22 & IFNγR-/- n=19 at 48hrs (b, d, f, h), except for FIZZ where n=13 & n=10 for Sv129 & 
IFNγR-/- respectively. 
* indicates statistical significance between cytokine treatments  
(* p<0.05, **p<0.005, *** p<0.0005) 
† indicates statistical significance between Sv129 and IFNγR-/- BMDMφ  
 indicates statistical significance between mock and infected BMDMφ. Significance was graded as 
for *. 
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which showed elevated CD206 expression following infection, but may reflect 
the small sample size of the preliminary experiments.  The data also showed a 
statistically significant interaction between infection and cytokine (p<0.005), 
indicating that the response to infection was significantly different depending 
on which activating cytokine had been given.  
  
At 16 hours post infection, IL-10 mRNA expression remained around baseline, 
with a marginal increase observed following infection in all groups (Figure 
4.9e).  However, by 48 hours, IFNγR-/- BMDMφ demonstrated significantly lower 
IL-10 expression than their wildtype counterparts following IFNγ (Figure 4.9f 1st 
and 2nd panels, 1st box, p<0.005) and IL-4 stimulation (Figure 4.9f, 3rd & 4th 
panels, 1st box, p<0.05).  Infection led to significantly enhanced IL-10 mRNA 
expression in alternatively activated BMDMφ of both strains (Figure 4.9f, 3rd & 
4th panels, 2nd box, p<0.05).  There was also a significant interaction between 
infection and cytokine (p=0.05), indicating that the IL-10 mRNA response to 
virus differed between alternative and classically activated BMDMφ.  The 
upregulation of IL-10 in infected BMDMφ may be a result of type I IFN 
signalling following detection of the virus and upregulated proinflammatory 
cytokine mRNA such as TNFα and iNOS, resulting in induction of IL-10 to 
return the cytokine microenvironment to homeostasis. 
 
BMDMφ from only one mouse of each strain expressed FIZZ in response to IFNγ 
followed by virus at 16 hours post infection, while IL-4 alone resulted in strong 
expression in both strains at this timepoint, as expected.  However, the 
alternatively activated Sv129 BMDMφ showed a significant decrease in FIZZ 
mRNA upon infection (Figure 4.9g, 3rd panel, 2nd box, p<0.0005).  By 48 hours, 
IFNγ stimulated BMDMφ demonstrated varying levels of FIZZ expression, and 
infection induced no significant alterations (Figure 4.9h, 1st and 2nd panels).  
IL-4 activated macrophages expressed significantly elevated FIZZ mRNA at 48 
hours compared to IFNγ stimulated cells (Figure 4.9h, 3rd and 4th panels, 1st 
box, p<0.005), but expression was significantly downregulated compared to the 
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IL-4 only group following infection (Figure 4.9h, 3rd and 4th panels, 2nd box, 
p<0.005).  It is interesting that FIZZ mRNA expression appears to be elevated 
transiently at early timepoints following exposure to IL-4, but declining by 48 
hours.  In vivo, this protein is thought to play a role in wound healing; 
expression of FIZZ is upregulated following surgery but not sustained in the 
absence of pathogen driven T cell help (Loke et al., 2007).  It would appear that 
FIZZ may be rapidly upregulated following macrophage activation but in the 
absence of suitable T cell stimulation, expression wanes.  IL-4 stimulation may 
be sufficient to induce FIZZ expression but the very high expression observed 
at 16 hours is not sustained. 
 
Taken together with the Arg-1 mRNA expression data, this demonstrates that 
influenza virus downregulates the alternative activation phenotype in both 
strains of BMDMφ, while inducing a proinflammatory response from these 
cells.  Despite being less capable of mounting an inflammatory reaction, IFNγR-
/- BMDMφ could not sustain an alternatively activated response in the presence 
of virus, similar to their wildtype counterparts.  
 
4.2.2 Functional cytokine response to A/WSN/33 infection in Sv129 
and IFNγR-/- BMDMφ 
 
Bioassays for functional iNOS and Arg-1 showed little increase in iNOS activity 
at 16 hours following IFNγ activation of Sv129 BMDMφ (Figure 4.10a, first solid 
red bar) when compared to non activated controls (Figure 4.10a, solid grey 
bar).  IFNγ stimulation resulted in a modest increase in iNOS activity, while 
mRNA expression was strongly upregulated.  A further modest increase in 
iNOS activity was observed following infection, but this failed to reach 
statistical significance (Figure 4.10a, solid red bars).  iNOS was substantially 
elevated by 48 hours post infection, but showed no difference between mock 
and infected BMDMφ (Figure 4.10b, solid red bars).  IL-4 stimulation failed to  
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Figure 4.10  Bioassay for functional iNOS and Arg-1. 
iNOS and Arg-1 activity in each BMDMφ population was assessed by bioassay.  iNOS activity was 
measured by incubating supernatants with Greiss reagent, while cell lysates were incubated with L-
Arg to determine Arg-1 activity, as described in Chapter 2.6 & 2.7.  
Non-activated mock infected controls have been included as grey bars to indicate baseline activity of 
each enzyme. 
n=3 per strain at 16 hour, n=6 per strain at 48 hours 
* indicates statistical significance between cytokine treatments (* p<0.05, **p<0.005, *** 
p<0.0005) 
† indicates statistical significance between Sv129 and IFNγR-/- BMDMφ  
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increase iNOS activity at either timepoint (Figure 4.10a&b, first solid green 
bar), consistent with the qPCR data.  However, at 16 hours, there was an 
increase in functional iNOS in the infected IL-4 activated Sv129 BMDMφ 
(Figure 4.10a, 2nd solid green bar), consistent with the PCR data which showed 
upregulation of iNOS mRNA in this population, although to a much greater 
extent.  However, by 48 hours post infection, iNOS activity was not elevated 
above baseline (Figure 4.10b, 2nd solid green bar). 
   
Levels of iNOS at 16 hours post infection in both IFNγ and IL-4 IFNγR-/- 
BMDMφ were comparable to M-CSF controls (Figure 4.10a, hatched bars).  
This was marginally enhanced upon infection of the IL-4 stimulated group 
(Figure 4.10a, hatched green bars), whereas mRNA data showed a two log 
increase in expression following infection of both classical and alternative 
BMDMφ at this timepoint (Figure 4.8a, 2nd & 4th panels).  At 48 hours post 
infection, influenza virus caused enhanced iNOS activity in both the IFNγ and 
IL-4 stimulated infected groups, which did not acheive statistical significance, 
while IL-4 alone remained unable to increase iNOS activity (Figure 4.10b, 
hatched bars). The discrepancies between mRNA expression and protein 
activity indicate that mRNA levels do not necessarily correlate with functional 
protein, as there is a delay in translation of mRNA to newly synthesised protein 
and also the sensitivity of the bioassay is much lower than that of qPCR.  
 
In Sv129 BMDMφ, Arg-1 activity remained around baseline in response to IFNγ 
at both 16 and 48 hours (Figure 4.10c&d, solid red bars).  Although activity 
increased significantly in response to IL-4 at both timepoints (Figure 4.10c&d, 
1st solid green bar, p<0.0005) and remained elevated upon infection at 16 
hours, by 48 hours following infection Arg-1 activity was elevated to a 
significantly lesser extent than that observed for IL-4 alone in Sv129 BMDMφ 
(Figure 4.10c&d, 2nd solid green bar, p<0.005). 
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Consistent with the mRNA data (Figure 4.9a&b, 2nd panel), Arg-1 activity was 
not increased in IFNγR-/- BMDMφ by treatment with IFNγ alone or following 
infection, as expected (Figure 4.10c&d, hatched red bars).  IL-4 stimulation 
resulted in significantly increased Arg-1 activity at 16 hours compared with 
non-activated M-CSF controls (p<0.0005), and maintained elevated levels upon 
infection of the IL-4 activated group at 16 hours post infection (Figure 4.10c, 
hatched green bars).  However, similar to Sv129 BMDMφ, IFNγR-/- macrophages 
showed significantly less Arg-1 activity in the infected IL-4 group than for IL-4 
alone at 48 hours (Figure 4.10d, hatched green bars, p<0.005).  These findings 
indicate that infection with WSN drives BMDMφ towards a classical, 
proinflammatory phenotype even in the absence of IFNγ signalling, yet a 
proportion of cells remain alternatively activated when given a secondary 
challenge with inflammatory stimuli.  As shown in Figure 4.3, complete 
infection of the BMDMφ population was not achieved and therefore it is 
possible that the uninfected population of cells are capable of maintaining their 
alternative phenotype and continue to exhibit Arg-1 activity despite the 
presence of influenza virus.  It is also interesting that decreased Arg-1 activity 
does not appear to occur until later in infection.  This indicates that although a 
percentage of cells may remain uninfected and therefore alternatively activated, 
the protein half-life of Arg-1 will have an effect on the activity observed at the 
later timepoint.  The estimated half-life of Arg-1 is 30 hours and so by 48 
hours, much of the protein induced by IL-4 will be degrading in the infected 
population. 
 
IL-12p40 and TGFβ were assessed by ELISA at both 16 and 48 hours post 
infection.  Consistent with the mRNA expression data, IL-12p40 concentration 
was significantly increased in Sv129 BMDMφ in response to IFNγ and not IL-4 
(p<0.005), but was very slightly enhanced upon infection at 16hrs (Figure 
4.11a, solid red bars).  IL-4 failed to upregulate IL-12p40, with a non-
significant elevation observed in response to virus (Figure 4.11a, solid green 
bars), while mRNA expression showed a two log increase (Figure 4.8e, 3rdpanel) 
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Figure 4.11  ELISA detection of IL-12p40 and TGFβ. 
IL-12p40 and TGFβ concentrations in the supernatant were measured by ELISA.  Baseline levels for 
each strain of BMDMφ are indicated by grey bars. 
n=3 per strain at 16 hour, n=6 per strain at 48 hours 
* indicates statistical significance between cytokine treatments (* p<0.05, **p<0.005, *** 
p<0.0005) 
† indicates statistical significance between Sv129 and IFNγR-/- BMDMφ  
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By 48 hours post infection, all groups demonstrated greatly elevated IL-12p40 
concentrations (Figure 4.11b, solid bars), with the biggest increase being in the 
classically activated population.  Infected groups showed lower concentrations 
of IL-12p40 when compared to cytokine alone, which achieved statistical 
significance in the IFNγ treated Sv129 BMDMφ only (p<0.005), although levels 
remained higher than baseline.  There was some variability within infected 
populations at the mRNA level, and mRNA expression may not necessarily 
relate to new protein synthesis.   
 
IFNγR-/- BMBMφ exhibited significantly lower IL-12p40 concentrations than 
Sv129 cells in all groups at 16 hours (Figure 4.11a, hatched bars, p<0.0005), 
consistent with the mRNA expression data (Figure 4.8e).  At 48 hours, 
increased concentration was evident in the infected IFNγ exposed BMDMφ only 
(Figure 4.11b, second hatched red bar), while the IL-4 stimulated cells showed 
decreased IL-12p40 (Figure 4.11b, 2nd hatched green bar), consistent with the 
qPCR data (Figure 4.8f, 2nd & 4th panels), although neither reached statistical 
significance.  As the alternatively activated BMDMφ showed a decrease in IL-
12p40 upon infection (Figure 4.11b, second hatched green bar), this suggests a 
reduced inflammatory response to the virus and maintenance of the alternative 
phenotype in this group, consistent with the iNOS and Arg-1 bioassay data.  
Overall, the ELISA data shows an impairment of IFNγR-/- BMDMφ to produce 
IL-12p40 in response to A/WSN/33 at both 16 and 48 hours post infection, 
compared with Sv129 BMDMφ. 
 
TGFβ was also assessed, but was below the level of detection at 16 hours in 
wildtype Sv129 BMDMφ (Figure 4.11c).  By 48 hours post infection, TGFβ could 
be readily detected in infected macrophages of both classical and alternative 
populations (Figure 4.11d, solid bars).  In contrast, IFNγR-/- BMDMφ showed 
significantly higher levels of TGFβ compared to wildtype macrophages (p<0.05) 
and maintained similar concentrations in all populations assessed at 16 hours 
(Figure 4.11c, hatched bars). By 48 hours, differences between groups were 
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emerging with infection of IL-4 activated BMDMφ maintaining TGFβ 
concentration, while infected IFNγ primed BMDMφ demonstrated a decrease, 
perhaps due to decreased cleavage activation of the protein or enhanced 
protein shut off induced by the virus in this population.  Interestingly, this 
cytokine appears to be constitutively expressed by IFNγR-/- BMDMφ with 
relatively little change between activated groups, while only induced late in 
infection in Sv129 macrophages indicating underlying discrepancies between 
these two strains of mice. 
 
Influenza virus is known to shut off host protein synthesis enabling it to 
produce viral proteins.  In both strains of BMDMφ, all infected groups 
demonstrated decreased protein concentrations or activities at 48 hours, with 
the exception of iNOS in IFNγR-/- cells.  As this consistently occurred at the 
later timepoint, it indicates that after the virus has shut off new protein 
synthesis, degradation of remaining cellular protein may be responsible for the 
observed decline in concentration.  The upregulated iNOS activity at 48 hours 
post infection may be a result of initial virus induced protein remaining active 
in the supernatant as, taking into account the variability between samples, 
levels of activity are similar at both 16 and 48 hours.  The lack of IFNγ 
signalling prevents an increase following exposure to IFNγ and so the infected 
groups demonstrate higher levels of activity due to virus induced iNOS prior to 
host protein shut off.    
 
4.3 Summary of results and discussion 
 
Immunofluorescent staining highlighted differing patterns of infectivity 
between alternative and classically activated macrophages.  The weaker anti-
NS1 staining observed in IL-4 primed Sv129 BMDMφ at 16 hours, concurrent 
with stronger polyclonal antibody staining suggests that alternative activation 
renders BMDMφ more readily infectable and so the infection progresses more 
rapidly.  There may be little NS1 protein remaining in the cytoplasm at this 
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timepoint, perhaps having already begun translocation to the nucleus.  The 
stronger polyclonal staining indicates that greater quantities of viral proteins 
may have been generated early in infection.  This is consistent with other 
studies demonstrating that nitric oxide can limit viral replication (Croen, 1993; 
Karupiah et al., 1993; Zaragoza et al., 1997), which may enable the virus to 
survive and replicate more efficiently within the alternatively activated 
macrophages.  Alternatively, it is possible that the enhanced phagocytic 
capacity of alternatively activated macrophages (Loke et al., 2007; Tiemessen et 
al., 2007)  enables them to take up viral particles and debris more efficiently 
than their classically activated counterparts and so there are more viral 
envelope proteins within the alternatively activated BMDMφ, which are then 
readily stained.  Priming with IL-4 led to enhanced infection and poor viability 
in both Sv129 and IFNγR-/- BMDMφ but despite this, very little infectious virus 
was retrieved from the supernatant of any population investigated.  It also 
appears unlikely that formation of defective particles was responsible for the 
polyclonal staining observed at late timepoints infection, rather that 
immunodominant proteins, most likely HA and NA, accumulate within the cell 
but do not assemble into virions.  HA and NA are known to assemble in rafts 
below the cell membrane at regions where budding occurs (Takeda et al., 
2003).  It is likely that this process occurs in infected BMDMφ as the polyclonal 
anti-influenza antibody detects clusters of antigen which are predominantly 
cytoplasmic, suggesting accumulation of protein.  However, what prevents 
these accumulated proteins from assembling into virions is unknown. 
 
Interestingly, activated IFNγR-/- BMDMφ show constitutively higher expression 
of CD206 mRNA than Sv129 macrophages (Figure 4.9c&d).  This surface 
receptor has been implicated in influenza virus attachment and infection of 
macrophages.  Reading and colleagues have demonstrated that the efficiency 
with which a given strain of virus can infect macrophages directly correlates 
with the ability to bind CD206, and that infection can be inhibited by 
competitive binding of mannan, a known ligand for CD206 (Reading et al., 
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2000).  The ability to bind and subsequently infect macrophages is dependent 
on the presence of glycosylation sites on the head regions of HA and NA 
proteins.  Reading et al demonstrated that the H1N1 influenza virus, PR8, 
possessed poorly glycosylated HA and NA proteins and hence was inefficient at 
infecting macrophages.  BJx109, a virus which shares all internal gene 
segments with PR8 but expresses H3N2 on its surface, infected macrophages 
efficiently and demonstrated glycosylated surface proteins (Reading et al., 
2000).  Although sialic acid is known to be the target receptor for influenza 
virus binding, these interactions do not necessarily lead to infection.  Recently 
a model has been proposed whereby the virus initially binds to sialic acid 
which brings it into close proximity with endocytic receptors such as CD206, 
which require an additional interaction via glycosylated residues to occur prior 
to efficient internalisation and infection (Tate et al., 2010a; Upham et al., 
2010).  Despite the elevated CD206 mRNA expression, IFNγR-/- BMDMφ 
demonstrate less efficient early infection than their Sv129 counterparts.  WSN 
virus is derived from the parent virus A/WS/33, and was generated by serial 
passage through mouse brain (Francis & Moore, 1940), during which time it 
obtained neurovirulence in mice.  A similar derivative was also generated, 
NWS/33 (Stuart-Harris, 1939), which is known to contain only one 
glycosylation site on its HA, while glycosylation is absent from the HA of the 
parent strain WS/33 (Job et al., 2010).  Sequence comparison between these 
and the WSN strain confirms that WSN has only two glycosylation sites on the 
HA head, and the absence of a conserved site on WSN NA has been implicated 
in the neurovirulence displayed by this virus (Li et al., 1993).  This indicates 
that the glycosylation pattern displayed by WSN HA & NA is unlikely to 
facilitate binding to the mannose receptor and so upregulation of this 
sialylated surface receptor would not contribute to viral infection.  
  
IFNγR-/- BMDMφ demonstrated lower percentage positivity for viral proteins 
early in infection, but by 48 hours, were comparable to wildtype counterparts.  
This impaired early infection observed in IFNγR-/- BMDMφ may be due to poor 
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entry of the virus into the cell or a non-permissive environment upon infection. 
As previously discussed, influenza virus binds sialic acid, and the role of this 
interaction may be to bring the virus into juxtaposition with endocytic 
receptors, rather than facilitate entry in its own right.  Similar to CD206, the 
IFNγ receptor becomes endocytosed into acidified vesicles where it releases its 
ligand and joins a cellular pool to be recycled back to the cell surface (Farrar & 
Schreiber, 1993), making it a candidate receptor for influenza virus attachment 
and entry.  Glycosylation of the IFNγ receptor has been shown to be vital for 
ligand binding, while removal of sialic acid by treatment of cells with 
neuramindase abrogated binding, implicating sialic acid in functional binding 
of IFNγ to its receptor (Fischer et al., 1990).  It is possible that the absence of 
the IFNγ receptor may result in a lack of suitable sialylated endocytic receptors 
and therefore restrict the amount of virus able to enter the cell and 
consequently lower levels of viral staining are observed at 16 hours post 
infection. 
 
However, by 48 hours post infection, the percentage of BMDMφ staining 
positive for viral proteins were similar in both wild type and receptor deficient 
macrophages.  Taken together with the PCR data that showed IFNγR-/- BMDMφ 
to be capable of mounting an early but unsustained inflammatory response to 
WSN, it is likely that IFNγR-/- BMDMφ become more permissive for viral 
replication as time progresses, as in the absence of IFNγ signalling, neither 
iNOS or IL-6 expression is maintained.  Sv129 BMDMφ also generated a rapid 
inflammatory response to infection and yet viral proteins were readily detected 
at 16 hours post infection, further suggesting that IFNγR-/- BMDMφ are less 
permissive for viral attachment and entry.  However, once inside, the lack of a 
sustained inflammatory response allows the virus to rapidly attain equivalent 
levels of viral positivity as those seen in wildtype Sv129 BMDMφ.  In addition to 
this, IL-4 stimulated BMDMφ of both strains show enhanced positivity, 
consistent with a less inflammatory environment being more permissive for 
infection.  Although alternatively activated BMDMφ are known to have greater 
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phagocytic capacity than their classically activated counterparts (Tiemessen et 
al., 2007), this is unlikely to contribute to the elevated positivity observed at 16 
hours postinfection in this group of cells as at this timepoint, NS1 positive cells 
were assessed.  NS1 is synthesised during active replication within the cell and 
so phagocytosed debris and virions would not result in significant detection of 
this protein, although it is possible that this phagocytic property of the 
alternative BMDMφ may enhance the level of staining observed at 48 hours 
using the polyclonal anti-influenza antibody. 
  
Conversely, it may be possible that viral entry is not altered or impaired by the 
absence of the IFNγ receptor but that differing metabolism of wildtype and 
IFNγR-/- macrophages following infection has an effect on viral permissiveness.  
Classical Sv129 BMDMφ are primed with IFNγ prior to infection, which results 
in enhanced ability to rapidly express antiviral and proinflammatory mediators 
(Nathan et al., 1983).  Furthermore, these cells are capable of responding to 
autocrine IFNγ induced by IL-12 (Di Marzio et al., 1994; Fultz et al., 1993), 
therefore amplifying a positive feedback loop by which these macrophages 
remain activated. Following WSN infection, Sv129 BMDMφ rapidly increase 
expression of proinflammatory mRNAs, a response which is sustained 
throughout the duration of the timecourse investigated.  However, IFNγR-/- 
BMDMφ demonstrate a reduced respiratory burst early in infection as these 
cells could not become primed by exposure to exogenous IFNγ (Figure 4.8).  
This limited burst is further impaired with time as the cells are unable to 
respond to either exogenous or autocrine IFNγ.  The influenza virus polymerase 
complex has been shown to localise with active RNA polymerase II in order to 
efficiently steal caps from cellular mRNAs undergoing synthesis (Engelhardt et 
al., 2005).  The reduced mRNA expression observed in IFNγR-/- cells may 
impede early virus replication as the cellular machinery utilised by the virus 
does not undergo the rapid and prolonged burst of activity that occurs within 
wildtype cells, ultimately limiting the amount of replicating virus observed at 
16 hours post infection.  However, this restriction may be overcome with time 
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due to the absence of antimicrobial mediators such as nitric oxide, allowing the 
virus to accumulate to comparable levels in the IFNγR-/- BMDMφ. 
 
Despite upregulated expression of inflammatory mediators iNOS and IL-12p40 
mRNA early in infection in both Sv129 and IFNγR-/-, corresponding increases in 
protein were not necessarily observed.  Surprisingly, IFNγR-/- BMDMφ showed 
higher baseline levels of functional iNOS and Arg-1 than their wildtype Sv129 
counterparts at both timepoints (Figure 4.10a&b, grey bars), but Sv129 
BMDMφ did not demonstrate increased iNOS activity following infection, while 
IFNγR-/- BMDMφ showed some enhancement demonstrating that the virus was 
capable of driving iNOS activity despite the absence of IFNγ signalling.  Both 
strains continued to demonstrate some Arg-1 activity in infected alternatively 
activated macrophages, suggesting that although strong, the proinflammatory 
signal given by influenza virus is not overwhelming and also that both strains 
of BMDMφ are capable of altering their phenotype in response to sequential 
stimuli.  Furthermore, infection of BMDMφ did not result in positive staining in 
every cell.  Between 15 and 30% of Sv129 and IFNγR-/- BMDMφ respectively 
remained negative for viral proteins at 48 hours post infection.  It is likely that 
these cells are capable of maintaining their alternative phenotype and 
exhibiting Arg-1 activity despite influenza virus infection in neighbouring cells, 
especially in the IFNγR-/- cells which are unable to respond to paracrine IFNγ.  
 
The differing levels of cell death and infection seen between strains and 
polarised groups, necessitate a cautious approach to interpretation of the 
qPCR data.  mRNA expression may not be fully representative of the whole 
population of cells, only the surviving proportion.  Therefore it is not possible 
to infer with certainty the effect that virus has on polarised BMDMφ as those 
surviving may be those remaining uninfected, or those most readily able to 
alter their phenotype. 
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In addition to this, it must be remembered that this source of macrophages is 
heterogeneous by nature.  When the bone marrow is harvested from femurs 
and macrophages isolated by adherence in the presence of M-CSF, a variety of 
maturational stages are present and it takes several days for all the monocyte 
progenitors to acquire a mature BMDMφ phenotype and adhere to the plastic.  
This may be of some importance in preventing 100% infection, as it has 
previously been shown that culture of elicited macrophages on plastic for three 
or seven days alters the total number of cells that can become infected 
(Rodgers & Mims, 1981).  The longer the cells remained in culture, the more 
permissive they were to infection.  This study used thioglycollate elicted 
peritoneal macrophages, which are more uniform in maturation than BMDMφ 
and so this suggests that the degree of maturation may be important in 
deciding the relative resistance of the cell to influenza virus infection.  This in 
turn is likely to have a downstream effect on the ability of a given cell to 
maintain its activated phenotype following infection. 
 
TGFβ appeared to be constitutively active in IFNγR-/- macrophages but only 
detectable late in infection in Sv129 BMDMφ.  This difference in baseline TGFβ 
expression between Sv129 and IFNγR-/- BMDMφ is intriguing as it appears that 
these strains of mice may have differing resting phenotypes of macrophage, or 
at least differing background expression of certain genes.  Previous studies 
utilising IFNγR-/- mice generated on the Sv129 background have found no 
discrepancies between these and wildtype animals with regards to lymphocyte 
composition or natural killer cell activity.  IgM responses were found to be 
normal, as was expression of both MHC I and II.  However, upon viral 
infection, the IgG2a response was impaired in the IFNγR-/- animals (Huang et 
al., 1993).  However, no study has addressed the role or the phenotype of 
macrophages derived from these mice, and consequently cytokine responses 
have also been ignored.  Therefore it is completely unknown whether 
disruption of the IFNγ receptor results in altered cytokine expression from 
macrophages and other cell types.  The data presented herein would suggest 
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that there is a difference in baseline levels at least in iNOS (Figure 4.10a & b), 
Arg-1(Figure 4.10c & d) and TGFβ (Figure 4.11c & d).  This may influence the 
ability of these BMDMφ to respond to virus and be important in the impeded 
early establishment of infection observed.  Each protein examined here 
demonstrated enhanced baseline levels in comparison with Sv129 cells, and so 
it may be simply that these mice are higher producers with no relative change 
in protein expression.  However, it may be important to further investigate 
baseline differences in protein expression and activity when making direct 
comparisons between IFNγR-/- and Sv129 BMDMφ in the future. 
 
In light of the data presented, it appears likely that the overall impairment of 
the proinflammatory response in influenza virus infected IFNγR-/- BMDMφ may 
have important implications in vivo, as a ‘cytokine storm’ like scenario may be 
avoided upon inhibition of IFNγ signalling.  
Chapter 5                                                     In vivo infection of Sv129 and IFNγR-/- mice 








5 IN VIVO INFECTION OF SV129 AND IFNγR-/- MICE .......................................................184 
5.1 Pilot infections of Sv129 and IFNγR
-/-
mice ..................................................................................184 
5.1.1 Clinical outcome of infection with A/WSN/33 ....................................................................... 184 
5.1.2 Immunopathology following A/WSN/33 infection................................................................. 188 
5.2 Infection of Sv129 and IFNγR
-/-
 mice ...........................................................................................190 
5.2.1 Clinical outcome of infection with A/WSN/33 ....................................................................... 190 
5.2.2 Influenza virus associated immunopthology ......................................................................... 194 
5.2.3 Cytokine expression following infection with WSN ............................................................... 219 
5.3 Summary of results and discussion ............................................................................................226 
Chapter 5                                                     In vivo infection of Sv129 and IFNγR-/- mice 




5 In vivo infection of Sv129 and IFNγR-/- mice 
 
Influenza virus infection of Sv129 or IFNγR-/- mice has not previously been 
documented, although B and T cell responses have been investigated in mice 
lacking the IFNγ gene on C57B/6 and BALB/c backgrounds (Bot et al., 1998; 
Graham et al., 1993).  These studies showed functional cellular and humoral 
responses following challenge, but did not address the role played by the 
innate immunity.  The following experiments aim to address this by infecting 
Sv129 and IFNγR-/- mice with A/WSN/33 and investigating differences in 
clinical outcome, viral load, immunopathology and cytokine expression profile 
between these strains of mice. 
 
5.1 Pilot infections of Sv129 and IFNγR-/-mice 
 
As demonstrated in Chapter 4, IFNγR-/- BMDMφ show an impaired 
inflammatory response when infected with influenza virus A/WSN/33.  It was 
also apparent that the kinetics of viral infection differed between the wildtype 
and knockout strains of BMDMφ.  These findings could have important 
implications in vivo, with the possibility of subverting the damaging ‘cytokine 
storm’ scenario.   
 
5.1.1 Clinical outcome of infection with A/WSN/33 
 
Due to the absence of information in the literature regarding infection of these 
strains of mice with influenza virus, it was first necessary to titrate the viral 
dose based on the available data for C57Bl/6 and BALB/c mice (Hashimoto et 
al., 2007; Jackson et al., 2008).  As such, a series of pilot experiments were 
performed with a range of infectious doses. 
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Sv129 mice were infected intranasally under anaesthesia with 1x103, 5x103 or 
1x104 pfu of WSN in 40µl PBS, as described in Chapter 2.1.2, and monitored 
daily for weight loss and clinical symptoms.  These included, in order of 
presentation, ruffling of the fur, hunched posture, increased respiratory rate 
and immobility.  Mice were euthanized at 2, 4, 6, and 8 days post infection, or 
upon loss of 30% of their starting weight, in accordance with terms of the UK 
Home Office project licence. 
 
Severity of disease increased in a dose dependent manner in Sv129 mice, as 
evidenced by weight loss and diminishing clinical score.  Mice infected with 
1x103 and 5x103 pfu displayed limited clinical symptoms (Table 5.1) and lost 
less than 20% of their initial body mass during the course of infection (Figure 
5.1a).  Those infected with the lowest infectious dose appeared to regain some 
weight by day 8 which, coupled with the lack of clinical symptoms, suggests 
these mice successfully recover from infection.  However, mice infected with 
1x104 pfu demonstrated rapid weight loss, with several mice losing up to 30% 
of their starting weight by day 7 (Figure 5.1a), when this pilot experiment was 
terminated due to the severity of illness.  Clinical symptoms manifested earlier 
and with greater intensity in these mice, compared with those infected at lower 
doses (Table 5.1).  
  
IFNγR-/- BMDMφ displayed poorer viability upon infection with WSN, compared 
with their Sv129 counterparts, and so it was possible that in the absence of a 
functional antiviral response, IFNγR-/- mice might display more severe disease, 
due to inability to control viral replication.  As such, IFNγR-/- mice were infected 
with the lowest dose of 1x103 pfu.  This, however, led to no observable 
symptoms and the infected mice maintained their starting body mass, 
although they failed to gain weight in line with mock infected controls (Figure 
5.1b).  This supports the hypothesis proposed in Chapter 4.3, that the absence 
of IFNγ signalling results in an impaired inflammatory response and therefore 
ameliorated disease. 
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1x103 PFU d2 - - - -
d4 - - - -
d6 - - - -
d8 + - - -
5x103 PFU d2 - - - -
d4 + + - -
d6 + + - -
d8 + + - -
1x104 PFU d2 - - - -
d4 + + + +
d6 + + + +
d8 + + ++ ++
Table 5.1  Clinical symptoms in Sv129 mice following infection with WSN at varying dose. 
Clinical symptoms were monitored daily and scored on the scale – (no clinical symptoms) to +++ 
(severe presentation).  Mock infected mice consistently showed no clinical symptoms, while infected 
animals presented increasingly severe symptoms with time in a dose dependent manner.  Average 
score of n=3/timepoint is presented. 
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Figure 5.1  Weight loss following infection with varying infectious dose. 
Sv129 and IFNγR-/- mice were infected with WSN to establish appropriate infectious dose for future 
infections.  Weight loss was monitored daily as an indication of disease severity.  Mock infected mice 
were inoculated intranasally with 40µl PBS as controls. n=3 per timepoint. 
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5.1.2 Immunopathology following A/WSN/33 infection 
 
Lungs were harvested following euthanasia of infected and control mice at day 
8 post infection.  Tissues were fixed and processed to sections as described in 
Chapter 2.8, followed by staining with haematoxylin and eosin to assess tissue 
damage as a result of infection. 
 
Infected Sv129 animals demonstrated congestion of the airspaces in a dose 
dependent manner, compared with mock infected controls (Figure 5.2a-d).  
Those infected with the lowest dose showed very slight congestion in small 
areas of the lung, but this increased in density and size with increasing 
infectious dose, until most of the lung was affected in the 1x104 pfu infected 
mice.  
 
Surprisingly, IFNγR-/- mice showed several areas of substantial cellular 
infiltration compared with mock infected controls (Figure 5.2e&f), which was 
not reflected in the clinical score.  The absence of clinical symptoms and 
weight loss suggested that these mice easily recovered from a subclinical 
infection, while the histology shows tissue damage at day 8 post infection. 
   
However, as this dose was insufficient to cause observable clinical symptoms 
in the IFNγR-/- mice, 1x104 pfu was selected for further experiments.  Although 
this led to severe disease in wildtype Sv129 animals, it was necessary to use an 
infectious dose that would cause manifestation of symptoms in the knockout 
mice. 
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Figure 5.2  Immunopathology in the lung following infection with varying infectious dose. 
Sv129 mice inoculated with infectious dose of 1x103 (b), 5x103 (c) or 1x104 (d) demonstrated 
cellular infiltration into the lungs compared to mock infected animals (a) in a dose dependent 
manner.  IFNγR-/- also demonstrated congestion in the lungs following infection with a low infectious 
dose, 1x103 (f), compared to strain matched mock controls (e). All x5 magnification. 
b, bronchiole; tb, terminal bronchiole; v, vein; bv, blood vessel; in, inflammation 
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5.2 Infection of Sv129 and IFNγR-/- mice 
 
Following the pilot studies described above, larger groups of mice of both 
backgrounds were infected with 1x104 pfu and the experiments repeated (n=7 
at each timepoint).  Lungs were harvested for virus titre, RNA extraction and 
histology following euthanasia at days 2, 4, 6 and 8 post infection. 
 
5.2.1 Clinical outcome of infection with A/WSN/33 
 
As demonstrated in the pilot studies, Sv129 mice infected with 1x104 pfu 
suffered severe disease, with early onset of clinical symptoms (Table 5.2).  
These mice rapidly lost weight and had reached around 75% of their original 
body mass by day 8 post infection (Figure 5.3a).  IFNγR-/- mice however, 
showed very little weight loss during the course of the infection, and had begun 
to recover their starting weight by day 8 (Figure 5.3a).  Similarly, only mild 
clinical symptoms were observed in these mice (Table 5.2), suggesting 
ameliorated disease and recovery.  
  
Lungs were harvested and homogenised for virus plaque assay, which revealed 
differences in lung virus titre between the two strains of mice (Figure 5.3b).  
IFNγR-/- mice demonstrated lower viral titres at each timepoint assessed 
compared with wildtype Sv129 mice.  However, both strains showed declining 
titres towards the end of the experiment, suggesting that both were capable of 
clearing the virus.  These strain discrepancies were also reflected in the viral 
M1 gene qPCR results (Figure 5.4), whereby IFNγR-/- animals showed 
significantly lower expression of this viral mRNA in the lungs than Sv129 mice 
(p=<0.0005).  Consistent with the virus titres, IFNγR-/- mice showed declining 
expression by day 8, but interestingly, elevated expression between days 4 and 
6 post infection was coincident with the point at which these mice showed 
most substantial weight loss, before beginning to recover concurrent with 
reduced titres and M1 expression.  Also of interest, IFNγR-/- BMDMφ were infec- 
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Sv129 d2 - - - -
d4 ++ + - +
d6 ++ ++ + +
d8 +++ ++ + +
IFNγR-/- d2 - - - -
d4 - - - -
d6 + + - +
d8 + + + +
Table 5.2  Clinical symptoms following infection with 1x104 PFU WSN. 
Sv129 mice demonstrated early onset of symptoms which became increasingly severe throughout 
the course of infection.  IFNγR-/- animals, however, displayed mild symptoms following infection with 
the same infectious dose, onset of which were delayed until day 6 post infection.  Mock infected 
control animals of both strains presented no clinical symptoms. Average scores presented, n=7 per 
timepoint. 
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Figure 5.3  Weight loss and viral titre following infection with 1x104 PFU WSN. 
a) Sv129 mice rapidly lost weight following infection, while weight loss in IFNγR-/- was less severe, 
having slowed by day 6.  Following this timepoint, IFNγR-/- began regaining weight, indicating 
recovery, while their wildtype counterparts continued to deteriorate. 
n=4 per timepoint, representative of 3 independent experiments 
b) Viral titres from homogenised lungs were higher in Sv129 animals than IFNγR-/- mice. 
n=7 per timepoint 
* <0.05, ** <0.005 
Weight Loss
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Figure 5.4  Expression of M1 viral mRNA following infection with 1x104 PFU WSN. 
RNA was extracted from lungs of Sv129 and IFNγR-/- mice and M1 mRNA expression was assessed.  
Absolute quantification of copy number was applied and normalised against housekeeping gene CNX
(M1 copy number per 103 copies CNX).  At each timepoint examined, Sv129 animals demonstrated 
significantly higher expression of this viral mRNA than did IFNγR-/- mice († = <0.05, †† = <0.005), which 
resulted in the overall difference in expression between Sv129 and IFNγR-/- mice being highly significant 
(p = <0.0005).  This indicates that Sv129 mice are more permissive for viral replication than their 
IFNγR-/- counterparts. 
n=3 per timepoint 
Chapter 5                                                     In vivo infection of Sv129 and IFNγR-/- mice 
                                                                                                                                            
194 
 
ted at lower levels than Sv129 cells, implying that the IFNγR-/- background 
results in reduced viral positivity in different cell types, both in vitro and in 
vivo. 
   
Together, these data show that disruption of IFNγ signalling leads to mild 
disease in vivo.  As discussed previously, it is possible that this is due to a net 
loss of sialylated residues on the surface of IFNγR-/- cells and so the virus is 
less able to gain entry and cause infection.  However, it is also possible that in 
the absence of IFNγ signalling, the immune system is able to generate a 
functional antibody and T cell response to the virus, as indicated by previous 
studies (Bot et al., 1998; Graham et al., 1993), resulting in viral clearance 
while avoiding the excessive inflammation and immunopathology driven by 
IFNγ.  This was further investigated by assessment of immunopathology and 
cytokine expression. 
 
5.2.2 Influenza virus associated immunopthology 
 
H&E staining revealed stark differences between infected Sv129 and IFNγR-/- 
mice. The lungs from wildtype animals showed substantial inflammatory 
infiltrate into the tissue, while the knockout mice demonstrated comparatively 
little congestion.  This was especially marked at day 4 post infection (Figure 
5.5a&e).  Infected Sv129 mice demonstrated thickening of the alveolar airspace 
walls and heavy cellular infiltration into the lung tissue and bronchioles.  At 
higher magnification, strong infiltration was seen around the bronchioles, 
which also demonstrated sloughing of the epithelial cell lining and appeared to 
contain cellular debris. (Figure 5.5b).  IFNγR-/- mice, however, showed minimal 
thickening of the airspace walls, with some cellular infiltration appearing in a 
focal pattern, compared to the diffuse congestion observed in the wildtype 
Sv129 mice (Figure 5.5e).  Under higher magnification, this infiltration was 
seen to be within the alveolar airspaces only   (Figure 5.5f)  rather than within 
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Figure 5.5  Immunopathology following infection with 1x104 PFU WSN. 
Infected Sv129 lungs under x5 magnifcation (a&c) and at x40 magnification (b&d), at days 4 and 8 
respectively, showed intense and diffuse cellular infiltrate.  IFNγR-/- lungs ((e) x5, day 4; (f) x40, day 
4; (g) x5, day 8; (h) x40, day 8) displayed reduced infiltration compared to wildtype counterparts.  
Mock infected controls of both strains failed to demonstrate infiltration. 
Representative of n=6 per timepoint. 
b, bronchiole; tb, terminal bronchiole; v, vein; bv, blood vessel; in, inflammation 
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bronchioles, again highlighting a difference in infection kinetics between 
wildtype and IFNγR-/- mice By day 8 post infection, both strains of mice 
demonstrated more extensive congestion within the lungs, but the wildtype 
Sv129 mice were most severely affected.  Lungs from these mice showed diffuse 
thickening of the alveolar airspace walls, with extreme cellular infiltration and 
oedema in every area examined (Figure 5.5c).  Higher magnification showed 
severe damage to the bronchiolar epithelium, with very few cells remaining 
intact and many inflammatory cells penetrating the alveolar airspaces (Figure 
5.5d).  IFNγR-/- mice showed more diffuse infiltration and thickening of the 
alveolar airspace walls than had been observed at day 4, but this was less 
severe than that seen in wildtype mice.  Moderate congestion with infiltrating 
cells was observed throughout the majority of the IFNγR-/- infected lung (Figure 
5.5g), and under x40 magnification, strong infiltration was seen around the 
bronchioles.  Similar to Sv129 mice, the bronchioles also showed evidence of 
damage to the epithelial layer. 
 
The delayed onset of cellular infiltration in the lungs of infected IFNγR-/- mice, 
together with the limited weight loss and clinical symptoms observed in 
Chapter 5.2.1 suggested differing patterns of infection in these mice compared 
to wildtype Sv129 animals.  This was further investigated by staining for 
influenza virus using either a broad spectrum polyclonal anti-influenza 
antibody, along with HRP detection or a polyclonal anti-NS1 antibody followed 
by detection with Alexfluor 488, as described in Chapter 2.8.  
 
Immunofluorescent staining for NS1 immediately highlighted differing patterns 
of infection in the two strains of mice.  At day 2 post infection, Sv129 mice 
demonstrated patches of positive staining cells throughout the lung, with 
bronchiolar epithelium staining very strongly (Figure 5.6a).  In contrast, IFNγR-
/- showed smaller groups of positive cells, with limited involvement of the 
epithelial lining (Figure 5.6b).  By day 4, both strains showed stronger 
positivity  for  virus,  with  the  majority of bronchiolar epithelial cells becoming 
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Figure 5.6  Immunofluorescent staining of NS1 viral protein. 
Sv129 mice demonstrated stronger staining for NS1 in the lungs at all timepoints examined, in 
addition to a different pattern of localisation compared with IFNγR-/- animals.  (a, c, e, g) Sv129 at 
days 2, 4, 6 and 8 respectively, (b, d, f, h) IFNγR-/- at days 2, 4, 6 and 8 respectively.  Mock infected 
lungs from both strains of mouse were negative for NS1 staining. 
Representative of n=3 per timepoint 
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positive for NS1 (Figure 5.6c&d).  At this timepoint, more NS1 was detected in 
the alveolar airspaces in both strains of mice.  However, by day 6 post 
infection, Sv129 mice demonstrated intense and diffuse positivity for NS1 
protein in the alveolar spaces and in the bronchioles (Figure 5.6e).  Some 
positive staining was still visible in the bronchiolar epithelium, but this was 
reduced compared to previous days.  However, debris and sloughed epithelial 
cells were apparent indicating extensive damage to the bronchioles in Sv129 
mice (Figure 5.6e, white arrow).  In contrast to this, IFNγR-/- mice showed very 
little staining within the bronchioles, with no visible debris (Figure 5.6f).  
However, there was a diffuse pattern of NS1 staining throughout the lungs 
indicating that the virus had successfully infected the tissue.  By day 8, 
however, very few NS1 positive cells remained within the IFNγR-/- lung (Figure 
5.6h), indicating that limited new viral synthesis was ongoing at this timepoint, 
and that IFNγR-/- animals had successfully controlled the infection.  Sv129 
mice continued to demonstrate intense NS1 staining at day 8, although there 
was no evidence of bronchiolar infection at this timepoint (Figure 5.6g).  This 
demonstrates that Sv129 mice are more permissive for viral replication than 
IFNγR-/- animals, with infection becoming established early and viral 
replication continuing throughout the course of infection in this strain of mice.  
Conversely, IFNγR-/- mice demonstrate a delayed onset of widespread viral 
replication, which is subsequently brought under control by day 8 post 
infection. 
 
The anti-NS1 staining was followed with detection of virus using the polyclonal 
anti-influenza antibody.  Due to the broad specificity of this antibody, virus 
particles and proteins remaining in the lung can be visualised after active 
replication has ceased, in order to determine the full extent of infection.  
Similar to the NS1 stained sections, at day 4 Sv129 mice demonstrated 
infection of the bronchiolar epithelium with occasional positive cells within the 
alveolar airspaces (Figure 5.7a).  By day 8 however, the infection had 
progressed, with the alveolar walls themselves showing strong positive staining 
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Figure 5.7  Immunohistochemistry for influenza virus proteins. 
Infected Sv129 lungs under x20 magnifcation (a&c) and at x40 magnification (b&d), at days 
4 and 8 respectively, showed intense and diffuse staining for influenza virus proteins.  
IFNγR-/- lungs ((e & g) x20, day 4 and 8; (f & h) x40, day 4 and 8) displayed less positivity for 
viral proteins compared to wildtype counterparts.  Black arrows indicate cells with 
macrophage-like morphology and strong staining for viral proteins.  Mock infected controls 
of both strains were negative for viral staining. 
Representative of 3 independent experiments 
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staining for virus (Figure 5.7c).  Under higher magnification it became evident 
that the bronchiolar epithelium was heavily infected but also undergoing 
strong inflammatory infiltration at day 4 (Figure 5.7b), while by day 8, all 
remaining epithelial cells were infected and the bronchioles were congested 
with debris (Figure 5.7d).  This is consistent with the pattern of infection 
observed with the NS1 antibody, whereby the infection progresses from the 
bronchioles to the lung tissue as a whole, with excessive damage to the 
epithelium. 
   
The virus staining pattern seen in IFNγR-/- lungs closely mimicked the pattern 
of infiltration seen in the H&E stained sections.  The walls of the alveolar 
airspaces were positive for viral proteins at both timepoints, and this was focal 
in nature at day 4 (Figure 5.7e) but more diffuse by day 8 (Figure 5.7g).  
However, this positivity was substantially weaker than that demonstrated by 
the wildtype Sv129 animals. Under higher magnification, it was apparent that 
the alveolar walls were thickened, but less heavily infected than their wildtype 
counterparts.  
  
In addition to this, both strains of mice demonstrated very strongly positive 
cells within the alveolar airspaces (Figure 5.7b, d, f, g, black arrow), which 
were most pronounced at day 8.  The position and morphology of these cells 
was suggestive of macrophages, either infected or phagocytosing infected 
material.  This was further investigated by staining for virus and the 
macrophage marker F4/80, followed by detection with Alexafluor 488 and 
Alexafluor 594, labelling the virus green and macrophages red (Chapter 2.8.2).  
Although DAPI was included as a counterstain, it was omitted from these 
images as it obstructed a clear view of the colocalised Alexafluor signals. 
 
Low numbers of alveolar macrophages were present in the lungs of mock 
infected Sv129 mice (Figure 5.8, white arrow).  However, even early in infection 
there was evidence of macrophages homing to the lung and exiting the blood at 
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Figure 5.8  Immunofluorescence for virus positive macrophages; Sv129 mock 
Mock infected Sv129 displayed low levels of macrophages (white arrow) within the lung in the 
absence of virus. Top left panel: anti-influenza virus + alexafluor 488; bottom left panel: anti-F4/80 
+ alexafluor 594; right panel: overlaid image. 
Representative of n=2 
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the site of infection (Figure 5.9).  At high magnification, virus was seen in the 
epithelial cells lining the alveolar spaces but also in macrophages (Figure 5.9b, 
white arrow), with infiltrating macrophages gathering at the interface of the 
blood stream and the lung.  By day 4 post infection, Sv129 showed vast 
numbers of cells leaving the blood and entering the lung, forming large 
perivascular cuffs around blood vessels (Figure 5.10a).  This infiltrate 
contained many macrophages (Figure 5.10a white arrows), which migrated 
towards the infected epithelium and contributed to thickening of the alveolar 
space walls (Figure 5.10b).  In addition to this intense inflammatory 
infiltration, these mice demonstrated strong infection and destruction of the 
bronchiolar epithelium (Figure 5.11a).  Once again, macrophages were seen to 
successfully home to these areas and were present in large numbers (Figure 
5.11a), localising below the epithelial layer (Figure 5.11b, white arrow).  
Migration of macrophages to the bronchioles continued through day 6 post 
infection (Figure 5.12a), when macrophages became visible within the 
bronchioles, engulfing infected debris within the airways (Figure 5.12b, white 
arrows).  By the end of the experiment, there was diffuse F4/80 positivity 
within the Sv129 lung, coinciding with the pattern of polyclonal virus staining 
observed in Figure 5.7, demonstrating that macrophages remained present in 
high numbers within the lung for the duration of infection and contributed in 
no small measure to the congestion and thickened appearance of the alveolar 
walls.  Much of the virus detected appeared to be localised with the 
macrophages, suggesting that these cells have successfully scavenged debris 
and infected epithelial cells, while some virus remained associated with 
epithelium alone (Figure 5.13b white arrows).  The presence of such numbers 
of macrophages within the airspace lining, along with other infiltrating cells, is 
likely to compromise gas exchange and contribute to the morbidity of these 
mice.  
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Figure 5.9  Immunofluorescence for virus positive macrophages; Sv129 d2. 
Sv129 mice demonstrated macrophages infiltrating from blood stream into the lung at day 2 post 
infection, with some double positive cells at this early timepoint (white arrow). (a) x20 magnification, 
(b) x63 magnification.  Top left panel: anti-influenza virus + alexafluor 488; bottom left panel: anti-
F4/80 + alexafluor 594; right panel: overlaid image. 
Representative of n=3 
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Figure 5.10  Immunofluorescence for virus positive macrophages; Sv129 d4. 
At day 4 post infection, large numbers of macrophages could seen surrounding the blood vessels 
and bronchioles, migrating towards infected epithelium (white arrows). (a) x20 magnification, (b) x63 
magnification.  Top left panel: anti-influenza virus + alexafluor 488; bottom left panel: anti-F4/80 + 
alexafluor 594; right panel: overlaid image. 
Representative of n=3 
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Figure 5.11  Immunofluorescence for virus positive macrophages; Sv129 d4. 
At day 4 post infection, destruction of bronchiolar epithelium was evident, with macrophages 
localising beneath the epithelial layer (white arrows). (a) x20 magnification, (b) x63 magnification.  
Top left panel: anti-influenza virus + alexafluor 488; bottom left panel: anti-F4/80 + alexafluor 594; 
right panel: overlaid image. 
Representative of n=3 
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Figure 5.12  Immunofluorescence for virus positive macrophages; Sv129 d6. 
At day 6 post infection, macrophages could be seen within the bronchioles, engulfing infected 
epithelial cells (white arrows). (a) x20 magnification, (b) x63 magnification.  Top left panel: anti-
influenza virus + alexafluor 488; bottom left panel: anti-F4/80 + alexafluor 594; right panel: overlaid 
image. 
Representative of n=3 
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Figure 5.13  Immunofluorescence for virus positive macrophages; Sv129 d8. 
At day 8 post infection, macrophages were seen throughout the lung, thickening the alveolar space 
walls.  Much of the remaining virus localised with macrophages but some remained associated with 
epithelium alone (white arrows). (a) x20 magnification, (b) x63 magnification.  Top left panel: anti-
influenza virus + alexafluor 488; bottom left panel: anti-F4/80 + alexafluor 594; right panel: overlaid 
image. 
Representative of n=3 
 
Chapter 5                                                     In vivo infection of Sv129 and IFNγR-/- mice 
                                                                                                                                            
211 
 
Mock infected IFNγR-/- mice appeared to demonstrate higher numbers of F4/80 
positive cells than their wildtype counterparts (Figure 5.14 white arrows), 
suggesting a potential difference in resident alveolar macrophage numbers 
between the two strains of mice, although this was not confirmed by 
quantitative analysis.  Upon infection, macrophages appeared to home rapidly 
to the site of infection with no evidence of infiltration from the vasculature.  At 
day 2 post infection, small patches of infected cells were visible within the lung 
and many macrophages were already present (Figure 5.15a).  Under higher 
magnification, macrophages could clearly be seen alongside infected epithelial 
cells and several were themselves strongly positive for virus (Figure 5.15b, 
white arrow), although many remained negative for virus even in close 
proximity to infected cells.  Similar to Sv129 animals, by day 4 strong infection 
was visible in the epithelial lining of the bronchioles, with large numbers of 
macrophages infiltrating into this region (Figure 5.16a).  These infiltrating 
macrophages were seen to converge on regions of infected epithelium and 
again, many were positive for virus while others appeared to be moving 
towards the infected regions (Figure 5.16b).  Day 6 post infection saw a further 
increase in macrophages numbers, with large cuffs forming around the 
bronchioles and thickening of the alveolar space walls (Figure 5.17a), similar to 
the wildtype Sv129 lung.  Infected epithelium and debris was observed in the 
larger bronchioles, in contrast to the NS1 stain.  However, this is likely to be 
late stage proteins and whole virions detected by the broad spectrum 
polyclonal antibody, indicating that antigen remains at these sites after viral 
replication has ceased and macrophages localise here to clear the debris.  
Under higher magnification, the thickened alveolar walls could be clearly seen 
and were strongly positive for viral proteins (Figure 5.17b).  Macrophages 
appeared to be infiltrating these regions and engulfing infected material (Figure 
5.17b, white arrow) and therefore contributing to congestion of the lungs.  
However, by day 8 post infection, very little viral staining was evident in the 
IFNγR-/- lung with a concurrent reduction in macrophage numbers.  F4/80 
positive cells remained around blood vessels (Figure 5.18a), but fewer were ob- 
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Figure 5.14  Immunofluorescence for virus positive macrophages; IFNγR-/- mock. 
IFNγR-/- mice displayed higher numbers of macrophages in the lung following inoculation with PBS 
(white arrows) than did their wildtype counterparts. (a) x20 magnification, (b) x63 magnification.  Top 
left panel: anti-influenza virus + alexafluor 488; bottom left panel: anti-F4/80 + alexafluor 594; right 
panel: overlaid image. 
Representative of n=2 
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Figure 5.15  Immunofluorescence for virus positive macrophages; IFNγR-/- d2. 
At day 2 post infection, IFNγR-/- mice displayed discrete areas of infection with macrophages 
localising to these regions and becoming positive for viral proteins (white arrows). (a) x20 
magnification, (b) x63 magnification.  Top left panel: anti-influenza virus + alexafluor 488; bottom 
left panel: anti-F4/80 + alexafluor 594; right panel: overlaid image. 
Representative of n=3 
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Figure 5.16  Immunofluorescence for virus positive macrophages; IFNγR-/- d4. 
At day 4 post infection, IFNγR-/- mice demonstrated large areas of infiltration, localising close to 
areas of infected epithelium. (a) x20 magnification, (b) x63 magnification.  Top left panel: anti-
influenza virus + alexafluor 488; bottom left panel: anti-F4/80 + alexafluor 594; right panel: overlaid 
image. 
Representative of n=3 
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Figure 5.17  Immunofluorescence for virus positive macrophages; IFNγR-/- d6. 
At day 6 post infection, macrophages were evident in the thickening alveolar space walls (white 
arrows) and surrounding the bronchioles. (a) x20 magnification, (b) x63 magnification.  Top left 
panel: anti-influenza virus + alexafluor 488; bottom left panel: anti-F4/80 + alexafluor 594; right 
panel: overlaid image. 
Representative of n=3 
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Figure 5.18  Immunofluorescence for virus positive macrophages; IFNγR-/- d8. 
Very little virus remained at day 8 post infection, with macrophages mainly localising around blood 
vessels and in areas where infected epithelium remained (white arrows). (a) x20 magnification, (b) 
x63 magnification.  Top left panel: anti-influenza virus + alexafluor 488; bottom left panel: anti-
F4/80 + alexafluor 594; right panel: overlaid image. 
Representative of n=3 
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served in the airspaces, and the alveolar space walls showed less pathology.  
Macrophages continued to localise with virus positive tissue (Figure 5.18b, 
white arrow), suggesting ongoing scavenging for any remaining infected cells.  
In contrast to the Sv129 animals, infection in IFNγR-/- mice appeared to be 
approaching clearance by day 8, consistent with the NS1 stain (Figure 5.6), 
and a similar decrease in macrophage numbers was apparent.   
 
In addition to macrophages accounting for a large proportion of infiltrating 
cells in the lungs of both strains of mice following infection with WSN, other 
cell types may also be involved in deciding the outcome of infection.  
Neutrophils are known to be recruited in large numbers to the influenza virus 
infected lung and contribute to the inflammatory environment following 
infection.  Therefore, sections were stained for Ly6G, a neutrophil specific 
marker (Daley et al., 2008), to assess differences between Sv129 (Figure 5.19a, 
c, e) and IFNγR-/- mice (Figure 5.19b, d, f) in their ability to recruit this cell 
type. 
 
Lungs from both strains of mice showed small numbers of Ly6G positive cells 
following mock infection with PBS (Figure 5.19a&b).  However, challenge with 
virus led to strong staining for this marker, especially in the wildtype Sv129 
animals.  At day 4 post infection, much of the Sv129 inflammatory infiltrate 
within the tissue appeared to be Ly6G positive (Figure 5.19c), although 
absolute quantification was not performed.  IFNγR-/- mice showed very strong 
staining around the bronchioles (Figure 5.19d) but not the diffuse pattern 
observed in the wildtypes.  By day 8, both strains showed reduced staining 
compared with day 4 levels.  However, neutrophils were still present in large 
numbers within the lungs of both wildtype and knockout mice at this late 
timepoint, distributed in focal patches of infiltration and with single cells 
scattered throughout the tissue.  Wildtype animals showed more widespread 
Ly6G expression throughout the lung than did the IFNγR-/- mice, suggesting 
that, in  addition  to  higher  numbers  of macrophages remaining in the Sv129  
Chapter 5                                                     In vivo infection of Sv129 and IFNγR-/- mice 
                                                                                                                                            
218 
 
Figure 5.19  Distribution of neutrophils following infection with WSN. 
Immunohistochemistry for the neutrophil specific marker Ly6G demonstrated high numbers of 
neutrophils infiltrating into the Sv129 lung at day 4 (c) and day 8 (e) post infection, along with those 
elicited by inoculation with PBS (a).  Although reduced in comparison to wildtype animals, IFNγR-/-
mice also demonstrated low level positivity following mock infection with PBS (b), and infiltration of 
neutrophils at days 4 (d) and 8 (f) post infection.  Representative of n=3 
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lung late in infection, large numbers of  neutrophils are also present.  
Together, these cells are likely to contribute to immunopathology and excessive 
cytokine production within the lung, potentially exacerbating infection and 
accounting for the differences in clinical outcome in the two strains of mice.   
 
5.2.3 Cytokine expression following infection with WSN 
 
It is evident that infection with influenza virus draws many inflammatory cells 
into the lungs of both Sv129 and IFNγR-/- mice.  Many of these are 
macrophages and neutrophils.  However, IFNγR-/- mice demonstrate reduced 
cellular infiltration and, taken together with the in vitro gene expression data 
presented in Chapter 4, it is likely that these mice may demonstrate a reduced 
inflammatory response to virus, resulting in ameliorated disease due to limited 
immunopathology.  As such, mRNA expression of classical and alternative 
markers was investigated in vivo in order to deduce the extent of the 
inflammatory response in the lungs of Sv129 and IFNγR-/- mice. 
 
Whole lungs were harvested following euthanasia at days 2, 4, 6 and 8, or 
upon 30% weight loss in accordance with UK Home Office project licence.  A 
small portion of lung was excised from the same position in each animal and 
stored in RNAlater for RNA extraction, as described in Chapter 2.9.2.  qPCR 
was then utilised to assess the extent of gene expression following infection 
with WSN.  Samples were normalised against two housekeeping genes, CNX 
and SDHA as described in Chapter 2.12.3, and fold changes were expressed 
relative to the average gene expression of the mock infected control group.  
Log10 fold changes were plotted and statistical analyses carried out using the 
software package R.  
 
Sv129 mice showed a pattern of increasing iNOS mRNA expression throughout 
the course of infection (Figure 5.20, red boxes), while IFNγR-/- mice 
demonstrated baseline levels until day  6,  at which point iNOS mRNA express- 
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Figure 5.20  ‘Classical’ mRNA expression profile following infection with WSN. 
RNA was extracted from lungs following infection with WSN and qPCR used to assess expression 
levels for inflammatory modulators.  Samples were normalised against two housekeeping genes, 
CNX and SDHA, followed by normalisation against average expression of mock infected controls. 
NA = qPCR not performed, ND = not detected 
† indicates statistical significance between Sv129 and IFNγR-/- mice  
(† p<0.05, †† p<0.005) 
  Sv129   IFNγR-/- 
n=7 per timepoint 
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ion peaked before declining by day 8 (Figure 5.20, green boxes).  Despite these 
differences in trend between Sv129 and IFNγR-/- mice, mRNA expression only 
reached statistical significance at day 8 post infection (p=<0.05), when wildtype 
expression of iNOS mRNA was still increasing but levels in the knockout 
animals were returning to baseline. 
 
TNFα mRNA expression demonstrated a similar trend to iNOS in both strains 
of mice, with an increasing pattern of expression in Sv129 mice (Figure 5.20, 
red boxes) but low levels expressed in the IFNγR-/- animals, with a peak at day 
6 (Figure 5.20, green boxes).  TNFα mRNA expression was significantly lower in 
the absence of IFNγ signalling at days 6 (p=<0.05) and 8 (p=<0.005) post 
infection, compared to wildtype Sv129 mice. 
 
IL-12p40 however, showed a different pattern of expression to the two 
previously discussed genes.  Sv129 mice demonstrated elevated IL-12p40 
mRNA expression at day 4 followed by a very slight declining trend towards day 
8 (Figure 5.20, red boxes).  qPCR failed to detect this mRNA at day 2 post 
infection in IFNγR-/- mice, but expression rapidly increased at day 4, with 
higher levels of IL-12p40 mRNA being expressed by IFNγR-/- animals at this 
timepoint than their wildtype counterparts (Figure 5.20, green boxes).  This 
elevated trend continued until termination of the experiment at day 8, but 
differences in expression between the two strains of mice failed to reach 
statistical significance. 
 
IL-6 mRNA expression was also examined, although no statistical analysis was 
carried out due to a limited number of samples being available for this 
particular PCR.  However, the two strains appeared to show differing patterns 
of expression for this mRNA.  Sv129 RNA was not assessed at day 2, but by 
day 4 showed strong upregulation compared to mock infected controls.  
Expression then began to decline towards day 8, but was extremely variable in 
nature (Figure 5.20, red boxes).  IFNγR-/- animals, however, demonstrated 
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increasing expression of IL-6 mRNA, reaching a peak at day 6, similar to TNFα 
and iNOS mRNA expression, followed by a slight decline at day 8 but 
remaining strongly upregulated from baseline even at this late timepoint 
(Figure 5.20, green boxes).  
  
Markers of alternative activation were also assessed to determine whether in 
the absence of IFNγ signalling, a more TH2 skewed environment was achieved 
within the infected lung.  Initially at day 2 post infection, Arg-1 mRNA 
expression was significantly higher in the IFNγR-/- lung than in Sv129 animals 
(Figure 5.21, first panel, p=<0.005).  By day 4, Arg-1 mRNA expression had 
achieved similar levels in both strains of mice, and despite substantial 
variation, a relatively constant trend of expression was observed in both 
wildtype and IFNγR-/- animals. 
 
Conversely, CD206 expression demonstrated significant differences in 
expression between the two strains of mice.  Sv129 mice showed declining 
mRNA expression throughout the course of infection (Figure 5.21, red boxes), 
while IFNγR-/- showed significantly higher expression at days 2 (p=<0.05), 6 
(p=<0.05) and 8 (p=<0.0005), although a temporary dip was observed at day 4 
(Figure 5.21, green boxes).  This is consistent with the CD206 mRNA 
expression data from the in vitro BMDMφ, which showed IFNγR-/- BMDMφ to 
upregulate this mRNA upon infection with WSN (Figure 4.9). 
 
Sv129 IL-10 mRNA expression followed a similar trend to that observed for 
iNOS and TNFα expression, steadily increasing with time (Figure 5.21, red 
boxes).  IFNγR-/- mice were elevated at day 2 post infection for this mRNA, 
followed by a temporary decrease in expression at day 4.  However, IL-10 
mRNA expression increased steadily from this timepoint until termination of 
the experiment (Figure 5.21, green boxes).   
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Figure 5.21  ‘Alternative’ mRNA expression profile following infection with WSN. 
RNA was extracted from lungs following infection with WSN and qPCR used to assess expression 
levels for markers of alternative activation.  Samples were normalised against two housekeeping 
genes, CNX and SDHA, followed by normalisation against average expression of mock infected 
controls. 
NA = qPCR not performed, ND = not detected 
† indicates statistical significance between Sv129 and IFNγR-/- mice  
(† p<0.05, †† p<0.005) 
  Sv129   IFNγR-/- 
n= 7 per timepoint 
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Similar to IL-6, analysis of FIZZ mRNA expression was limited.  However, 
Sv129 mice appeared to show a surprisingly high level of expression (Figure 
5.21, red boxes).  This was highest at day 4 post infection, the earliest 
timepoint assessed, and then declined towards day 8.  This level of expression 
was substantially higher than that observed in the IFNγR-/- mice (Figure 5.21, 
green boxes).  Interestingly, the pattern of FIZZ expression was remarkably 
similar to that of IL-6 mRNA.  IL-6 is known to induce IL-4 production from 
naive T cells (Rincon et al., 1997), and taken together with the elevated IL-10 
mRNA expression, it is possible that the observed upregulation in FIZZ and 
Arg-1 mRNA is due to induction of these immunomodulatory cytokines.  
 
IL-12p40 and TGFβ were also measured by ELISA (Figure 5.22).  Wildtype 
Sv129 mice demonstrated a steady increase in IL-12p40 concentration (Figure 
5.22a, red bars), while in contrast to this, IFNγR-/- showed a peak at day 4 post 
infection, with levels being significantly higher in the knock out than the 
wildtype animals at days 4 and 6 (p<0.0005 & p<0.05 respectively).  IL-12p40 
then declined to significantly lower levels than Sv129 mice (Figure 5.22a, green 
bars, p<0.005).  This is in agreement with the mRNA expression data which 
showed elevated IL-12p40 mRNA at day 4 followed by decreasing levels in the 
IFNγR-/- animals, and elevated but steady expression in Sv129 mice (Figure 
5.20). 
 
TGFβ however, was detectable at low levels in Sv129 mice at day 2 post 
infection, but subsequently declined to undetectable levels by the end of the 
experiment.  IFNγR-/- animals demonstrated higher concentrations of this 
cytokine early in infection, but this failed to reach statistical significance due 
to some animals within both strains failing to express TGFβ.  By day 4, TGFβ 
levels were similar between the two strains.  However, in contrast to wildtype 
animals, the knockout mice retained some TGFβ at day 8 (Figure 5.22b).  
Despite the role this cytokine plays in wound healing and tissue repair, it 
appears that neither strain of mice upregulate TGFβ  following  influenza  virus 
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Figure 5.22  ELISA detection of IL-12p40 and TGFβ. 
IL-12p40 (a) and TGFβ (b) concentrations in lung homogenates were measured by ELISA. The 
average concentration of cytokine for mock infected mice was subtracted to determine induction of 
cytokine in response to virus.  The average background concentration of both cytokines was higher in 
Sv129 mice than IFNγR-/- animals; 226pg/ml vs 126pg/ml for IL-12p40 and 56pg/ml vs 30pg/ml for 
TGFβ. 
† p<0.05, †† p<0.005, ††† p<0.0005 
n= 7 per timepoint 
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infection, regardless of the need to repair damage within the lung and return 
this fragile environment  to  homeostasis. 
 
5.3 Summary of results and discussion 
 
The data presented in this chapter demonstrate that inhibition of IFNγ 
signalling results in ameliorated disease and mild immunopathology in vivo.  
Sv129 mice suffered from severe disease, rapid weight loss and early onset of 
symptoms, while IFNγR-/- mice were protected.  Further investigation revealed 
that wildtype Sv129 mice showed intense and diffuse cellular infiltration 
throughout the lungs, a large proportion of which consisted of macrophages 
and neutrophils.  This in turn led to elevated mRNA expression for 
proinflammatory genes iNOS, TNFα and IL-6, ultimately resulting in the 
extreme morbidity observed in this strain of mice, despite a concurrent 
increase in IL-10 and FIZZ mRNA expression. 
 
Conversely, IFNγR-/- mice demonstrated mild clinical symptoms with limited 
weight loss.  Although largely composed of macrophages and neutrophils, 
cellular infiltration into the lung appeared less extreme than that observed in 
wildtype mice, and consistent with this, lower levels of mRNA for inflammatory 
modulators were detected.  However, inflammatory infiltration was qualitatively 
assessed by examination of histological sections only.  Quantitative analysis is 
required to confirm differences between the two strains under investigation. 
 
Viral titres also differed between the two strains of mice, with Sv129 mice 
showing titres of around one log higher than IFNγR-/- animals.  This was 
corroborated by immunohistochemical analysis of lung sections which showed 
more widespread and intense staining for viral proteins in the wildtype 
animals.  Sv129 animals also appeared to show more severe damage to the 
bronchiolar epithelium compared to IFNγR-/- mice.  As previously discussed, it 
is possible that IFNγR-/- cells are less permissive to either viral entry or 
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replication and therefore this may limit the amount of replicating virus and 
consequent pathology and cytokine production observed in the lungs of these 
mice compared to their wildtype counterparts.  Macrophages from both strains 
of mice stained positive for viral proteins to a similar extent in vitro, indicating 
that the differing pathology observed is likely due to finite numbers of 
infiltrating cells, recruited by cytokine production in the epithelium and 
resident macrophages, rather than differing infectivity or efficiency of 
macrophage function within the lung, although absolute quantification of 
cellular influx is required to confirm this.  This suggests that differences in 
viral permissiveness between Sv129 and IFNγR-/- epithelial cells have an 
important effect on the overall pathology and clinical outcome of the disease. 
 
Interestingly, IFNγR-/- mice demonstrated most weight loss at day 6 post 
infection.  This timepoint coincides with highest expression of iNOS, TNFα and 
IL-6 mRNA expression, as well as that of the viral mRNA M1, despite declining 
viral titres at this timepoint.  This strongly suggests that the severity of 
symptoms observed is closely linked to the levels of proinflammatory cytokines 
induced by the virus.  Sv129 mice demonstrated increasing expression of 
mRNA for proinflammatory modulators throughout the course of infection, 
indicating that excessive production and accumulation of cytokines within the 
lungs exacerbates disease.  This is in agreement with previous studies which 
have shown peak titres of PR8 virus and maximal cytokine expression to be 
temporally distinct (Hennet et al., 1992), resulting in a cytokine storm-like 
illness as the virus is cleared.  Infection with highly pathogenic influenza 
viruses H5N1 and the 1918 H1N1 virus have similarly shown dramatically 
elevated cytokine expression, resulting in severe disease and organ failure 
(Cheung et al., 2002; Kobasa et al., 2007; Perrone et al., 2008), and so the 
pattern observed during WSN infection is characteristic of a highly pathogenic 
virus.   
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Two potential hypotheses may explain the lack of a cytokine storm in the 
IFNγR-/- mice.  Firstly, it is possible that reduced replication in these animals 
limits pathology and induction of proinflammatory cytokines.  This hypothesis 
implies that the substantial and rapid replication observed in wildtype animals 
is responsible for induction of the uncontrolled cytokine response rather than 
immune dysregulation per se.  Alternatively, the lack of IFNγ signalling may 
impair the inflammatory response sufficiently that no cytokine cascade occurs.  
However, this second hypothesis does not explain the lower viral titres 
observed and necessitates further investigation of potential mechanisms of 
viral clearance and control in the absence of a strong cytokine response. 
 
Infection with highly pathogenic influenza viruses of both avian and human 
origin have been shown to increase infiltration of neutrophils and macrophages 
to the respiratory tract (Perrone et al., 2008; Sakai et al., 2000).  
Immunostaining for F4/80 and Ly6G positive cells strongly suggests that 
increased numbers of macrophages and neutrophils found in the wildtype 
Sv129 lung contribute to the inflammatory cytokine environment, and this 
high expression of inflammatory mediators may result in further influx of these 
cells, ultimately resulting in a cytokine storm and severe morbidity.  
  
Neutrophils play a vital role during influenza virus infection and are 
responsible, along with macrophages, for clearance of infected cells.  This 
phagocytic process results in activation of macrophages, further enhancing 
clearance of the infection (Hashimoto et al., 2007).  Targeted depletion of 
neutrophils using a monoclonal antibody against Ly6G resulted in infection 
with the low pathogenic HKx31 influenza virus becoming systemic and lethal 
(Tate et al., 2009).  However, despite this crucial role in clearance, neutrophils 
also contribute to the proinflammatory cytokine environment in the lung, 
adding to excess tissue damage and organ failure.  Inhibiting recruitment of 
neutrophils to the infected lung reduced immunopathology, and although mice 
ultimately succumbed to infection, survival was prolonged in comparison to 
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infected controls (Sakai et al., 2000).  IFNγR-/- mice appeared to demonstrate 
fewer infiltrating neutrophils compared with Sv129 animals, although absolute 
quantification is required to confirm this observation.  However, taken together 
with the findings of previous studies, this suggests that infiltration of reduced 
numbers of neutrophils may be beneficial to the host, as this limits the 
production of damaging proinflammatory cytokines while still facilitating 
clearance of infected material. 
 
A functional CTL response is known to be protective against influenza virus 
infection.  However, infection may result in dysregulation of this response, 
leading to enhanced viral replication and immunopathology.  Upon infection, 
macrophages upregulate expression of TNFα and TRAIL (Herold et al., 2008), 
which has been implicated in induction of apoptosis of human T cells during 
highly pathogenic influenza virus infection in vitro (Zhou et al., 2006).  It is 
possible that during in vivo infection, CTL numbers are reduced by TRAIL 
mediated apoptosis, resulting in a poor CTL response and prolonged viral 
replication.  Additionally, nitric oxide production by mφ has been shown to 
suppress T cell activation (Hamilton et al., 2010).  WSN infected IFNγR-/- mice 
express reduced iNOS and TNFα and it is tempting to speculate that a 
reduction in TRAIL expression may also occur compared with Sv129 
counterparts.  It may, therefore, be possible that by impairing the 
inflammatory response to virus, the CTL response is protected from TRAIL and 
nitric oxide mediated dysregulation and may function efficiently to clear the 
infection.  However, neither expression of TRAIL, nor CTL numbers or 
responses were assessed during this project.  Investigation of these parameters 
on the IFNγR-/- background may help to elucidate the role that dysregulated 
cytokine production plays in functional immune responses to virus. 
 
Further to this, the speed of viral replication has been implicated in generation 
of an efficient CTL response.  Rapidly replicating virus induces a poor CTL 
response, due to increased FasL expression in the lymph nodes.  This results 
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in apoptosis of circulating CTLs and reduction of the overall magnitude of the 
anti-influenza response.  However, delayed replication fails to upregulate FasL, 
allowing an efficient CTL response to proceed (Legge & Braciale, 2005).  IFNγR-
/- animals demonstrate delayed replication in comparison to Sv129 mice, 
evidenced by limited NS1 staining at early timepoints.  However, FasL induced 
apoptosis of circulating CTLs was found to be IL-12p40 dependent.  IFNγR-/- 
mice demonstrate delayed onset of IL-12p40 expression, being detectable at 
day 4 rather than day 2 as in Sv129 mice, but expression of this mRNA was 
higher in the IFNγR-/- animals than their wildtype counterparts, so protection 
of these mice is unlikely to be due to subversion of this interaction. 
  
Inhibition of IFNγ signalling leads to lower cytokine production and fewer 
inflammatory cells, but whether this is due to cells within the IFNγR-/- lung 
being less permissive to viral replication and therefore recruiting fewer 
inflammatory cells to the lung, or whether the lack of IFNγ signalling merely 
limits the inflammatory potential of infiltrating cells remains to be elucidated.  
TRAIL expression on infiltrating macrophages induces apoptosis in alveolar 
epithelial cells (AEC) (Herold et al., 2008), which aside from causing 
immunopathology in itself, also reduces the number of epithelial cells available 
to interact with macrophages.  AEC express inhibitory molecules such as 
CD200, which are involved in maintaining macrophage quiescence during 
homeostasis and preventing inappropriate inflammatory responses.  However, 
disruption of the CD200:CD200R interaction results in macrophage activation, 
and during influenza virus infection, apoptosis and sloughing of AEC leads to a 
loss of CD200 expression and further activation of macrophages in the lung 
(Snelgrove et al., 2008).  The reduced level of infection, as observed using anti-
NS1 staining, concurrent with the inhibition of proinflammatory mediators in 
IFNγR-/- mice may ultimately result in enhanced survival of AEC and 
maintenance of suppressive interactions with macrophages, further reducing 
the inflammatory environment within the lung. 
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Infection was established in a delayed manner in IFNγR-/- mice compared to 
Sv129 animals, similar to the kinetics observed following in vitro infection of 
BMDMφ.  As previously discussed, it is possible that absence of the sialylated 
IFNγ receptor on the surface of both AEC and macrophages alike substantially 
impedes viral entry to the cell, leading to delayed and limited infection.  
Consistent with this hypothesis, IFNγR-/- mice show lower viral titres in the 
lung compared to their wildtype counterparts and reduced staining for viral 
antigens in the epithelium.  This in turn will have a dramatic effect on the 
cytokine environment, as fewer infected cells results in lower induction of 
proinflammatory cytokines, further indicating a vital role for viral replication in 
development of the cytokine storm.  It is interesting that IFNγR-/- and wildtype 
Sv129 mice showed no difference in survival following infection with the H3N2 
virus, HKx31 (Price et al., 2000).  Despite seemingly being in contrast to the 
data presented here, this could be explained by the ability of the HKx31 virus 
to utilise CD206 on the surface of macrophages, facilitating efficient infection 
of this cell type (Reading et al., 2000) and leading to reduced free virus 
available to infect epithelial cells and cause disease (Tate et al., 2010c).  
Infection of macrophages via CD206 and subsequent sequestration of virus 
strains such as HKx31 may negate the role played by the IFNγ receptor in 
internalisation of a strain of virus such as WSN, which does not bind to 
CD206.  However, many other sialylated endocytic receptors are present on the 
surface of both epithelial cells and macrophages in addition to the IFNγ 
receptor, limiting the likelihood of this receptor playing a major role in the 
protection of IFNγR-/- cells from infection. 
 
An alternative hypothesis regarding the limited infection observed in IFNγR-/- 
mice suggests that macrophages play a limiting role in virus dissemination.  It 
has previously been reported that influenza virus more readily infects resident 
rather than infiltrating macrophages, demonstrated by culturing of resistant 
“exudate” macrophages for 7 days, by which time they acquire a “resident” 
phenotype and are susceptible to influenza virus infection (Rodgers & Mims, 
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1981).  It is possible that potential differences in the numbers of resident 
alveolar macrophages between wildtype Sv129 and IFNγR-/- mice may affect the 
outcome of disease.  Following mock infection with PBS, it appeared that 
IFNγR-/- mice showed higher numbers of macrophages, which may be resident 
rather than recruited to the lungs.  As it has also been shown that efficient 
infection of macrophages in vivo ameliorates disease (Tate et al., 2010c), it is 
possible that higher numbers of resident alveolar macrophages may limit the 
early dissemination of virus and delay establishment of infection by becoming 
infected themselves in an abortive infection.  Enhanced infection of resident 
alveolar macrophages may result in less free virus coming into contact with the 
epithelium and therefore limit spread of the virus.  Macrophages in the lungs 
of both Sv129 and IFNγR-/- mice stain positive for viral proteins, but whether 
this is phagocytosed material or active infection is unknown.  Further staining 
using the polyclonal anti-NS1, or an equivalent antibody to detect newly 
synthesised proteins would elucidate this, shedding light on whether 
differences arise in viral replication within macrophages of these strains of 
mice.  Additionally, clarification of the cellular constitution of the naive lung in 
both strains of mice is necessary to identify any underlying differences, 
especially in CTL and resident macrophage numbers, which may have an effect 
on disease outcome. 
 
Interestingly, CD206 was upregulated in IFNγR-/- mice following infection.  As 
discussed in Chapter 4, WSN is unlikely to interact with this receptor due to a 
lack of glycosylation sites on its HA and NA proteins.  However, CD206 can 
exist as a truncated, soluble form of the receptor (sCD206) which is secreted 
and may act as an opsonin for pathogens displaying mannosylated moieties 
(Martinez-Pomares et al., 1998).  sCD206 has subsequently been reported to 
bind macrophages and dendritic cells via sialoadhesin (Martinez-Pomares et 
al., 1999) and simultaneously bind mannosylated antigens, transporting them 
to the subcapsular sinus and presenting them to circulating B cells (Carrasco 
& Batista, 2007; Junt et al., 2007; Martinez-Pomares & Gordon, 1999).  In the 
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absence of IFNγ mediated suppression, CD206 mRNA is upregulated following 
infection with influenza virus, further implicating this receptor in host defence 
against infection. 
 
Surprisingly, FIZZ, a known marker of alternative activation in macrophages, 
was upregulated in a manner similar to IL-6, following infection of both Sv129 
and IFNγR-/- animals.  FIZZ was initially identified during allergic inflammation 
of the lung, where it is produced by epithelial cells, type II pneumocytes and 
macrophages (Holcomb et al., 2000).  It has been demonstrated to play a role 
in wound healing and fibrosis and is abundantly found in injured lungs where 
it induces expression of type I collagen (Liu et al., 2004).  Interestingly, it has 
recently been shown that FIZZ may also play a role in immune modulation, as 
FIZZ deficient mice demonstrated exacerbated TH2 inflammation following 
implantation of S. masoni eggs (Nair et al., 2009).  This study showed FIZZ to 
inhibit expression of IL-4, while having no effect on expression of TH1 
cytokines.  This role is in apparent contradiction of its expression in 
alternatively activated macrophages, which are generally thought of as TH2 
type cells.  However, FIZZ appears to limit excessive TH2 responses induced by 
alternatively activated macrophages while promoting repair of damaged tissue.  
In the present study, the concurrent expression of IL-6 and alternative 
markers FIZZ and Arg-1 is intriguing, as the latter are induced by IL-4, while 
IL-6 induces early IL-4 expression from naive T cells (Rincon et al., 1997), yet 
TH1 cytokines TNFα and IL-12 dominate the response to influenza virus.  It 
may be possible that elevated IL-6 induces IL-4 expression from T cells present 
in the bronchus associated lymphoid tissue which, in addition to priming these 
T cells for a TH2 response, may be released within the lung resulting in 
alternative activation of macrophages and upregulation of wound healing 
molecules FIZZ and Arg-1.  FIZZ may then function to inhibit this TH2 
response, ultimately allowing progression of the inflammatory response to 
virus.  No evidence of fibrosis is detectable within the lungs during the 8 day 
observation period.  Further timepoints may indicate development of fibrosis, 
Chapter 5                                                     In vivo infection of Sv129 and IFNγR-/- mice 
                                                                                                                                            
234 
 
but as IFNγR-/- mice display lower FIZZ expression consistent with milder 
infection, it is likely that high expression of this gene is a result of severe 
disease, and as such the mice would not survive a longer course of infection. 
 
The Sv129 background has been identified as TH1biased, as determined by 
failure of splenocytes to produce IL-4 in response to concavalin A, even in the 
presence of exogenous IL-4 (Schijns et al., 1994).  This strain of mouse also 
demonstrates resistance to infection with L. major in an IL-12 dependent 
manner (Mattner et al., 1996), while the prototype TH2 BALB/c mouse is 
susceptible.  Interestingly, disruption of either subunit of IL-12 on the Sv129 
background results in strong IL-4 expression following L. major infection 
(Mattner et al., 1996), while IFNγR-/- animals demonstrate a predominantly TH1 
cytokine profile with expression of  IL-2 and IFNγ, but reduced IL-10 in 
response to psuedorabies virus (Schijns et al., 1994).  This suggests that IL-12 
controls development of a functional TH1 response on this background.  The 
detection of IL-12 mRNA and functional protein in the present study indicates 
that IFNγR-/- mice may develop a TH1-like response in CD4+ T cells, and that 
limited viral replication detected may play a greater role in the decreased 
proinflammatory cytokine mRNA expression observed than an overt skewing of  
the immune response.  However, to truly understand the extent to which a TH2 
response develops in the mutant mice versus their wildtype counterparts, it 
would be vital to measure expression of IL-4, especially in light of the 
intriguing FIZZ and Arg-1 expression observed. 
 
In summary, disruption of the IFNγ receptor results in reduced 
immunopathology and ameliorated disease following infection with influenza 
virus, but whether this is due to impaired inflammation, limited viral 
replication or altered viral clearance remains to be elucidated. 
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Infection with the mouse adapted influenza A virus, WSN, resulted in release of 
pro-inflammatory cytokines in Sv129 BMDMφ in vitro and within the lung 
following in vivo infection.  Infection resulted in severe weight loss, clinical 
symptoms and decreased survival.  Symptoms were largely attributed to the 
excessive inflammatory response and cellular infiltration into the lung, 
ultimately resulting in severe pneumonia and organ failure.  This thesis aimed 
to investigate the hypothesis that alteration of the inflammatory response may 
be beneficial to the host and limit the tissue damage suffered as a result of the 
classical immune response to influenza virus.  
 
BMDMφ can be alternatively activated by incubation with IL-4 (Stein et al., 
1992), resulting in a broadly anti-inflammatory phenotype.  It was 
hypothesised that inhibition of the classical, inflammatory macrophage 
response to influenza, by infecting alternatively activated macrophages or mice 
unable to respond to IFNγ, may lead to ameliorated disease. 
 
Both classical and alternatively activated BMDMφ were successfully infected 
with the WSN strain of influenza virus, but the alternatively activated group 
demonstrated enhanced positivity for virus concurrent with reduced survival.  
The same was true of IFNγR-/- BMDMφ, although establishment of infection on 
this background was somewhat delayed.  However, by 48 hours post infection, 
BMDMφ of both backgrounds demonstrated similar levels of staining for viral 
proteins, although those on the IFNγR-/- background were markedly reduced in 
their ability to survive infection, especially in the alternatively activated group.   
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Delayed infection was also evident in vivo following infection of IFNγR-/- mice.  
Wildtype Sv129 mice displayed strong and widespread positivity for the viral 
protein NS1 as early as day 2, which remained evident until termination of the 
experiment at day 8.  IFNγR-/- mice, however, showed substantially less NS1 
positivity at day 2, and following the peak of NS1 production at day 4, declined 
to almost undetectable levels by day 8.   
 
Both the in vitro and in vivo infection data suggest that a block is imposed by 
IFNγR-/- cells during the infection process, most likely either at the attachment 
and entry stage or during early replication.  BMDMφ from both strains of mice 
can become alternatively activated in the presence of IL-4, and both display 
similar levels of viral positivity by 48 hours post infection, suggesting that 
induction of an anti-inflammatory environment within the cell does not provide 
a substantial block to replication.  However, cells on the IFNγR-/- background 
are unable to respond to IFNγ, either given exogenously in vitro, or locally 
produced in vivo, and therefore no IFNγ-induced inflammatory burst occurs 
early in infection.  It is possible that the virus hijacks this rapid burst of 
metabolic activity to synthesis its own early proteins such as NS1, and in the 
absence of this activity, establishment of infection is delayed.  However, the 
cellular microenvironment may ultimately be more permissive for viral 
replication due to reduced iNOS expression, allowing the virus to replicate to 
similar levels as seen in Sv129 cells, but with delayed kinetics. 
 
Influenza virus binds to SA, which is ubiquitously expressed on the cell 
surface.  However, avian and mammalian influenza viruses differ in their 
specificity for SA linkages, with avian viruses preferentially binding α2,3 linked 
SA and mammalian viruses binding α2,6 (Connor et al., 1994).  This preference 
dictates the host species restriction of influenza viruses.  Despite binding of SA 
being a prerequisite for infection, it does not necessarily lead to efficient 
internalisation of the virus.  Reading and colleagues have recently proposed a 
model whereby influenza interacts with SA on the surface of the cell to bring 
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the virion into close contact with endocytic receptors, which then facilitate 
entry and uncoating of the virus in acidified vesicles (Tate et al., 2010a; Upham 
et al., 2010).  This could explain the differences in infection kinetics between 
Sv129 and IFNγR-/- animals both in vitro and in vivo.  The IFNγ receptor is 
internalised following binding of its ligand, whereby it enters the endosomal 
pathway.  It is possible to speculate that sialic acid mediated binding of 
influenza virus to the IFNγ receptor may facilitate entry and infection via 
binding of SA followed by internalisation through the normal IFNγ receptor 
pathway.  IFNγ receptors are highly expressed on the surface of many cell 
types, including macrophages and epithelial cells (Valente et al., 1992) and 
therefore disruption of this receptor may result in a net loss of suitable SA and 
receptors to mediate internalisation in both in vitro generated BMDMφ and 
during in vivo infection of IFNγR-/- mice. 
 
Upon establishment of infection, it is evident that inhibition of IFNγ signalling 
leads to an impaired inflammatory response both in vitro and in vivo.  IFNγR-/- 
BMDMφ generated a transient upregulation of iNOS and TNFα mRNA at 16 
hours, which was not sustained in the absence of IFNγ signalling.  These 
proinflammatory mediators were markedly reduced compared to Sv129 
BMDMφ by 48 hours post infection.   
 
Following infection of alternatively activated macrophages, BMDMφ from both 
genetic backgrounds demonstrated a reduced inflammatory response.  This 
was intriguing as infection with WSN was evidently sufficiently 
proinflammatory to induce a subset of alternatively activated macrophages into 
classical activation.  However, complete infection of the BMDMφ population 
was not achieved, suggesting that the subset that remained uninfected may be 
capable of sustaining their alternative activation profile.  Furthermore, 
alternatively activated BMDMφ from both Sv129 and IFNγR-/- mice 
demonstrated enhanced positivity for viral proteins and reduced survival in 
vitro following infection.  This may result in efficient elimination of virus as it 
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has recently been demonstrated that the efficiency with which macrophages 
become infected by influenza virus is inversely correlated with disease severity 
(Tate et al., 2010c).  This, along with the subdued inflammatory response to 
virus in alternatively activated BMDMφ and the impaired response observed 
from IFNγR-/- BMDMφ suggested that the inflammatory response may be 
subverted in vivo using either genetically modified mice or alternatively 
activating stimuli.  
 
Indeed, infection of IFNγR-/- mice did result in ameliorated disease and 
improved clinical score, associated with a reduction in immunopathology and 
cytokine expression.  As seen in vitro, IFNγR-/- mice displayed significantly 
lower iNOS and TNFα mRNA, although IL-12p40 mRNA expression was slightly 
higher in the IFNγR-/- animals than their wildtype counterparts.  
  
High concentrations of inflammatory mediators TNFα and iNOS have often 
been associated with highly pathogenic influenza viruses and severe pathology 
(Cheung et al., 2002).  These mediators were elevated in Sv129 animals and 
BMDMφ compared to those on the IFNγR-/- background, which achieved a 
greatly reduced peak expression at day 6 post infection.  This timepoint 
correlated with maximum weight loss in these animals, while virus titres were 
declining.  Although it has also been shown that elevated TNFα does not 
necessarily preclude immunopathology (Monteerarat et al., 2010), it certainly 
appears to be involved in this model.   Furthermore, several studies have 
demonstrated the contribution made by this cytokine to the damaging 
immunopathology observed.  TNFαR-/- mice showed delayed morbidity with a 
highly pathogenic strain of H5N1 (Szretter et al., 2007), while blocking TNFα 
with monoclonal antibodies resulted in maintenance of body weight and 
improved clinical score following infection (Hussell et al., 2001).  Anti-TNFα 
therapy has proved successful in treating inflammatory diseases such as 
rheumatoid arthritis (Maini et al., 1995), while pharmacological inhibition of 
NFκB signalling using Sulfasalazine has been of benefit in treating the 
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inflammatory arthritis resulting from macrophage derived TNFα during Ross 
River Virus infection (Lidbury et al., 2008).  Inhibition of iNOS and TNFα using 
the drug Pioglitazone ameliorated PR8-induced inflammation and 
immunopathology (Aldridge et al., 2009), demonstrating an important role of 
these proinflammatory molecules in disease progression.  Consistent with this, 
inhibition of IFNγ signalling ultimately results in ameliorated disease due to 
reduced recruitment of inflammatory cells and subsequently, reduced 
expression of inflammatory mediators. 
 
Other mechanisms of protection are also of interest, for example, maintaining 
the structural integrity of the lung in order to prevent induction of 
inflammatory responses.  CD200 is an inhibitory molecule expressed on the 
surface of epithelial cells and interacts with CD200R on macrophages within 
the lung.  Loss of this interaction leads to activation of macrophages and 
inflammatory responses (Snelgrove et al., 2008).  During influenza virus 
infection, epithelial cells become infected and apoptotic, sloughing off in the 
process, therefore decreasing the available CD200 to inactivate macrophages, 
ultimately leading to higher cytokine expression, failure to resolve 
inflammation and severe disease.  Treatment with an agonising anti-CD200R 
antibody resulted in decreased macrophage activation and improved clinical 
score (Copland et al., 2007; Snelgrove et al., 2008). 
 
Interestingly, IFNγR-/- BMDMφ demonstrated higher baseline levels of TGFβ 
than wildtype Sv129 counterparts.  Expression of this cytokine is also higher 
early in infection in vivo in IFNγR-/- mice.  TGFβ and IL-10 upregulate the 
expression of CD200R on macrophages (Snelgrove et al., 2008), suggesting that 
in addition to an impaired inflammatory response resulting from inhibition of 
IFNγ signalling, macrophages in this strain of mice may be more responsive to 
CD200-mediated inactivation, further preventing development of inflammatory 
responses in the lung following infection with WSN. 
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TGFβ, along with IL-6, is required for development of TH17 cells.  IL-6 
expression increased with time during infection of IFNγR-/- mice, a pattern of 
expression which corresponds temporally to development of the T cell 
response.  It has been suggested that TH17 responses may be protective during 
influenza virus infection as IL-17 induces proliferation of airway epithelial cells 
(Inoue et al., 2006), thereby reducing influenza mediated immunopathology 
and additionally, may enhance CD200, CD200R interactions by replenishing 
the epithelial cell layer.  This is, however, controversial as while some groups 
demonstrate protection following adoptive transfer of ex vivo activated TH17 
cells (McKinstry et al., 2009), others show disruption of IL-17 signalling to be 
beneficial in reducing TNFα and IL-6 levels (Crowe et al., 2009).  However, it 
may be of interest to investigate whether in the absence of IFNγ signalling, a 
TH17-like environment develops. 
 
IFNγR-/- mice demonstrated increased expression of CD206 mRNA both in vivo 
and following in vitro activation of BMDMφ compared with wildtype Sv129 
animals.  Wildtype Sv129 BMDMφ displayed efficient upregulation of this 
receptor following IL-4 stimulation as expected, but strongly downregulated 
expression in vivo.  This receptor has been implicated not only in facilitating 
influenza virus attachment and entry (Reading et al., 2000), but also as a 
soluble opsonin capable of displaying antigen to B cells in its native form in the 
subcapsular sinus (Junt et al., 2007; Martinez-Pomares & Gordon, 1999).  The 
upregulation of this receptor on the IFNγR-/- background is intriguing.  It may 
be possible that upregulation of this receptor, especially in its soluble form, 
may be a non specific defence against infection, upregulated in the absence of 
IFNγ signalling.  Given the TH1 skewed phenotype of Sv129 and the elevated 
expression of CD206 observed in the BALB/c BMDMφ following infection 
(Figure 4.9), it would be interesting to investigate the expression and potential 
role of this receptor in vivo on the TH2 oriented BALB/c background. 
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Inhibition of respiratory virus associated immunopathology has been the 
subject of investigation by many studies, and subversion of this response 
appears to efficiently enhance clinical outcome.  However, each of the many 
studies has investigated a different mediator in the inflammatory response, 
often using genetically modified animals.  NOS2-/- (Karupiah et al., 1998), 
TNFαR-/- (Szretter et al., 2007), platelet activating factor R-/- (Garcia et al., 
2010)  and TLR3-/- mice (Le Goffic et al., 2006), along with depletion of TNFα 
and iNOS using monoclonal antibodies (Hussell et al., 2001) or drugs (Aldridge 
et al., 2009) have all demonstrated protection from influenza induced 
immunopathology to varying degrees.  Conversely, disruption of TLR4 
(Hashimoto et al., 2007), CD200 (Snelgrove et al., 2008) and CCL5 (Tyner et al., 
2005) genes exacerbated disease severity and inflammatory responses following 
respiratory virus infection.  While individually significant, taken together as a 
whole, these studies serve to emphasise the complexity of the inflammatory 
response to viral infection, with a high degree of redundancy between 
mediators further complicating dissection of this response.  The results 
presented herein provide further evidence as to the validity of subverting the 
inflammatory response as a means to ameliorate influenza virus induced 
immunopathology.  
  
Chapter 6                                                      Discussion and Future Directions 
                                                                                                                                            
243 
 
6.2 Future directions 
 
Although ablation of the INFγ receptor ameliorated disease following influenza 
virus infection, this raises further questions with regards to the wildtype 
mouse.  For example, does inhibition of IFNγ signalling using monoclonal 
antibodies result in the same degree of amelioration in Sv129 mice as observed 
in IFNγR-/- animals?  This may also help to investigate the role of the IFNγ 
receptor in viral entry versus impairment of the inflammatory response on 
disease severity.   
 
Likewise, is it possible to alter the course of disease in the wildtype mouse by 
intra-tracheal transfer of ex vivo activated macrophages? Given the enhanced 
capacity of alternatively activated BMDMφ to take up virus and undergo 
apoptosis, it is possible that free virus may be more efficiently captured by 
these macrophages either due to enhanced infection or phagocytosis, 
ultimately resulting in abortive infection and protection of epithelial cells from 
infection. 
 
If this indeed proves to be possible, then investigating means of inducing 
alternative activation of in vivo macrophages may be important.  For example, 
helminth worms and their products are known to induce this activation state 
in vivo and so would co-infection of mice with a parasitic worm, or treatment 
with worm products eg implantation of schistosome eggs, provide protection 
from influenza virus induced pathology?  This approach is of course, 
complicated by the presence of a second pathogen and the possibility of 
pathology induced by the parasite or its derived products, for example fibrosis 
due to enhanced FIZZ and Arg-1 expression. 
   
On a more fundamental level, there appears to be some discrepancy between 
Sv129 and IFNγR-/- animals in their baseline expression of several cytokines 
and cellular composition in the lung.  It is possible that due to these 
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differences, and to the altered cytokine environment following infection, cells 
such as CTLs may become differentially activated in IFNγR-/- animals.  It may 
be of interest to further characterise the IFNγR-/- mouse on the Sv129 
background with regards to cytokine expression and cell distribution during 
homeostasis, especially cells of the innate immunity which have thus far been 
overlooked by previous studies.  The downstream effects of differences in 
cytokine expression and cell proportions may have important consequences for 
the immune response to viral infection.   
 
Although further study is clearly warranted, the data presented in this thesis 
show that subversion of the host inflammatory response by inhibiting IFNγ 
signalling results in ameliorated disease and improved prognosis following 
influenza virus infection and furthermore, implicate the IFNγ receptor as a 
facilitator of efficient influenza virus infection.   
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